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LONGITUDINAL GROWTH 
 
Longitudinal growth results in an increase in body stature and depends on many factors, 
including environmental influences, nutrition, genetic factors, systemic hormones and growth 
factors. Longitudinal growth in man consists of different phases. The highest overall growth 
rate occurs during fetal development. Postnatally, the highest longitudinal growth rate is 
achieved just after birth, followed by a slower growth rate during mid-childhood. A growth 
spurt follows during puberty, until the age of peak height velocity has been reached and 
longitudinal growth ceases 1. Responsible for longitudinal bone growth are the growth plates 
located at the proximal and distal ends of the long bones, by a process called endochondral 
ossification.  
 
ENDOCHONDRAL OSSIFICATION 
 
During endochondral ossification in the growth plates, the chondrocytes (cartilage cells in the 
growth plate), follow a highly coordinated program of proliferation, differentiation, 
maturation and eventually apoptosis, leaving the cartilaginous scaffold on which new bone is 
formed. These processes result in longitudinal bone growth 2-4. 
 
Development of the growth plate 
 
The process of endochondral ossification begins during the formation of the long bones in the 
embryo. In the embryo, mesenchymal cells condense, differentiate into chondrocytes and 
form the cartilaginous model of the bone. The chondrocytes start to hypertrophy in the 
diaphysis of the bone, osteoclasts (bone resorbing cells) and blood capillaries start to invade 
the diaphysis and the initial bone is formed in the primary ossification centre. This primary 
ossification centres spreads outwards to the ends of the bones. A secondary ossification centre 
develops in the epiphyseal cartilage at the ends of the bones. The primary and secondary 
ossification centre remain separated by a layer of cartilage, the growth plate, which is located 
between the epiphyseal and methaphyseal bone (Fig. 1). During postnatal growth, 
endochondral ossification continues in these growth plates, resulting in longitudinal bone 
growth 3,4. After puberty, growth velocity rapidly decreases and the growth plates fuse (not in 
rodents), resulting in cessation of longitudinal bone growth. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 The growth plate as visible on a X-ray. 
X-ray of a child's long bone, showing the upper leg 
(femur) and the lower leg (tibia). The epiphyseal 
growth plate is visible as a thin line, located 
between the metaphyseal and epiphyseal bone. 
metaphyseal 
bone 
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Structure of the epiphyseal growth plate 
 
The growth plate is an organized structure, consisting of three functionally and structurally 
distinct layers, the resting, proliferative and hypertrophic zone (Fig. 2). The chondrocytes in 
these different zones are at different stages of differentiation. In all three zones, the growth 
plate chondrocytes are embedded in a cartilaginous extracellular matrix (ECM) 4,5.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The resting zone 
The most immature chondrocytes are located at the distal epiphyseal end of the growth plate, 
in the resting zone. Resting chondrocytes are small, spherical progenitor cells that divide 
rarely and lie as single cells or in small clusters in a dense cartilaginous ECM consisting 
largely of type II collagen and proteoglycans 5,6. The resting chondrocytes act as stem-like 
cells, as removal of the growth plate in vivo in rabbits, leaving only the resting zone, resulted 
in a complete regeneration of the growth plate 7. In the same study, resting zone cartilage 
placed ectopically alongside the proliferative zone, induced a 90-degree shift in the 
orientation of nearby proliferative chondrocytes. This indicates that resting chondrocytes also 
direct the alignment of chondrocyte columns parallel to the long axis of the bone 7.  
 
The proliferative zone 
In the proliferative zone, chondrocytes display a flattened shape and they divide rapidly, 
followed by the two daughter cells lining up along the long axis of the bone. This clonal 
expansion results in organized longitudinal chondrocyte columns, a characteristic feature of 
the growth plate. The increase in the number of proliferative chondrocytes contributes to 
longitudinal bone growth 5. After a finite number of cell divisions, the proliferating 
chondrocytes loose their ability to divide and start to enlarge as they mature to the 
hypertrophic phenotype 5. The ECM between the proliferative chondrocyte columns consists 
mainly of longitudinally oriented collagen II fibrils. 
 
The hypertrophic zone 
The transition zone between the proliferative and hypertrophic zones, where proliferative 
chondrocytes start to round up and begin to enlarge, is often referred to as the prehypertrophic 
zone 4,5. The hypertrophic chondrocytes continue to enlarge up to five- to tenfold, which 
substantially contributes to the increase in longitudinal bone growth, and eventually they die 
by apoptosis (programmed cell death). In the hypertrophic zone, the secreted ECM differs 
Figure 2 Structure of the 
epiphyseal growth plate. 
Schematic representation of 
a growing long bone, 
showing the major 
structures of the bone. The 
right hand panel shows a 
detailed view of the growth 
plate and the organization in 
the different zones, as 
indicated (derived from 6). 
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from the other zones and is rich in type X collagen. In the lower part of the hypertrophic zone, 
the ECM becomes mineralized in the zone of provisional calcification 5.  
 The terminal hypertrophic chondrocytes (most distal hypertrophic chondrocytes) undergo 
apoptosis 8 and leave empty lacunae which are separated by the ECM (Fig. 3). This 
cartilaginous scaffold is the template on which new bone will be formed. The formation of 
new bone requires angiogenesis, the invasion of blood vessels from the metaphyseal bone at 
the base of the hypertrophic zone 9. Angiogenesis and apoptosis are associated processes in 
the growth plate 9.  
 Chondroclasts or osteoclasts (bone resorbing cells) partially resorb the calcified ECM and 
blood vessels enter this resorption front. The invading blood vessels allow the osteoblasts to 
invade and to lay down new metaphyseal trabecular bone, completing the process of 
endochondral ossification 4,6,9,10. 
 
 
 
 
 
 
 
 
 
 
 
 
 
The Extracellular Matrix (ECM) 
The chondrocytes of the different zones are embedded in an extracellular matrix (ECM), 
which also exhibits a structural organization. The ECM is produced by the chondrocytes and 
mainly consists of collagens and proteoglycans. The collagens type II, IX and XI are 
expressed in all three zones of the growth plate, whereas collagen type X is only present in the 
hypertrophic zone 5,11. The proteoglycans, which require sulphation for their activation and 
cross-linking to the ECM, are also present in all three zones. The ECM interacts with the 
chondrocytes through cell surface adhesion receptors, the integrins 12, which is important for 
chondrocyte differentiation and survival 13.  
 ECM remodelling enzymes, as matrix metalloproteinases (MMPs), are important players in 
endochondral ossification. They are crucial in the modelling and degradation of the ECM, and 
in the process of angiogenesis 14. Furthermore, degradation of the ECM also releases growth 
factors which may be present in the ECM, which in turn may have their effect on growth plate 
chondrocytes. 
 
GROWTH FACTORS 
 
Different growth factors play an important role in endochondral ossification. Besides their 
local effects on the growth plate, they also exert systemic effects, which will not be discussed. 
Among these growth factors are vitamin D3, parathyroid hormone-related peptide (PTHrP), 
Indian hedgehog (Ihh), bone morphogenetic proteins (BMPs), fibroblast growth factors 
(FGFs), sex steroids, thyroid hormones, vascular endothelial growth factor (VEGF) and 
Figure 3 Processes in the 
hypertrophic zone of the growth plate. 
Schematic representation of the lower 
part of the growth plate and the 
metaphyseal bone. Chondrocytes 
mature in the hypertrophic zone and die 
by apoptosis, followed by matrix 
degradation. This facilitates the invasion 
of blood vessels and osteoblasts into the 
lower part of the growth plate, to lay 
down new bone (derived from 6). 
apoptosis of hypertrophic
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provisional calcification
capillary sprout invasion
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primary spongiosum
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components of the growth hormone (GH) - insulin-like growth factor (IGF) axis. These 
factors also interact with each other and are responsible for the correct regulation of 
longitudinal bone growth.  
 
Vitamin D3 
 
Vitamin D3 plays an important role in bone formation, as vitamin D3 receptor inactivation in 
mice resulted in severe impairment of bone formation and growth retardation. In these mice 
the growth plate was enlarged, due to widening of the hypertrophic zone, suggesting a role for 
vitamin D3 in the differentiation of chondrocytes 15. Vitamin D3 is thought to stimulate the 
differentiation of proliferating chondrocytes into hypertrophic chondrocytes and to inhibit the 
terminal differentiation of hypertrophic chondrocytes. Chondrocytes thus respond differently 
to vitamin D3, depending on their differentiation stage in the growth plate 16,17. 
 
Indian hedgehog - Parathyroid hormone-related peptide negative feedback-loop 
 
Parathyroid hormone-related peptide (PTHrP) is also important in the regulation of 
differentiation of chondrocytes. In PTHrP and in PTHrP/PTH-receptor knock-out mice, the 
growth plate displayed reduced chondrocyte proliferation, premature hypertrophic 
differentiation and advanced endochondral ossification, resulting in dwarfism 18-20. In 
contrast, overexpression of PTHrP in mice resulted in delayed endochondral ossification, with 
persistent chondrocyte proliferation, also resulting in dwarfism 21. These data strongly suggest 
a role for PTHrP in the transition zone between the proliferative and hypertrophic zone. In 
this transition zone, the PTHrP/PTH-receptor is indeed expressed 22,23. PTHrP expression is 
stimulated by Indian hedgehog (Ihh), a morphogen that is also a regulator of chondrocyte 
differentiation 24. Overexpression of Ihh suggested that Ihh blocks hypertrophic 
differentiation and delays or prevents endochondral ossification, mediating its effects via 
PTHrP, as reviewed by Vortkamp 25. Ihh stimulates PTHrP expression, which acts on the 
PTHrP/PTH receptor, which in turn maintains chondrocyte proliferation, inhibits hypertrophic 
differentiation and inhibits Ihh expression. In this negative feedback-loop, PTHrP and Ihh 
regulate the rate of chondrocyte proliferation and hypertrophic differentiation 23,25. 
 
Bone Morphogenetic Proteins 
 
The bone morphogenetic proteins (BMPs) are part of the TGF-β superfamily and play a major 
role in the control of chondrogenesis. They were originally identified as bone-derived factors 
able to induce formation of ectopic cartilage and bone 4. In the embryonic chick limb, BMPs 
were shown to regulate the progression of chondrocyte differentiation into the 
prehypertrophic phenotype and to be able to increase apoptosis 26. Several of the BMPs, 
BMP-2, -4, -6 and -7, and the BMP receptors are also expressed in the proliferative and 
prehypertrophic zones of the postnatal growth plate 27-30. The expression in these zones, 
suggests that the BMPs might play a similar role in the postnatal growth plate as shown in the 
embryonic growth plate. 
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Fibroblast Growth Factors  
 
The fibroblast growth factors (FGFs) consist of at least 21 members, which interact with at 
least 4 receptors (FGF-R) and play a role in endochondral ossification 31,32. Several in vivo 
data suggest that the FGF system inhibits longitudinal bone growth. In FGF-2 (bFGF) 
transgenic mice, longitudinal bone growth was decreased 33, whereas FGF-R3 knock-out mice 
displayed increased longitudinal bone growth 34,35. Activating mutations in FGF-R3 in 
humans causes the most common form of dwarfism, achondroplasia 56. The FGFs are 
suggested to act at the local level of the growth plate by decreasing chondrocyte proliferation, 
chondrocyte hypertrophy and cartilage matrix production 36. FGF-2 and FGF-R3 are also 
suggested to stimulate angiogenesis of the growth plate 9.  
 
Thyroid hormones 
 
Thyroid hormone (T3), and its precursor (T4), are essential regulators of longitudinal bone 
growth 37. In the growth plate, resting and proliferative chondrocytes express both thyroid 
hormone receptors (TR) α and β, suggesting that the resting and proliferative chondrocytes 
are the primary targets of thyroid hormone 38. Thyroid hormones are suggested to stimulate 
hypertrophic differentiation of chondrocytes. Treatment of mice with T4 indeed stimulated 
hypertrophic differentiation 39. This is confirmed in the TRα knock-out mice, which showed 
growth arrest, delayed bone formation and failure of hypertrophic chondrocyte 
differentiation40,41. The TRβ isoform can compensate for TRα in the growth plate, but is itself 
dispensable in the growth plate 37. Besides the actions of T3 on the chondrocytes itself, it is 
also required for angiogenesis 42.  
 
Sex steroids 
 
Sex steroids are crucial for the pubertal growth spurt and cessation of growth in adulthood 6. 
In a human male patient with a mutation in the estrogen receptor α (ERα), growth continued 
into adulthood, as the growth plates did not fuse and there was no evidence of a pubertal 
growth spurt 43. This discovery led to the suggestion that estrogen, and not androgen, is the 
main regulator of pubertal growth in both sexes 44. ERα knock-out mice displayed a similar 
phenotype as the human patient, whereas ERβ knock-out mice did not have this phenotype. 
This indicated that mainly ERα mediates the effects of estrogens on the growth plate 45. 
However, besides ERα, ERβ 46,47 and the androgen receptor 48,49 are also expressed in the 
growth plate. The actions of androgens in chondrocytes is still not clear, however, they may 
be involved in establishing gender differences in the skeleton 48. Besides the presence of sex 
steroid receptors in the growth plate, key enzymes involved in sex steroid synthesis are also 
expressed in the growth plate, indicating that intracrinology might be a major source of local 
steroid delivery 50. 
 
Vascular Endothelial Growth Factor 
 
One of the last stages in endochondral ossification is the invasion of the growth plate by 
bone-forming osteoblasts, which requires vascular invasion or angiogenesis. As the growth 
plate itself is avascular and resistant to angiogenesis, it has been suggested that hypertrophic 
chondrocytes express activators of angiogenesis, whereas resting and proliferative 
Chapter 1 
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chondrocytes express inhibitors of angiogenesis 6,9,51. One of the suggested angiogenic 
activators is vascular endothelial growth factor (VEGF) 6,9, which is a chemo-attractant for 
endothelial cells and one of the important growth factors for endothelial cells 52. VEGF is 
expressed by hypertrophic chondrocytes 9,53-55. Inactivation of VEGF by administration of a 
soluble receptor in mice resulted in suppression of vascular invasion, trabecular bone 
formation and an increase of the width of the hypertrophic zone, resulting in decreased 
longitudinal bone growth 53. This established a key role for VEGF in angiogenesis during 
endochondral ossification 9,53. 
 
Growth hormone - insulin-like growth factor axis 
 
Of all the growth factors, the components of the growth hormone (GH) - insulin-like growth 
factor (IGF) axis are suggested to be main regulators of postnatal longitudinal bone 
growth 57,58, which will be discussed in detail below. 
 
THE INSULIN-LIKE GROWTH FACTOR SYSTEM 
 
The insulin-like growth factors (IGFs) were originally identified as factors stimulating 
sulphation of the proteoglycan chondroitin, mediating the "sulphation factor activity" of GH. 
The IGFs are structurally homologous to proinsulin, resulting in their names 59,60. The IGFs 
are part of the IGF system, which comprises of two ligands, IGF-I and IGF-II, two 
IGF receptors, and six IGF-binding proteins, IGFBP-1 to -6.  
 The IGFs are potent mitogenic, anti-apoptotic and differentiating promoting growth factors 
and in high doses also have insulin-like metabolic actions 61. They are produced by multiple 
tissues, and can act both in an endocrine and autocrine/paracrine fashion. Their gene 
expression is tissue specific and developmentally regulated 61.  
 
GH 
 
Growth hormone (GH) has no apparent embryonic role, but is a major growth regulator of 
postnatal development 62,63. This is illustrated in GH knock-out mice, which displayed severe 
postnatal growth retardation and delayed bone development, which became apparent 2 weeks 
postnatally 63. In humans, GH deficiency and insensitivity, including GH receptor defects, 
also result in dwarfism 64-66. GH has IGF-I independent, stimulating effects on longitudinal 
bone growth 58 and in vitro on the proliferation of chondrocytes 67. Besides its IGF-I 
independent effects, many of the actions of GH are mediated by IGF-I. GH is also suggested 
to stimulate the proliferation and differentiation of chondrocytes by local IGF-I production 68.  
 
IGF-I 
 
IGF-I is expressed at low levels embryonically and is induced postnatally 69-71. Exogenously 
added IGF-I has been shown to have a stimulatory effect on longitudinal bone growth 72-74 
and to stimulate chondrocytes at all stages of differentiation 68. IGF-I is suggested to play a 
role both in embryonic and postnatal longitudinal growth, as shown in IGF-I knock-out mice. 
These mice, some of which survive into adulthood, displayed severe growth retardation and 
delayed bone development, resulting in dwarfism 75,76. The growth retardation already 
occurred during embryonic development and continued during postnatal development, as was 
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also evident in the human counterpart of the IGF-I knock-out mouse 77. In IGF-I knock-out 
mice, the decreased longitudinal bone growth was due to a reduced chondrocyte 
proliferation 58 and a decrease in linear dimension of hypertrophic chondrocytes 58,78.  
 
IGF-II 
 
In contrast to IGF-I, IGF-II is expressed at high levels embryonically, beginning at 
postimplantation stages 79,80. Its serum levels decrease postnatally in rodents, whereas levels 
remain high in humans 81. IGF-II is essential for normal embryonic development and is 
suggested not to be involved in postnatal development, as IGF-II knock-out mice were growth 
retarded at birth, but displayed a normal postnatal growth rate 82,83. However, exogenously 
added IGF-II has been shown to have a stimulatory effect on longitudinal bone growth 
postnatally 72,74. IGF-I and IGF-II both have independent and essential activities on 
longitudinal growth, as the double knock-out mice had a growth deficiency which was 
approximately the sum of the single knock-outs growth deficiency 76.  
 
The IGF receptors 
 
The actions of both IGFs are mediated by the type I IGF receptor (IGF-IR) 84. The IGF-IR is a 
tyrosine kinase receptor with high homology to the insulin receptor 85. It is a transmembrane 
glycoprotein, consisting of 2 extracellular, ligand-binding α subunits and 2 intracellular β 
subunits, containing tyrosine-kinase domains 85. The IGF-IR has a high affinity for IGF-I, a 
slightly lower affinity for IGF-II and a weak affinity for insulin, which is tissue-dependent 86. 
IGF-IR is, as IGF-I, also suggested to play a role in both embryonic and postnatal longitudinal 
growth, as shown in IGF-IR knock-out mice 75,76 
 The type II IGF receptor (IGF-IIR) is a single-chain transmembrane glycoprotein with no 
tyrosine kinase domains, also known as the cation-independent mannose-6-phosphate 
receptor 87. It binds IGF-I with a much lower affinity than IGF-II and does not bind insulin 88. 
The IGF-IIR is suggested to be important for clearance of IGF-II from the extracellular 
environment, although it may also mediate some of the actions of IGF-II 89. IGF-IIR 
knock-out mice, which generally die at birth, are larger and showed that IGF-IIR is essential 
for embryonic development and growth regulation 90. 
 
IGFBPs 
 
The IGFBPs (IGFBP-1 to -6) are crucial modulators of both IGFs and they can act as 
endocrine as well as autocrine/paracrine factors 61,91. Each of the IGFBPs is expressed in a 
tightly regulated developmental- and tissue-specific manner. The IGFBPs modulate IGF 
activity by i) acting as transport proteins of the IGFs in the circulation, ii) prolonging the half-
lives of the IGFs, iii) providing tissue-and cell-type specific localization of the IGFs and 
iv) competing for the interaction of the IGFs with their receptors 61. The IGFBPs have 
different affinities for the IGFs and can either enhance or inhibit IGF activity. Their biological 
activities depend on possible cell surface or ECM association and on posttranslational 
modifications as phosphorylation, glycosylation and proteolysis by specific IGFBP proteases, 
which alter their affinity for the IGFs 61.  
 The major pool of IGFs in the circulation is bound to the IGFBPs. IGFBP-3 is responsible 
for the majority of the IGF-binding capacity in serum. IGFBP-3 forms a 150 kDa complex 
Chapter 1 
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together with IGF and a third component, the acid-labile subunit (ALS). The role of ALS 
appears to increase the molar mass of the IGF/IGFBP-3 complex, in order to limit the access 
of circulating IGF to various tissues 91. The other IGFBPs circulate as binary complexes with 
the IGFs in serum 91.  
 Knock-out models of the different IGFBPs resulted only in small morphological 
alterations, which were suggested to be caused by functional compensation by the other 
IGFBPs 92. Therefore, to study the functions of the IGFBPs, one should use transgenic 
animals and in vitro and in vivo techniques.  
 IGFBP-1 mainly inhibits, but can also enhance, IGF actions 61, and exerts its major role in 
the female reproductive system, as shown both in vitro and in vivo and in transgenic 
animals 93. Both in vitro and in vivo studies showed that IGFBP-2 has mainly inhibitory 
effects on IGF actions 94, e.g. IGFBP-2 was shown to inhibit GH-stimulated growth in vivo 95. 
IGFBP-2 transgenic mice showed that the main target of IGFBP-2 is bone, as it is a potent 
negative regulator of bone growth and remodeling 96,97. IGFBP-3 has been shown to both 
enhance 98,99 and inhibit 100,101 IGF-dependent actions in vitro 61. IGFBP-3 administration in 
vivo showed that IGFBP-3 is a negative regulator of growth 102. In contrast, IGFBP-3 
transgenic mice showed selective organomegaly of the spleen, liver and heart 103. IGFBP-4, in 
contrast to IGFBP-1, -2, -3, and -5, only functions as an inhibitor of IGF actions, as shown by 
several in vitro studies 104-106. IGFBP-4 plays an important role in bone formation and 
resorption, as shown in vivo 107,108. As IGFBP-4, IGFBP-5 also plays an important role in 
bone 107-109. Recently, IGFBP-5 has also been identified to form a ternary complex with IGF 
and ALS in the circulation, as IGFBP-3 110. IGFBP-6 functions as an inhibitor of IGF action, 
both in vitro and in vivo 61. 
 Besides the IGF-dependent functions, more evidence is emerging that the IGFBPs also 
have direct, IGF-independent, effects on cellular functions 111. These IGF-independent 
functions involve specific receptors or binding to integrins. IGFBP-1 was shown to bind with 
its RGD sequence to α5β1 integrins (fibronectin receptor), which mediated IGFBP-1 
stimulated cell migration 112 and it was also involved in cell detachment and subsequent 
apoptosis 113. The role of the RGD sequence in IGFBP-2 has not been elucidated yet, although 
it is proposed to bind also to α5β1 integrins 114. Some of the IGF-independent actions of 
IGFBP-3 and -5 are thought to be mediated through specific signaling receptors 112. IGFBP-3 
can inhibit cell growth and it induces apoptosis, by its own presumed receptor 115. IGFBP-5 
functions as a growth factor in bone, as shown both in vitro and in vivo 116. For IGFBP-4 and 
-6 no clear IGF-independent functions have yet been described. 
 The IGFBPs thus have overlapping and unique functions, which involve cell proliferation 
and differentiation in both an IGF-dependent and -independent fashion. 
 
The somatomedin hypothesis 
 
In 1957, the "somatomedin hypothesis" was proposed to understand the regulation of somatic 
growth. It stated that pituitary-derived GH stimulated the liver production of a growth factor 
named sulphation factor, renamed as somatomedin (IGF-I), which in turn regulated 
longitudinal growth in an endocrine fashion 59 (Fig. 4A). In the mid-eighties, the original 
somatomedin hypothesis was extended with an additional direct effect of GH and IGF-I on 
the growth plate 117, resulting in "the dual effector theory" 62 (Fig. 4B). Local GH injections in 
the tibia of rats had shown that GH could also stimulate longitudinal bone growth directly 118. 
GH would stimulate resting chondrocytes and IGF-I production in the growth plate, which in 
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turn (together with the endocrine IGF-I) would stimulate the clonal expansion of proliferative 
chondrocytes. The GH receptor (GHR) is indeed expressed by chondrocytes. In neonatal 
rabbits and humans the GHR is detected in the proliferative and hypertrophic zone 119,120 and 
its expression is extended to the resting zone during postnatal development 121,122. In IGF-I 
knock-out mice, the width of the resting zone was increased, which was suggested to be 
caused by increased GH levels 78.  
 The somatomedin hypothesis has recently been adapted again, due to new evidence 
obtained from liver-specific IGF-I knock-out mice. These mice had reduced IGF-I serum 
levels (25% of normal), but showed normal growth rates 123. However, double knock-out mice 
of the liver-specific IGF-I knock-out mouse and the ALS knock-out mouse, had further 
reduced levels of circulating IGF-I and did show a decrease in longitudinal bone growth. This 
suggested that a threshold of circulating IGF-I is necessary for normal longitudinal bone 
growth 124, although autocrine/paracrine IGF-I levels are suggested to be still the major player 
in the growth plate (Fig. 4C). These data show that both endocrine as well as 
autocrine/paracrine IGF-I are important in the regulation of longitudinal bone growth.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The IGF system in the growth plate 
 
It has been suggested that IGF-I and IGF-II both have a unique and complementary role in 
stimulating longitudinal bone growth at the local level 125. They are indeed both expressed in 
the growth plate. IGF-I was detected in the proliferative zone in the growth plates of postnatal 
mice 58, whereas in rats, IGF-I was detected in proliferative and hypertrophic 
Figure 4 Evolving concepts in the somatomedin hypothesis. (A) The original somatomedin hypothesis 
proposed that GH controlled longitudinal growth in an endocrine fashion, by stimulating the liver-production of 
somatomedin (IGF-I), which in turn mediated longitudinal bone growth. (B) In the eighties, GH and IGF-I were 
also shown to have a direct effect on longitudinal bone growth, (with IGF-I also being produced locally) besides 
their endocrine effect, resulting in the dual effector theory. (C) Recently it was shown that minimal (min.) 
endocrine levels of IGF-I are required for normal longitudinal growth, although autocrine/paracrine actions of 
IGF-I still remain important (adapted from 125). 
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chondrocytes 126,127. In fetal cows 128 and sheep 129, IGF-I was also detected in proliferative 
and hypertrophic chondrocytes. Together with the decreased proliferation and hypertrophic 
differentiation in IGF-I knock-out mice 58,78, this might indicate that IGF-I both stimulates 
proliferation and differentiation of chondrocytes. The IGF-IR is expressed in all zones of the 
growth plate 68,128. Expression of IGF-II was primarily shown in the proliferative zone in both 
fetal and postnatal animals 128-131. Although postnatally, endocrine IGF-II levels are low in 
rodents, IGF-II is expressed in growth plate chondrocytes 130,131, indicating a possible role for 
IGF-II in postnatal growth.  
 The IGFBPs are also present in growth plate chondrocytes. In fetal cows, IGFBP-3, -4 and 
-5 were predominantly expressed by proliferative chondrocytes, whereas IGFBP-2 was 
equally expressed in all zones 128. In fetal sheep, IGFBP-2 to -5 were detected in the reserve 
and proliferative zone and little in the hypertrophic zone 129. IGFBP-1 was not detected in the 
growth plate and only low levels of IGFBP-6 129. In vivo studies on murine growth plates only 
showed expression of IGFBP-5 and -6, which rapidly declined with age. Only low levels of 
IGFBP-6 were still detectable postnatally 130. Several factors, including IGF-I and IGF-II, 
modulate the expression of IGFBPs by chondrocytes in vitro 132,133. This suggests that the 
IGFBPs are also involved in the local regulation of longitudinal bone growth. 
 
GLUCOCORTICOIDS 
 
Glucocorticoids (GCs) are steroid hormones secreted from the adrenal glands in response to 
various stimuli and they are implicated in carbohydrate and protein metabolism. GCs diffuse 
across cell membranes and bind to the intracellular GC receptor (GR), which mediates their 
actions 1. 
 
GC action 
 
In the cytoplasm, the GR forms a heterocomplex with several chaperone proteins as hsp90 
and immunophilins 134. Upon binding with GCs, the chaperone proteins release from the GR 
and a nuclear localization signal and a DNA-binding domain are exposed. The GR-GC 
complex translocates to the nucleus 135, where it forms homodimers. Subsequently, the 
homodimers bind to specific consensus DNA sequences, the Glucocorticoid Response 
Elements (GREs), and activate gene expression 135.  
 Besides the activation of genes, GCs are also known to be involved in the transcriptional 
repression of genes. GC-induced repression of genes is not mediated via GREs, but is 
suggested to involve several other mechanisms, as transcriptional interference via interactions 
with other transcription factors as AP-1 and NF-κB or involvement of other DNA binding 
sites 136. Inhibition of gene transcription by GCs does not require homodimerization of the 
GR 136. Knock-out mice in which the GR cannot form homodimers and thus cannot activate 
but only repress genes, survive 137, whereas GR knock-out mice, in which both repression and 
activation is abolished, are not viable 138. This indicates the importance of negative gene 
regulation by GCs 137,139. Besides these genomic actions of GCs, they are also known to 
display rapid non-genomic actions, which are suggested to be mediated via GC-membrane 
associated receptors 140. 
  General introduction 
 19
Use of GCs 
 
Due to the potent and multiple inhibitory effects of GCs on the immune system, including 
lymphoid tissues as thymus and spleen, they are widely used as anti-inflammatory and 
immunosuppressive drugs in all kinds of diseases 1. They are very effective to treat diseases 
like asthma, rheumatoid arthritis, chronic inflammatory or autoimmune diseases, as well as 
after organ transplantations.  
 For these applications in the clinic, synthetic GCs as prednisolone, dexamethasone and 
others are commonly used. These synthetic GCs have a greater GC activity than the naturally 
occurring cortisol, making them more suitable for clinical applications 1. However, the use of 
GCs may result in several severe side-effects. Among these side-effects are suppression of the 
Hypothalamus-Pituitary-Adrenal (HPA) axis, skin thinning, metabolic changes, osteoporosis 
and growth retardation 141. Growth retardation caused by GC treatment in children is 
becoming a greater problem, as the use of GCs in the treatment of mild-to-moderate asthma 
expands 142.  
 
GC-induced growth retardation 
 
GCs have been shown to induce not only growth retardation in man, but also in several 
experimental animal models, such as mice 143,144, rats 145, chickens 146, rabbits 147 and 
piglets 148,149, creating the possibility to study the effects of GCs in detail. 
 GCs are shown to act locally to inhibit growth, suggesting a mechanism intrinsic to the 
growth plate 150,151. Local GC infusion in rabbits only decreased tibial length of the treated 
tibia, whereas the contralateral vehicle-treated tibia was not affected 150. The GR has indeed 
been shown to be present in the growth plate, in the proliferative and hypertrophic zones 152, 
as well as in the resting zone 153,154, indicating that the chondrocytes of the different zones are 
GC target cells.  
 Several in vitro studies on growth plate chondrocytes have shown the susceptibility of 
proliferative chondrocytes to GCs 155,156. GC treatment decreased chondrocyte proliferation, 
due to an increase in cell doubling times with a reduced number of S phase cells 157. In vivo 
studies also showed effects of GCs on total growth plate width 144,151,158 and on the different 
zones of the growth plate. GCs are suggested to inhibit the growth of resting chondrocytes, 
which would result in fewer proliferative chondrocytes 159. They also decrease the 
proliferation of chondrocytes in the proliferative zone 158,160 and increase the number of 
apoptotic chondrocytes in the hypertrophic zone 151,160. In addition, angiogenesis activity, 
which is closely linked to apoptosis, is also suggested to be diminished by GCs 160. 
Furthermore, they also affect the cartilaginous ECM, by inhibiting ECM production 158 and 
mineralization 161, which is confirmed in a recent in vitro study 153. GCs thus disturb 
endochondral ossification at several stages, such as proliferation, apoptosis and angiogenesis, 
resulting in inhibition of longitudinal bone growth. 
 
Catch-up growth 
 
It is well established that growth retardation, caused by different diseases, malnutrition or GC 
treatment, could be of a temporary state. When the cause of the growth retardation is restored 
or removed, catch-up growth can occur; a phase of accelerated linear growth toward the 
"original" growth curve 162.  
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 Catch-up growth after GC treatment is suggested to be a mechanism intrinsic to the growth 
plate 163. Recent experiments showed that GCs inhibit proliferation of chondrocytes, but 
conserved their proliferative potential. The normal senescence of the growth plate is 
suggested to depend on the cumulative number of divisions chondrocytes have undergone 164. 
Inhibition of proliferation by GCs would slow senescence and after GC treatment is 
terminated, the affected growth plate would be less senescent, resulting in catch-up growth. In 
recent experiments, accelerated senescence, caused by estrogen treatment, indeed showed 
exhaustion of proliferative potential of chondrocytes and consequently earlier fusion of the 
growth plates in rabbits 165.  
 Nevertheless, it should be borne in mind that catch-up growth is often not complete, 
depending on severity and duration of the GC therapy, but also on the age at onset of the 
treatment and at the termination of the treatment 142,159. If children are treated for prolonged 
periods with GCs, permanent growth retardation is inevitable 142. 
 
Glucocorticoids and the IGF system 
 
For several years already, the adverse effects of GCs on growth have been suggested to 
involve impaired action of the GH-IGF system 155,166,167. The IGFs have also been suggested 
to be able to counteract the adverse effects of GCs. This was shown in vivo for GH 168, 
in vitro for IGF-I 155 and for IGF-II in human IGF-II transgenic mice, which showed partial 
protection of the skeleton against the adverse effects of GCs 143.  
 Several studies, however, showed conflicting data concerning effects of GCs on serum 
levels of the IGFs and IGFBPs. GCs have been reported to alter the pulsatile secretion of 
GH 142,169, although no effects on GH have also been reported 155,170. IGF-I plasma levels can 
be normal, decreased or increased during GC treatment 142, in both humans 169-171, as well as 
in experimental animal models 143,146,172. However, serum IGF bioactivity has been shown to 
be decreased by GCs 167,173, this could be due to changes in levels of inhibitors of IGF action, 
the IGFBPs 174,175. Analyses of GC effects on IGFBP serum levels, however, also showed 
conflicting data 169,171,175-177. Serum levels of the IGF system therefore provide limited insight 
into the mechanism of GC-induced growth retardation and the possible involvement of the 
IGF system 177.  
 Because GC-induced growth retardation has been shown to occur at the local level of the 
growth plate 150,151, the effects of GCs on the IGF system in the growth plate appear to be 
much more important than the effects on serum levels 155,167, although no conclusive studies 
are yet performed. Several in vitro studies have indicated that GCs indeed regulate 
components of the IGF system in chondrocytes. In cultured rat growth plate chondrocytes, 
GCs suppressed GH-induced IGF-I and IGF-IR expression, although basal IGF-IR expression 
was not affected 156. In rabbit costal chondrocytes, IGFBP-5 levels were inhibited and 
IGFBP-3 levels were increased upon GC treatment 133, whereas in fetal ovine growth plate 
chondrocytes, IGFBP-2 and -5 levels were inhibited by GCs 132.  
 No in vivo data, however, are available concerning the possible involvement of the local 
IGF system in the growth plate in GC-induced growth retardation. Besides this deficit in 
studies on GC-induced growth retardation and the local IGF system, the data available of 
in vitro studies on epiphyseal chondrocytes are scattered. Some have studied the IGFBPs, 
others only IGF-I. Also, IGF-II has been left out as a possible player in GC-induced growth 
retardation. Therefore, as a first step to unravel the involvement of the IGF system in 
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GC-induced growth retardation, one should study the effects of GCs on the IGF system at the 
local level of the growth plate, both in vitro and in vivo. 
 
OUTLINE OF THIS THESIS 
 
Several studies indicate a possible involvement of the components of the IGF axis in 
GC-induced growth retardation. However, effects of GCs on the endocrine IGF system have 
been shown to provide little information on the mechanism of GC-induced growth 
retardation. Furthermore, GCs are known to act locally at the level of the growth plate. 
Although a few in vitro studies in chondrocytes on the effects of GCs on the IGF system exist, 
these are incomplete and the involvement of the IGF system in GC-induced growth 
retardation still remains elusive. We aimed to elucidate the role of the IGF system in GC-
induced growth retardation at the local level of the growth plate, using different experimental 
animal models. 
 We first studied in chapter 2 the role of IGFBPs in the regulation of growth, in lymphoid 
tissues of hIGF-II transgenic mice, using non-radioactive in situ hybridization. In chapter 3, 
we investigated the in vivo effects of a long-term GC treatment of 4 weeks in 3-week-old 
mice, on the expression of the IGF system in the growth plates. To further elucidate a possible 
protective role of IGF-II against GC-induced growth retardation, we also performed in 
parallel a study using human IGF-II transgenic mice. We extended this study in chapter 4, 
where we performed a short-term GC treatment of 1 week in 3-week-old mice and analyzed 
the effects on general growth as well as on the growth plate and the effects on expression of 
the IGF system. In chapter 5, we used prepubertal (6-week-old) piglets to study the short-
term effects of GC treatment on the growth plate, apoptosis and angiogenesis. To study the 
effects of GCs on angiogenesis in more detail, we studied in chapter 6 the effects of GCs on 
VEGF, an important regulator of angiogenesis, in growth plate chondrocytes in vitro, derived 
from neonatal piglets. In chapter 7, we returned to the IGF system and studied the effects of 
GCs on proliferation and the IGF system in the same chondrocytes as used in chapter 6. In an 
addendum of chapter 7, we performed a preliminary study on the regulation of IGFBP-2 by 
GCs at the transcriptional level. In chapter 8, the possible involvement of the IGF system in 
GC-induced growth retardation at the local level of the growth plate is discussed, using the 
results described in chapters 2 to 7. 
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ABSTRACT 
 
Overexpression of human insulin-like growth factor II (IGF-II) in transgenic mice does 
not result in increased overall body growth. The IGF-II overexpression, however, 
specifically causes growth of the thymus and not of the spleen. We address the question 
whether the observed differences in growth induction in lymphoid tissues by IGF-II can 
be related to differences in local IGF-binding protein (IGFBP) production, using non-
radioactive in situ hybridization and Northern blot analysis.  
 IGFBP-2, -4 and -5 are expressed in both lymphoid tissues of normal mice. The 
spleen additionally expressed IGFBP-3 and IGFBP-6. IGFBP-1 expression was not 
detected. Although the expression pattern of the IGFBPs did not change upon IGF-II 
overexpression, the level of expression changed in a specific manner for each IGFBP. In 
both the thymus and the spleen of transgenic mice, IGFBP-2 and -5 gene expression was 
slightly increased, whereas the level of IGFBP-4 expression was not altered. In the 
spleen, IGFBP-6 expression was not altered by IGF-II overexpression, whereas IGFBP-3 
expression was strongly increased.  
 The differences in IGFBP expression, and the difference in response of these IGFBPs 
to IGF-II overexpression in thymus and spleen suggests an important role for these 
proteins in growth regulation of both lymphoid tissues. We speculate that an increase of 
IGFBP-3 expression together with changes in expression of other IGFBPs, inhibits 
IGF-II stimulated growth in the spleen by an autocrine/paracrine pathway.  
 
 
INTRODUCTION 
 
The insulin-like growth factors (IGF-I and -II) are potent mitogenic and differentiation 
promoting growth factors 1. Furthermore, the IGFs can inhibit cell death, induce 
differentiation and stimulate differentiated functions in several cell types 2. The IGFs play an 
important role in pre- and postnatal growth. In rodents, IGF-I is presumed to be important in 
pre- and postnatal growth, whereas IGF-II only seems to be important in prenatal growth 3,4. 
 IGFs are produced in multiple tissues and can act both in an endocrine and 
autocrine/paracrine fashion. The activity of IGFs is regulated at various levels, resulting in a 
complex regulation of IGF bioactivity 2,5. Their intracellular effects are mediated 
predominantly via the type I IGF receptor 6. 
 IGFs are present in the circulation and throughout the extracellular space bound to 
members of high affinity IGF binding proteins (IGFBPs). The availability of the IGFs for 
their receptor is modulated by these IGFBPs, of which six are cloned and characterized 7,8. 
IGFBP genes are widely expressed in the developing tissues of rodents 9, sheep 10 and 
humans 11. The IGFBPs act mainly as autocrine and/or paracrine factors at or close to their 
sites of synthesis 2. The individual IGFBPs differ in their tissue distribution and may either 
inhibit or potentiate IGF activity. Furthermore, they differ in their IGF-binding capacity 2,12. 
IGFBP-3 is the major serum carrier of IGFs, in a complex with an acid-labile subunit 
(ALS) 13. 
 Transgenic mice with recombinant human IGF-II under the control of the H-2Kb promoter 
show increased IGF-II serum levels, whereas overall body growth is not affected 14. The 
hIGF-II transgene is highly expressed in the two lymphoid tissues, the thymus and the spleen, 
causing thymic but no splenic growth 14-16.  
Chapter 2 
  32  
 Because there are indications that the IGFBPs regulate actions of locally produced IGFs in 
lymphoid tissues 5,17, we studied the IGFBP expression in the spleen and the thymus of 
normal and the hIGF-II transgenic mice in situ. The observed differences in IGFBP 
expression and the difference in response to IGF-II overexpression suggest an important role 
for the IGFBPs in growth regulation. The IGFBP-3 gene, expressed in the spleen only, is most 
susceptible to IGF-II overexpression. We speculate that IGFBP-3 plays a prominent paracrine 
role with respect to the inhibition of the hIGF-II transgene bioactivity in the spleen, by either 
an IGF-dependent or IGF-independent mechanism.  
 
MATERIALS AND METHODS 
 
Materials 
All restriction enzymes and modifying enzymes were purchased from Roche Molecular Biochemicals 
(Mannheim, Germany), as well as the digoxigenin-UTP, anti-digoxigenin Fab-fragments, nitro blue tetrazolium, 
5-bromo-4-chloro-3-indolyl-phosphatase, blocking reagent, the Tripure isolation reagent and the Agarose Gel 
DNA extraction kit. Nylon membranes were purchased from QIAGEN (Westburg, The Netherlands). 
[α32P]dCTP (10 mCi/ml) and the RediPrime Random Primer labeling mixture were obtained from Amersham 
(Buckinghamshire, UK). Polyvinyl alcohol was obtained from Aldrich (Milwaukee, MI). Euparal mounting 
medium was purchased from Klinipath (Duiven, The Netherlands). 
 Mouse IGFBP-1 to -6 complementary DNAs (cDNAs) were kindly provided by Prof. Dr. S. L. S. Drop and 
Dr. J.W. van Neck (Department of Pediatrics, subdivision of Pediatric Endocrinology, Rotterdam, The 
Netherlands). GAPDH cDNA was kindly provided by Dr. H. van Teeffelen (Department of Physiological 
Chemistry, Utrecht, The Netherlands). 
 
Mice and tissue preparation 
hIGF-II transgenic mice were generated by introduction of a human IGF-II gene into FVB/N control mice as 
described in detail by Van Buul-Offers and colleagues 14. Throughout the study, the line designated 5'-74 (TgII), 
was used for our experiments. As controls, normal FVB/N mice were used. The animals were kept under 
standardized laboratory conditions. The mice were killed by decapitation after ether anaesthesia at the age of 
4 weeks. Thymus and spleen were dissected, frozen in liquid nitrogen and stored at -80°C. The protocol received 
approval of the committee for Animal Experiments of the Medical Faculty, University of Utrecht. 
 
Probes 
Digoxigenin-labeled complementary RNA (cRNA) probes 
Standard RNA synthesis reactions using T7- or T3-RNA polymerase were carried out using digoxigenin-UTP as 
substrate 18. cDNAs encoding human IGF-II 19 and mouse IGFBP-1, -2, -3, -4, -5 and -6 cDNAs, corresponding 
to amino acid position 100-133, 98-258, 137-204, 131-205, 88-182, 83-140 respectively 9, were used as 
templates for the synthesis of antisense and/or sense digoxigenin-labeled RNA probes.  
[α 32P]dCTP-labeled cDNA probes 
Twenty nanograms of gel-purified inserts of plasmids containing mouse IGFBP-2, -3 and -5 cDNA, were 
radiolabeled with 50 µCi [α32P]dCTP, using random primed DNA labeling as described by the manufacturer. 
 
In situ hybridization 
Tissues used for in situ hybridization were fixed for 18 hours in 4% (wt/vol) paraformaldehyde at 4°C, washed 
in PBS, dehydrated through a series of ethanol and embedded in paraffin.  
 Paraffin tissue sections (10 µm) were dewaxed, hydrated, rinsed in PBS and treated with proteinase K 
(0.07 units/ml) for 30 minutes at 37°C and subjected to an acetylation treatment 20. Sections were rinsed in 
2xSSC and kept in this solution until the start of the hybridization. Hybridization was performed in a solution 
containing 50% formamide, 2xSSC, 1x Denhardt's solution, 1 µg/µl yeast RNA and 10% dextran-sulphate and 
the digoxigenin labeled cRNA probe at a concentration of 500-1500 pg/µl. Sections were hybridized overnight 
at 53°C. After hybridization, sections were washed with 50% formamide in 2xSSC at 53°C for 30 minutes and 
treated with RNase A (1 unit/ml) for 30 minutes at 37°C. Subsequently, sections were rinsed in 2xSSC, treated 
with 10% lamb serum for 30 minutes and incubated with sheep antidigoxigenin Fab-fragments coupled to 
alkaline phosphatase (1:500) for 2 h at room temperature.  
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 Chromogenesis was performed with 0.38 mg/ml nitroblue tetrazolium and 0.19 mg/ml 5-bromo-4-chloro-3-
indolyl-phosphatase in the presence of 6% (wt/vol) polyvinylalcohol 21, resulting in a blue precipitate. Sections 
were counterstained with nuclear fast red, dehydrated through a series of ethanol and mounted with Euparal. 
 Three to four different animals of each strain were used per analyzed IGFBP messenger RNA (mRNA) and 
for each probe, the in situ hybridization was repeated 5 to 6 times.  
 
Northern blot analysis 
RNA extraction 
Total RNA was extracted from frozen spleen and thymus from 4-week-old normal (FVB/N) and hIGF-II 
transgenic mice, using Tripure solution reagent according to the procedures of the manufacturer, based on the 
single step acid guanidinium thiocyanate method 22 . 
Northern blot analysis 
Twenty micrograms of total RNA was separated by electrophoresis in a 1% (wt/vol) agarose/2.2M formaldehyde 
gel in 1x 3-(morpholino) propanesulphonic acid (MOPS) buffer and transferred to a 0.2 µm nylon membrane and 
crosslinked by UV radiation (1200 µJ). 
 The membranes were prehybridized for 2 hours at 60°C in a solution containing 0.1% SDS, 3xSSC, 
5xDenhardt's solution, 10% dextran-sulphate and 50 µg/ml denaturated salmon sperm DNA. Hybridization was 
performed at 60°C overnight in the same solution, containing the [α32P]dCTP-labeled probe. 
 Following hybridization, the membranes were washed to a stringency of  0.2xSSC, 0.1% (wt/vol) SDS. 
Membranes were analyzed using the GS-363 Molecular Imager (Biorad, Hercules, CA) and subsequently 
quantified using the Molecular Analyst software program, version 1.4 (Biorad). The signals were also visualized 
by autoradiography on Fuji RX X-ray film. 
 Tissues of at least three different animals of each strain were analyzed. 
 
Statistical analysis 
Data of the Northern blot analyses were analyzed with Student's two-tailed test. A P value of less than 0.05 was 
considered statistically significant.   
 
RESULTS 
 
IGFBP expression patterns and changes therein upon IGF-II overexpression 
Thymus 
Representative thymus sections of 4-week-old normal and hIGF-II transgenic mice, analyzed 
with in situ hybridization using specific IGFBP probes, are shown in Fig. 1. 
 Control in situ hybridizations of thymus sections of transgenic mice with non-radioactive 
human IGF-II RNA probe showed very strong staining in the medulla and in a small number 
of cells in the cortex (Fig. 1B), whereas hardly any IGF-II transcripts could be detected in the 
thymus of FVB/N non-transgenic mice (Fig. 1A). As a control for specific hybridization, 
sections were hybridized with the corresponding sense RNA probes, which showed no signals 
(see e.g., Fig. 1C). In the thymus of normal mice no expression of IGFBP-1, -3, and -6 could 
be detected (Fig. 1, D-F). IGFBP-2, -4 and -5 transcripts were present, each showing a unique 
expression pattern (Fig. 1, G-J). Transcripts of IGFBP-2 were present in groups of cells, 
mainly at the boundary of the medulla and the cortex and, at a low level, in the medulla 
(Fig. 1G). IGFBP-4 was exclusively detected  in the medulla (Fig. 1H). A similar expression 
pattern was seen for IGFBP-5 (Fig. 1J); however the number of cells expressing IGFBP-5 was 
lower than for IGFBP-4. IGFBP-4 and -5 transcripts were detected in single positive cells and 
not in groups of positive cells as seen for IGFBP-2. 
 To study the influence of IGF-II overexpression on IGFBP expression, thymus sections of 
4-week-old hIGF-II transgenic mice were analyzed with in situ hybridization (Fig. 1, K-M). 
No expression of IGFBP-1, -3, or -6 could be detected (data not shown). The expression 
patterns of IGFBP-2, -4 and -5 in the transgenic thymus was similar to that found in the 
thymus of normal mice (Fig. 1, K-M). However, the level of expression was slightly increased 
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for IGFBP-2, (Fig. 1, G and K), and to a higher extent for IGFBP-5 (Fig 1, J and M). 
IGFBP-4 transcripts were present at the same level as in normal mice. Although the shown 
data suggests a lower level of IGFBP-4 mRNA in the transgenic thymus (Fig. 1L), most of the 
performed experiments showed no difference in levels of expression. However, the picture 
shown was chosen to illustrate the expression pattern. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Spleen  
Representative spleen sections of 4-week-old normal and hIGF-II transgenic mice, analyzed 
using in situ hybridization with specific mouse IGFBP probes are shown in Fig. 2.  
 Control in situ hybridizations of spleen sections of the transgenic mice with non-
radioactive hIGF-II RNA probe showed high IGF-II transgene expression in the white pulp 
and a few positively stained cells in the red pulp and/or marginal zone (Fig. 2B). Spleen 
sections of the non-transgenic FVB/N control mice showed a very weak IGF-II expression in 
Figure 1 IGFBP expression in the thymus. Expression patterns of IGF-II and IGFBP-1 to -6 mRNA in 
representative sections of the thymus of 4-week-old normal (FVB/N) (A; D-J) and hIGF-II transgenic (B; K-M) 
mice, as analyzed by in situ hybridization, under brightfield illumination. (C) A representative section of the 
transgenic thymus hybridized with an IGF-II sense RNA probe (IGF-IIs). Sections were hybridized with 
antisense digoxigenin-labeled cRNA probes, specific for human IGF-II and mouse IGFBP-1 to -6 as indicated. 
All sections were counterstained with nuclear fast red. The mRNA signal is shown as a blue precipitate under 
brightfield illumination. The signal of IGFBP-2 mRNA (G and K) is shown as a dark brownish precipitate, due to 
the used mounting medium. M, medulla; C, cortex. Magnification, 100 times. The black bar in the right conner 
refers to the actual size of 100 µm. 
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the red pulp (Fig. 2A). In the spleen of normal mice, no IGFBP-1 gene expression could be 
detected (data not shown). IGFBP-2, -3, -4, -5 and -6 mRNAs were present, each showing a 
unique expression pattern (Fig. 2, C, D, G-J). Control sections hybridized with the appropriate 
sense probes exhibited no signal (data not shown). 
 IGFBP-2 is expressed at a high level in groups of cells in the red pulp (RP) and at a very 
low level in the white pulp (WP) (Fig. 2C). IGFBP-3 transcripts were detected, at a low level, 
in the inner lining of the marginal zone (MZ) and in some cells in the white pulp, whereas no 
IGFBP-3 transcripts could be detected in the red pulp (Fig. 2D). IGFBP-4 transcripts were 
detected all through in the white pulp only (Fig. 2G).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IGFBP-5 transcripts were detected in the white pulp in sparsely scattered cells and in cells 
concentrated around the veins. IGFBP-5 expression was also detected at a low level at the 
exterior part of the red pulp (Fig. 2H). At the exterior part of  the red pulp, also a considerable 
amount of IGFBP-6 transcripts were detected, whereas lower amounts were detected in the 
other parts of the red pulp and in the white pulp (Fig. 2J). 
Figure 2  IGFBP expression in the spleen. Expression and localization of IGF-II and IGFBP-2 to -6 mRNA in 
representative sections of the spleen of 4-week-old normal mice (A; C-D; G-J) and hIGF-II transgenic mice (B; 
E-F; K-M) by in situ hybridization, under brightfield illumination. Sections were hybridized with antisense 
digoxigenin-labeled cRNA probes, specific for human IGF-II and mouse IGFBP-1 to -6 as indicated. Sections 
were further treated as described in Fig. 1. WP, white pulp; RP, red pulp; MZ, marginal zone. Magnification: 
100 times. The black bar in the right conner refers to the actual size of 100 µm. 
MZ 
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 To study the influence of IGF-II overexpression on IGFBP expression, spleen sections of 
4-week-old hIGF-II transgenic mice were analyzed using in situ hybridization (Fig. 2, E, F, 
K-M). No expression of IGFBP-1 could be detected in the transgenic spleen (data not shown). 
Although the level of expression of some IGFBPs changed upon IGF-II overexpression, the 
pattern of expression remained the same, as was observed in the thymus. IGFBP-4 and -6 
transcripts were detected at the same level as in normal mice (cf. Fig. 2, G and K and 
cf. Fig. 2, J and M, respectively). On the contrary, the level of expression of IGFBP-2, -3 and 
-5 was increased as compared to the expression level in the normal spleen.The expression of 
IGFBP-2 was slightly increased in the white pulp, whereas the level of expression  in the red 
pulp was not altered (cf. Fig. 2, C and E). The expression of IGFBP-5, detected in the red pulp 
at the edge of the section and in the white pulp, showed an increase in level of expression 
(Fig. 2, H and L). IGFBP-3 expression in the marginal zone and the white pulp was strongly 
increased (Fig 2, D and F). 
 
Quantification of changes in IGFBP-3 expression 
To quantify the changes in IGFBP-3 expression upon IGF-II overexpression, Northern blot 
analysis was performed. Total RNA was extracted from the spleen and the thymus of 4-week-
old normal and hIGF-II transgenic mice and subsequently hybridized with a mouse IGFBP-3 
[α32P]dCTP-labeled cDNA probe, a representative experiment is shown in Fig. 3A. This 
revealed a transcript of 2.6 kb (Fig. 3A), corresponding to an IGFBP-3 transcript length as 
described previously 23. This transcript was only present in the spleen of normal and hIGF-II 
transgenic mice (Fig. 3A, lanes 4 and 1, respectively) and not in the thymus of either mice 
strain (Fig. 3A, lanes 2 and 3, respectively). Quantification of the detected IGFBP-3 
transcripts in the normal spleen (n=3) and hIGF-II transgenic spleen (n=5), after 
normalization with the GAPDH mRNA signal, showed a statistically significant increase in 
level of expression in the transgenic spleen of 1.75 ± 0.11-fold (P<0.01) (Fig. 3B).  
 
 An increase in expression of IGFBP-2 and -5 in the thymus and spleen of hIGF-II 
transgenic mice is shown using in situ hybridization, although not as strong as seen for 
IGFBP-3 in the spleen. Quantification of IGFBP-2 and -5 expression using Northern blot 
analysis showed the presence of IGFBP-2 and -5 mRNA in the spleen and the thymus of 
normal and hIGF-II transgenic mice, however, no statistically significant differences were 
detected (data not shown). 
Figure 3 Quantitative analysis of changes in IGFBP-3 expression. Total RNA 
extracted from the spleen and the thymus of 4-week-old normal and hIGF-II 
transgenic mice was analyzed using Northern blot analysis. The membrane was 
hybridized with a cDNA probe specific for mouse IGFBP-3. The filter was 
subsequently hybridized with a GAPDH probe as a control for the amount of 
transferred RNA in each sample. Representative Northern blot data are shown in 
panel A. (A) The RNA in lanes 1 and 4 were derived from the spleen; in lanes 2 
and 3 from the thymus. The RNAs in the lanes 2 and 4 were derived from normal 
mice; in lanes 1 and 3 from hIGF-II transgenic mice. (B) Data obtained from 
Northern blots of the spleen, which have been quantified by densitometry. The 
open bar represents IGFBP-3 mRNA levels of the spleen of normal mice (FVB/N) 
and the cross-hatched bar of hIGF-II transgenic mice (Tg-II). The data are 
expressed as a percentage of the IGFBP-3 mRNA level detected in the spleen of 
normal mice, which has been attributed a value of 100%. Means ± S.E.M. are 
given. The numbers of animals is FVB/N: 3; Tg-II: 5. **P<0.01 compared with the 
mean normal spleen value. 
 
  IGFBP expression in lymphoid tissues 
 37
DISCUSSION 
 
Besides the endocrine actions of  IGFs, these hormone peptides can exert actions locally in a 
variety of tissues and cell types. Tissue-specific regulation of the IGF-bioactivity may be 
accomplished by the presence of IGFBPs, which are differentially expressed in various 
tissues 2. The relative concentration of each IGFBP changes, depending on the physiological 
and pathological environment 12,24. In hIGF-II transgenic mice, both the spleen and the 
thymus express the hIGF-II gene at a high level 14,16, which might therefore induce a change 
in local IGFBP expression. Furthermore, it was shown that both IGF receptors are present in 
both organs, enabling IGF-II bioactivity 16. However, the thymus displayed growth in 
response to this IGF-II overexpression, whereas the size of the spleen was unaffected, 
although both organs displayed an increase in CD4+ T cells 15. 
 To answer the question whether the difference in response to IGF-II overexpression was 
related to differences in IGFBP expression, we studied the expression of the six IGFBP genes 
in both lymphoid tissues of  normal and hIGF-II transgenic mice . 
 
Normal IGFBP expression patterns in lymphoid organs 
Each IGFBP gene has a specific, unique expression pattern in both lymphoid tissues, as 
shown in this study using non-radioactive in situ hybridization analysis. In both lymphoid 
tissues, IGFBP-2, -4 and -5 transcripts were detected. In addition to these genes, the spleen 
expressed the IGFBP-3 and -6 gene. IGFBP-4 and -5 displayed a similar expression pattern, 
in both tissues. On the contrary, IGFBP-2 transcripts showed a different localization, and 
were mainly present in the red pulp of the spleen and at the boundary of the medulla/cortex in 
the thymus. IGFBP-6 transcripts were mainly detected in the red pulp of the spleen and at a 
low concentration in the white pulp, colocalizing with IGFBP-2, -4 and -5 transcripts. 
IGFBP-3 transcripts showed a completely different localization, and were present mainly in 
the marginal zone. Colocalization and differences in localization of certain IGFBPs was 
previously shown at the tissue level in human fetus, mouse kidney and mouse skeleton 11,25,26. 
In both the spleen and the thymus, the IGFBP transcripts are detected in mature lymphocytes, 
based on the localization and morphology of the positively stained cells. IGFBP-3 transcripts, 
however, are predominantly present in the  macrophages of the marginal zone, based on 
staining results with an antibody specific for the detection of macrophages (MOMA) present 
in the marginal zone (Koster, personal communication), although a low expression in 
lymphocytes in the white pulp is also shown. 
 The observed differences in IGFBP expression in the spleen and the thymus of normal 
mice suggest a putative difference in mediating local IGF activity in these tissues. 
 
IGF-II induced changes in  IGFBP expression 
Previous findings in the literature already suggested a direct relationship between IGFs and 
IGFBPs at the serum level 27-30, especially of IGF-II on IGFBP-3 in Pit-1 deficient Snell 
dwarf mice 30. In this study a direct relationship between IGF-II and a number of IGFBPs is 
shown at tissue level, varying in different tissues. In spleen and thymus, IGFBP-2 and -5 
mRNA are positively correlated with IGF-II mRNA, as previously shown also at the protein 
level for IGFBP-2 in serum of PEPCK-IGF-II transgenic mice 27 and for IGFBP-5 in human 
serum 28. IGFBP-4 mRNA does not seem to be correlated with IGF-II mRNA levels, in 
accordance with data concerning the protein in human serum 29. IGFBP-6 expression, only 
present in the spleen, seems also not to be correlated with levels of IGF-II mRNA, as shown 
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here in this study. The IGF-II-induced changes in IGFBP expression are summarized in 
Table 1. 
 
Table 1 IGF-II-induced changes 
 
mRNA Tissue Growth 
IGF-II IGFBP-2 IGFBP-3 IGFBP-5 
Thymus + ⇑⇑⇑⇑ ↑ - ⇑ 
Spleen - ⇑⇑⇑⇑ ↑ ⇑⇑ ⇑ 
 
 
 
 
 
 Previous studies in IGF-I transgenic mice have shown an in vivo temporally and spatially 
relationship between IGF-I mRNA and IGFBP-5 mRNA, in the brain 31. This previous study 
with IGF-I transgenic mice and our study with IGF-II transgenic mice, indicate the possibility 
of tissue-specific direct regulation of the expression of IGFBPs by their ligands, the IGFs. 
 In the spleen, the IGFBP-3 gene seems to be most susceptible to IGF-II overexpression, 
which is confirmed by Northern blot analysis. hIGF-II transgenic Snell dwarf mice also show 
an increase in IGFBP-3 mRNA in the spleen and an increase in IGFBP-3 serum levels, as 
compared to normal Snell dwarf mice 14 (unpublished results). In these hIGF-II transgenic 
Snell dwarf mice no IGF-I is present 14,24. Furthermore, IGF-I serum levels are not elevated in 
normal hIGF-II transgenic mice 14, indicating that the increase of IGFBP-3 in hIGF-II 
transgenic normal and Snell dwarf mice cannot be caused by IGF-I. In addition, IGF-II 
treatment of dwarf mice results in a pronounced increase of IGFBP-3 in serum 30. 
 
Role of IGFBP-3 in growth regulation 
As discussed above, the main difference between the spleen and the thymus in terms of 
regulation of IGFBP expression by IGF-II is the considerable increase in IGFBP-3 expression 
in the macrophages of the marginal zone of the spleen. The number of these macrophages in 
the marginal zone is not increased in the spleen of hIGF-II transgenic mice, indicating that the 
increase in IGFBP-3 expression is due to constitutive IGF-II expression and not due to 
changes in morphology of the marginal zone. The presence and upregulation of IGFBP-3 is 
independent of GH and/or IGF-I, since similar results were obtained in hIGF-II transgenic 
Snell dwarf mice (unpublished results). The IGF-II-induced increase in IGFBP-3 expression 
can have effects on several mechanisms involving growth regulation. First, it has been 
demonstrated in vitro 32-35 and in vivo 36, that IGFBP-3 can act as a negative growth regulator 
of cell proliferation by sequestering the IGF-II. Thus, the spleen-specific enhanced IGFBP-3 
expression might inhibit the growth-inducing effect of the IGF-II transgene in the spleen by 
sequestering IGF-II and thereby diminishing the IGF-II bioactivity. Observations in IGFBP-3 
transgenic mice 37 seem to contradict this speculation, as in these mice an increase of 
IGFBP-3 serum levels results in growth of the spleen. However, no IGFBP-3 mRNA could be 
detected in the spleen of these mice, excluding high levels of IGFBP-3 in the spleen. 
Furthermore, the enhanced IGFBP-3 serum levels were of the binary complex. As this 
IGF-IGFBP-3 complex can cross the capillary endothelium, enhanced serum levels can 
transport more IGF-I or -II into the spleen causing enhanced IGF-bioactivity. Thus, in these 
animals, IGFBP-3 probably acts mainly by an endocrine pathway, instead of the proposed 
autocrine/paracrine way of action in our transgenics. 
Changes of growth and IGF-II and IGFBP expression in the thymus and the spleen of 4-week-old hIGF-II 
transgenic mice, as compared to normal mice, are indicated. The size of the arrow(s) is representative for the 
observed increase in level of expression. The increase in IGFBP-2 and -5 is based on the in situ results, while 
the increase of IGFBP-3 is based on the in situ and the Northern blot analysis. 
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 Besides the growth-inhibitory effect of IGFBP-3 caused by regulating the availability of 
free IGFs, IGFBP-3 can also induce growth arrest 38-40 and apoptosis, mediated through a 
pathway independent of the IGF-IGF-receptor interaction 41. The relatively high 
concentrations of IGFBP-3 in the transgenic spleen could have such an IGF-II independent 
activity.  
 Therefore, although the influence of other IGFBPs on the IGF-II bioactivity should not be 
neglected, the considerable increase in IGFBP-3 mRNA and selective expression in the 
spleen, suggest that this IGFBP plays a prominent role in the reduction of the growth 
promoting effect of IGF-II in the spleen. 
 In conclusion, in this study it has been shown that the thymus and the spleen display a 
tissue-specific IGFBP expression. In all likelihood, it is the difference in IGFBP expression 
that causes a difference in local IGF-II bioactivity, resulting in a strong growth promoting 
effect of IGF-II in the thymus and hardly any in the spleen. This suggests that the growth-
inducing effect of IGF-II depends on its local environment. 
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ABSTRACT 
 
Glucocorticoid (GC) treatment in childhood can lead to suppression of longitudinal 
growth as a side-effect. The actions of GCs are thought to be mediated in part by 
impaired action of the insulin-like growth factors (IGF-I and IGF-II) and their binding 
proteins (IGFBP-1 to -6). We have studied the effects of GCs on IGF and IGFBP 
expression at the local level of the growth plate, using non-radioactive in situ 
hybridization. 
 We treated 3-week-old normal mice for 4 weeks with dexamethasone (DXM). We also 
treated human IGF-II (hIGF-II) transgenic mice in order to investigate whether IGF-II 
could protect against the growth retarding effect of this GC. DXM treatment resulted in 
general growth retardation in both mice strains, however, only in normal mice was tibial 
length decreased. In both normal and hIGF-II trangenic mice, the total width of the 
growth plate was not affected, whereas the width of the proliferative zone decreased as a 
result of the DXM treatment. Additionally, only in normal mice, the width of the 
hypertrophic zone thickened. 
 Only expression of IGF-I, IGF-II and IGFBP-2 could be detected in the growth plates 
of 7-week-old normal mice. IGFBP-1, -3, -4, -5 and -6 mRNAs were not detected. DXM 
treatment of normal mice induced a significant 2.4-fold increase in the number of cells 
expressing IGF-I mRNA, whereas IGF-II and IGFBP-2 mRNA levels were not affected. 
 In hIGF-II transgenic mice, IGF-I mRNA levels were significantly increased, while 
endogenous IGF-II and IGFBP-2 mRNAs were unaffected, compared to normal 
animals. DXM treatment of the hIGF-II transgenic mice induced a further increase of 
IGF-I mRNA expression, to a similar extent as in DXM-treated normal mice.  
 The increase of IGF-I due to DXM treatment in normal mice might be a reaction in 
order to minimize the GC-induced growth retardation. Another possibility could be that 
the increase of IGF-I would contribute to the GC-induced growth retardation by 
accelerating the differentiation of chondrocytes, resulting in accelerated ossification. In 
the growth plates of hIGF-II transgenic mice, the higher basal level of IGF-I, might be 
responsible for the observed partial protection against the adverse effects of GCs on 
bone. 
 
 
INTRODUCTION 
 
Long-term high-dose glucocorticoid (GC) treatment as anti-inflammatory and 
immunosuppressive therapy is associated with marked skeletal growth retardation in 
children 1,2. In experimental animal models, high doses of GCs also have a growth-
suppressive effect on longitudinal bone growth 3-7. GCs have been shown to act locally to 
inhibit longitudinal growth, suggesting a local mechanism within the growth plate 8. 
 Locally produced insulin-like growth factor (IGF) axis components, including both IGF-I 
and -II, their binding proteins (IGFBP)-1 to -6 and their receptors, play a key role in 
longitudinal bone growth 9,10. Disruption of the IGF signaling results in growth retardation 11. 
Besides being produced by growth plate chondrocytes, exogenously added IGFs have a 
stimulatory effect on longitudinal bone growth 12,13. IGF-I and IGF-II both have a unique and 
complementary role in augmenting longitudinal bone growth 14. However, there still exists 
some doubt whether both IGF-I and IGF-II are produced in the growth plate. Several in vitro 
Chapter 3 
 46
data have shown expression of both IGFs 10,15, while several in vivo studies have shown 
conflicting results 16-20.  
 It has been suggested that the growth-inhibiting side-effect of GCs is partially mediated by 
impaired action of the IGF axis components in in vitro studies 21-24. GCs and IGF axis 
components have opposite effects on growth, as described above. In addition, GCs regulate 
the expression of IGFs 21 and IGFBPs 23 in chondrocytes in vitro. Few data are available, 
however, concerning the regulation by GCs in vivo 5 and it has been reported that serum levels 
of IGF axis components provide little insight into the mechanisms of GC-induced growth 
retardation and the possible involvement of the IGF axis components therein 2. Therefore, in 
order to elucidate the possible involvement of IGF axis components in GC-induced growth 
retardation, it is important to study locally produced IGFs and IGFBPs and their regulation by 
GCs in the growth plate. 
 We have previously treated 3-week-old female mice for 4 weeks with 20 µg 
dexamethasone (DXM)/day or saline (phosphate-buffered saline; PBS) 3. These mice showed 
general growth retardation and a significant reduction in tibial length and weight. We have 
now studied the effects of this GC treatment on growth plate morphology. We have also 
studied the possible involvement of locally expressed IGFs and IGFBPs in this GC-induced 
growth retardation, by analyzing their expression in the growth plates of these mice using 
non-radioactive in situ hybridization. This study also served to analyze whether only IGF-II or 
both IGF-I and IGF-II are expressed by growth plate chondrocytes. 
 We have previously suggested a possible protective effect of IGF-II against GC-induced 
growth retardation 3. It was shown that DXM did not affect tibial length and weight in the 
same degree in human (h) IGF-II transgenic mice as in normal mice 3. This suggested that 
hIGF-II overexpression might be able to partially counteract the growth inhibitory effect of 
DXM at the level of the growth plate. In order to study the possible role of the hIGF-II 
transgene in GC-induced growth retardation, we also analyzed the morphology of the growth 
plates of these mice and the expression patterns of the IGFs and IGFBPs, which were 
compared with normal PBS- and DXM-treated animals. 
 
MATERIALS AND METHODS 
 
Materials 
Restriction enzymes and modifying enzymes, digoxigenin-UTP, anti-digoxigenin Fab-fragments, nitro blue 
tetrazolium (NBT), 5-bromo-4-chloro-3-indolyl-phosphatase (BCIP) and blocking reagent were purchased from 
Roche Molecular Biochemicals (Mannheim, Germany). Polyvinyl alcohol was obtained from Aldrich 
(Milwaukee, WI, USA). Euparal mounting medium was purchased from Klinipath (Duiven, The Netherlands). 
 
Mice and tissue preparation 
hIGF-II transgenic mice were generated by introduction of a human IGF-II gene, under the control of the H-2Kb 
promoter and containing the SV40 small t intron and early polyadenylation signal, into FVB mice as described in 
detail previously 25. Throughout the study, the transgenic line designated 5'-74 (TgII) and normal FVB/N mice 
were used for our experiments. The animals were kept under standardized laboratory conditions.  
 Three-week-old female FVB and TgII mice were divided into two groups of five mice each. The animals 
were injected subcutaneously with 0.1 ml vehicle (PBS; pH 7.4) or 20 µg DXM once a day, 5 days a week for 
4 weeks (Experiment 2, 3). The mice were killed by decapitation after ether anesthesia 2 h after the last injection, 
at the age of 7 weeks. At this age the animals are maturing sexually and are still growing 26. The protocol 
received the approval of the committee for Animal Experiments of the University Medical Center Utrecht, the 
Netherlands. 
 The tibiae were dissected and fixed in buffered 3.8% formalin for 24 h. Tibiae were subsequently decalcified 
for 24 h in 0.45 M phosphate-buffered EDTA, pH 8.0, washed in PBS, dehydrated through a series of ethanol 
and embedded in paraffin in a standardized way to ensure proper orientation.  
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Morphometry of the growth plate 
Growth plate sections were stained with hematoxylin and eosin and photographs of the sections were taken with 
a Zeiss Axiomat HRC camera equipped with the AxioVision software version 3.0 (Zeiss, München-
Hallbergmoos, Germany). The interactive measurement module was used for measurements of the growth plate 
width. Corresponding sections of the tibia of the different groups were used to ensure correct comparison 
between the different groups. Total width of the growth plate (distance between the epiphysis and the chondro-
osseous junction) was determined from one image (magnification X50) per growth plate section, covering the 
entire transverse area excluding the periphery of the growth plate. Five animals per treatment group were 
analyzed (two sections per animal). From the images, measurements at 100 µm intervals were performed (about 
18 measurements per growth plate) and averaged. The measuring lines were subsequently shortened to the first 
appearance of regular chondrocyte columns (the boundary between the resting and the proliferative zone) and to 
the first enlargement of the flattened cells (the boundary between the proliferative and the hypertrophic zones). 
From the lengths of these lines the widths of the three different zones of the growth plate were calculated.  
 
Probes 
Standard RNA synthesis reactions using T7- or T3-RNA polymerase were carried out using digoxigenin-UTP as 
substrate 27. cDNAs encoding human IGF-I and IGF-II 28,29, cDNA encompassing the 1 kb BamHI – BamHI 
SV40 fragment 25 and mouse IGFBP-1, -2, -3, -4, -5 and -6 cDNAs (kindly provided by S.L.S. Drop and J.W. 
van Neck, Department of Pediatrics, Rotterdam, The Netherlands) 30 were used as templates for the synthesis of 
antisense and sense digoxigenin-labeled cRNA probes. All probes used were specific for the mRNAs analyzed. 
The human IGF-II probe detects both endogenous mouse IGF-II as well as the hIGF-II transgene mRNA 31. The 
SV40 fragment detects specifically the hIGF-II transgene, making it possible to discriminate between the 
endogenous and transgene IGF-II mRNAs. Probes were checked for possible cross-hybridization using in situ 
hybridization on different types of mouse tissues (spleen, thymus and complete mice embryos) 30,31 for the 
IGFBP probes, and brain for the IGF probes (C. Reijnders, personal communication). The various probes 
displayed distinct expression patterns in these tissues. Northern blot analysis of different tissues using the same 
probes, yielded bands of the expected sizes, verifying the correct identity of the probes.  
 
In situ hybridization 
Paraffin tissue sections (10 µm) were cut in a standardized way and mounted on 2% amino-propyl-triethoxy 
silane/3% glutaraldehyde-coated glass slides. Corresponding sections of the tibia of the different groups were 
used for the same probes to ensure reliable comparison between the groups. Sections were dewaxed, hydrated, 
rinsed in PBS and treated with proteinase K (0.21 units/ml) for 30 minutes at 37ºC, treated with 0.2 M HCl for 
10 min at room temperature and subjected to an acetylation treatment 32. Sections were rinsed in 2xSSC and kept 
in this solution until the start of the hybridization. Hybridization was performed in a solution containing 
50% formamide, 2xSSC, 1x Denhardt's solution, 1 µg/µl yeast RNA and 10% dextran sulphate and the 
digoxigenin-labeled cRNA probe at a concentration of 1000-1500 pg/µl. Sections were hybridized overnight at 
51ºC, except for IGF-II where 58ºC was used. After hybridization, sections were washed with 50% formamide in 
2xSSC at the hybridization temperature for 30 min and treated with RNase A (1 unit/ml) for 30 min at 37ºC. 
Subsequently, sections were rinsed in 2xSSC, treated with 10% lamb serum for 30 min and incubated with sheep 
anti-digoxigenin Fab-fragments coupled to alkaline phosphatase (1:1250) overnight at 4ºC. Chromogenesis was 
performed with 0.38 mg/ml NBT and 0.19 mg/ml BCIP in the presence of 6% (w/v) polyvinylalcohol 33 at room 
temperature in the dark, resulting in a blue precipitate. Sections were counterstained with nuclear fast red, 
dehydrated through a series of ethanol and mounted with Euparal. 
 Five different animals per treatment group were used per analyzed mRNA. Each analyzed glass slide 
contained six sections, three of a PBS- and three of a DXM-treated mouse (either a normal or a hIGF-II 
transgenic mouse). Both strains were analyzed in the same in situ hybridization experiment. For quantitative 
evaluation of the number of chondrocytes expressing mRNA, sections were coded and analyzed using the 
Image-Pro Plus software program from Media Cybernetics (Silver Springs, MD, USA). The number of positive 
cells in the growth plates (excluding the periphery of the growth plates) were counted and expressed relative to 
the number of positive cells in the FVB PBS-treated group (control group). 
 
Statistical analysis 
Data are expressed as means ± SEM. The effects of the DXM treatment and the hIGF-II transgene were 
statistically tested by one-way ANOVA with Bonferroni-Dunn post hoc tests using InStat version 3.00 
(GraphPad Software, Inc., San Diego, CA, USA). The effects of the DXM treatment on body and tibial length of 
both mice strains (FVB and hIGF-II transgenic) were calculated using Student’s t-test. A P value of less 
than 0.05 was considered statistically significant. 
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RESULTS 
 
Growth plate morphology 
Normal FVB mice were treated for 4 weeks with 20 µg/day DXM, which resulted in a 
significant inhibition of body length and weight 3. Tibial length was also significantly 
inhibited, to a similar extent as total body length, as summarized in Table 1. DXM treatment 
of hIGF-II transgenic mice resulted in a similar inhibition of body length as in FVB mice. 
However, tibial length was not significantly affected in the hIGF-II transgenic mice (Table 1).  
 DXM treatment of FVB mice had no effect on the total width of the proximal tibial growth 
plate. However, the width of the proliferative zone was significantly decreased (by 11%), 
whereas the width of the hypertrophic zone was significantly increased (by 17%). The resting 
zone was not affected by the DXM treatment (Table 2). hIGF-II transgenic mice showed a 
significantly larger width of the growth plate compared with untreated FVB mice (12% 
increase). This increase was caused by a non-significant increase in the width of all three 
zones of the growth plate. Treatment with DXM caused a significant decrease in the width of 
the proliferative zone (14%), a similar decrease as that seen in FVB mice. In contrast, in 
hIGF-II transgenic mice, DXM did not affect the width of the hypertrophic zone (Table 2). As 
in FVB mice, the resting zone was not affected by the DXM treatment.  
 
 
 
  Body  Tibia   
Group length(cm) P value1 inhibition by DXM 
(%) 
length (mm) P value1 inhibition by DXM 
(%) 
FVB PBS 18.06 ± 0.26   17.11 ± 0.23   
FVB DXM 17.24 ± 0.06 <0.02 4.5 16.49 ± 0.10 <0.05 3.6 
TgII PBS 17.86 ± 0.07   16.58 ± 0.13   
TgII DXM 17.00 ±0.09 <0.01 4.8 16.27 ± 0.18 NS 1.9 
 
1compared with PBS control within the same strain; NS, not significant. Means ± SEM are given. 
 
 
   
 
Group total growth plate  resting zone  proliferative zone hypertrophic zone 
FVB PBS 168.2 ± 4.9 21.9 ± 1.1 85.6 ± 3.7 59.7 ± 1.8 
FVB DXM 170.9 ±1.8 24.4 ± 0.8 76.6 1 ± 1.1 69.9 1 ± 1.5 
TgII PBS 188.0 1 ± 2.6 25.6 ± 1.8 93.2 ± 1.5 68.9 ± 1.8 
TgII DXM 177.0± 4.6 26.4± 1.1 80.2 2 ± 1.6 70.3 ± 3.9 
    
 
 
Expression of IGF axis components in the postnatal growth plate 
To analyze the endogenous expression of the IGFs and their binding proteins, IGFBP-1 to -6, 
in the postnatal epiphyseal growth plate of mice, non-radioactive in situ hybridization was 
performed on tibial epiphyseal growth plates of 7-week-old PBS-treated normal mice. At the 
age of 7 weeks, the mice are maturing sexually and are still growing 26. As a control for 
specific hybridization, sections were hybridized with the appropriate sense probes, which 
showed no signals in any of the treatment groups (Figs 1E, 2E and 3E). 
Table 1 Effect of dexamethasone (DXM) treatment on body length and tibial length of normal (FVB) and hIGF-II 
transgenic (TgII) mice. n = 5 in all cases 
Table 2 Effect of DXM treatment on total growth plate width and width of the three zones (µm)  
of the growth plate in normal (FVB) and hIGF-II transgenic (TgII) mice. n = 5 in all cases 
1 P<0.05 compared to the normal, PBS group; 2 P<0.05 compared to the TgII, PBS group.  
Means ± SEM are given. 
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 In the growth plates of these mice, IGF-I, IGF-II and IGFBP-2 transcripts were present, 
each showing a similar expression pattern. However, no expression of IGFBP-1, -3, -4, -5 and 
-6 could be detected (data not shown). Using the same probes, we have previously 
demonstrated the expression of IGFBP-2, -3, -4, -5 and -6 in lymphoid tissues 31.  
 IGF-I mRNA was predominantly present in hypertrophic chondrocytes and less in late 
hypertrophic chondrocytes (Fig. 1A). IGF-I transcripts were also detected in proliferative 
chondrocytes located at the periphery of the growth plate (not shown), but not in proliferative 
chondrocytes in the central area. Weak expression of IGF-I was present in some of the resting 
chondrocytes. In addition, IGF-I transcripts were also detected in osteoblasts aligning the 
trabeculae. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Like IGF-I, IGF-II was predominantly expressed in the hypertrophic zone. However, in the 
late hypertrophic zone fewer cells expressed IGF-II than was observed for IGF-I (Fig. 2A). 
IGF-II mRNA was also present in proliferative chondrocytes located at the periphery of the 
growth plate (not shown), but not in proliferative chondrocytes in the central area. In contrast 
to IGF-I, IGF-II mRNA was not detected in the resting zone. In the peripheral sections of the 
growth plate, more cells expressed IGF-I and IGF-II mRNA (not shown) than in sections of 
the center of the tibia. In these peripheral sections also, more proliferative chondrocytes 
showed expression of both IGFs. As IGF-I, IGF-II was also expressed in osteoblasts aligning 
the trabeculae.  
 
 
Figure 1 IGF-I expression in the postnatal growth plate. Expression patterns of IGF-I mRNA in representative 
sections of the growth plates of 7-week-old mice. (A) PBS-treated FVB mice, (B) DXM-treated FVB mice, 
(C) PBS-treated hIGF-II transgenic mice, (D) DXM-treated hIGF-II transgenic mice and (E) section of the PBS-
treated FVB mice hybridized with an IGF-I sense probe, as analyzed by non-radioactive in situ hybridization, 
under brightfield illumination. Magnification X200. Sections were counterstained with nuclear fast red. The mRNA 
signal is shown as a blue precipitate under brightfield illumination. (a) Detail of signal in PBS-treated FVB mice, 
magnification X400. R, resting zone; P, proliferative zone; H, hypertrophic zone; LH, late hypertrophic zone. 
Arrowheads indicate IGF-I mRNA in the resting zone. Scale bar, 100 µm. 
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 Of the IGFBPs, only IGFBP-2 could be detected in the postnatal growth plate (Fig. 3A). 
IGFBP-2 transcripts were mainly detected in the hypertrophic zone and fewer cells in the late 
hypertrophic zone expressed IGFBP-2 mRNA. As for IGF-I and IGF-II, IGFBP-2 mRNA was 
also detected in the proliferative cells located at the periphery of the growth plate, but not in 
the proliferative cells in the center of the tibia. No IGFBP-2 mRNA was detected in the 
resting zone. IGFBP-2 was also expressed in osteoblasts aligning the trabeculae. 
 
Effects of DXM treatment on IGF axis components in the growth plate 
DXM treatment resulted in a significant 2.4-fold (± 0.3, P<0.001) increase in the number of 
IGF-I-expressing chondrocytes in the epiphysial tibial growth plate (Fig. 1B). In the center of 
the growth plate, more rows of cells were positive for IGF-I, including proliferative 
chondrocytes. In contrast, in PBS-treated FVB mice, no proliferative chondrocytes were 
positive for IGF-I. IGF-I expression in the resting zone was not altered because of the DXM 
treatment. Although the width of the hypertrophic zone increased because of the DXM 
treatment, this could only partially account for the increase in IGF-I-expressing cells as, 
besides hypertrophic chondrocytes, proliferative chondrocytes also expressed IGF-I. The 
expression patterns and levels of IGF-II (Fig. 2B) and IGFBP-2 (Fig. 3B) were similar to 
those found in the growth plates of control mice. 
 As in the control animals, no expression of IGFBP-1, -3, -4, -5, and -6 was detected (data 
not shown). 
Figure 2 IGF-II expression in the postnatal growth plate. Expression patterns of IGF-II mRNA in representative 
sections of the growth plates of 7-week-old mice. (A) PBS-treated FVB mice, (B) DXM-treated FVB mice, (C)
PBS-treated hIGF-II transgenic mice, (D) DXM-treated hIGF-II transgenic mice and (E) section of the PBS-treated 
FVB mice hybridized with an IGF-II sense probe. Sections were treated as described in Fig. 1. 
Magnification X200. (a) Detail of signal in PBS-treated FVB mice, magnification X400. Arrows indicate the lower 
level of expression in the late hypertrophic (LH) zone, compared to the hypertrophic (H) zone. Scale bar, 100 µm. 
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Expression of IGF axis components in the postnatal growth plate of hIGF-II transgenic mice 
To analyze the influence of hIGF-II overexpression on the expression of IGF axis components 
in the growth plate, sections of the growth plates of PBS-treated hIGF-II transgenic mice were 
also analyzed. The hIGF-II transgene itself was detected using a transgene specific probe 
(SV40 probe). The transgene was not detected in the epiphyseal growth plate, although 
transgene mRNA was detected in osteoblasts aligning the trabeculae (Fig. 4C). The number of 
IGF-I-expressing cells was significantly increased 1.9-fold (±0.3, P<0.05) in hIGF-II 
transgenic mice (Fig. 1C). This included positive cells in the proliferative zone. In contrast, 
the number of cells expressing endogenous IGF-II (Fig. 2C) and IGFBP-2 (Fig. 3C) in the 
growth plate were not changed in hIGF-II transgenic mice as compared to normal mice. No 
expression of IGFBP-1, -3, -4, -5 and -6 was detected in the postnatal growth plates of 
hIGF-II transgenic mice (data not shown). 
 
 
 
Figure 3 IGFBP-2 expression in the postnatal growth plate. Expression patterns of IGFBP-2 mRNA in 
representative sections of the growth plates of 7-week-old mice. (A) PBS-treated FVB mice, (B) DXM-treated 
FVB mice, (C) PBS-treated hIGF-II transgenic mice, (D) DXM-treated hIGF-II transgenic mice and (E) section of 
the PBS-treated FVB mice hybridized with an IGFBP-2 sense probe. Sections were treated as described in Fig. 1. 
Magnification X200. (a) Detail of signal in PBS-treated FVB mice, magnification X400. Scale bar, 100 µm. 
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Effect of DXM treatment on IGF axis components in the growth plates of hIGF-II transgenic 
mice 
When DXM-treated hIGF-II transgenic mice were compared with PBS-treated normal mice, 
the number of IGF-I-expressing chondrocytes in the epiphyseal tibial growth plate, increased 
2.6-fold (±0.3), to a similar level to that observed in DXM-treated normal mice, including 
proliferative chondrocytes (Fig. 1D). This increase was significant when compared with 
control normal mice (P<0.001), but not significant when compared with PBS-treated hIGF-II 
transgenic mice. Endogenous IGF-II and IGFBP-2 gene expression were not affected by the 
DXM treatment (Fig. 2D and 3D respectively). IGFBP-1, -3, -4, -5 and -6 transcripts were not 
detected in hIGF-II transgenic mice treated with DXM (data not shown). We observed no 
change in transgene expression levels caused by the DXM treatment (Fig. 4D).  
 
DISCUSSION 
 
There are strong indications that GC-induced growth retardation involves impaired action of 
the IGF axis components 5,21-24. In the present study, we analyzed the in vivo effects of GCs 
on the expression of the IGF axis components at the local level of the epiphyseal growth plate, 
where longitudinal growth is regulated and adverse effects of GCs on growth are expected to 
be targeted 34. Besides studying the effects of GCs on the expression of the IGF axis 
components, the possible protective effect of IGFs against GCs was also studied using 
hIGF-II transgenic mice.  
 The analyses performed in this study on the endogenous expression of the IGF axis 
components in the mouse postnatal growth plate (postnatal day (P) 49), showed expression of 
IGF-I, IGF-II and IGFBP-2. Until now, there have been conflicting reports whether both the 
IGFs are expressed in the postnatal epiphyseal growth plate. Expression of IGF-I was shown 
in the rat epiphyseal growth plate (P10, P28, P35) 17,20 and costochondral growth plate 35. In 
contrast, Wang et al. 16 detected only IGF-II in murine growth plates (P25) and Shinar et al. 19 
reported similar results in rat growth plates (P10 - P35). Although species differences and age 
variables will influence the observed expression signals, the conflicting data are more likely 
Figure 4 Transgene expression in 
the postnatal growth plate. 
Expression patterns of transgene 
mRNA in representative sections of 
the growth plates of 7-week-old mice. 
SV40 is a transgene sprecific probe. 
(A) PBS-treated FVB mice, (B) DXM-
treated normal mice, (C) PBS-treated 
hIGF-II transgenic mice and (D)
DXM-treated hIGF-II transgenic 
mice. Sections were treated as 
described in Fig. 1. Magnification, 
X200. Blue staining observed in the 
extracellular matrix of the growth 
plate is non-specific. Scale bar, 
100 µm. 
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caused by the detection method used. In previous studies 16,19,20, in which radioactive in situ 
hybridization was used, less clear expression of IGF-I and IGF-II was found. This was 
confirmed by Reinecke et al. 17, who also showed a better visible signal of IGF-I expression 
using non-radioactive in situ hybridization than that shown previously by the radioactive 
method 20. It is unlikely that the detection of both IGF-I and IGF-II is due to cross-
hybridization between the probes used (described in Materials and Methods). In addition, 
there are differences in the expression patterns and responses to DXM treatment and the 
presence of the hIGF-II transgene, as discussed below. 
 IGF-I was mainly detected in cells of the hypertrophic zone and fewer positive cells were 
detected in the late hypertrophic zone. Only a few cells expressing IGF-I were detected in the 
resting and proliferative zones. This distribution confirms previous data 17. Local IGF-I 
synthesis of proliferative chondrocytes was previously thought to stimulate the clonal 
expansion of chondrocyte columns in the proliferative zone in an autocrine/paracrine manner, 
as described by the “dual effector theory” 9. It should be borne in mind, however, that the 
mitogenic properties of the IGFs have only been demonstrated in cultured cells, and not in 
in vivo models. In our study, only a small number of cells in the proliferative zone expressed 
IGF-I, whereas IGF-I expression was mainly detected in the hypertrophic zone, suggesting 
that IGF-I could be involved in the differentiation of proliferative to hypertrophic 
chondrocytes. In IGF-I knock-out mice, hypertrophic chondrocytes are reduced by 30% in 
linear dimension, accounting for most of the observed decrease in longitudinal growth 36. This 
further strengthens the notion that IGF-I plays an important role in augmenting chondrocyte 
hypertrophy 14,34,37. Furthermore, infusion of IGF-I in hypophysectomized rats showed that 
IGF-I stimulates growth plate chondrocytes at all stages of differentiation, including 
hypertrophic chondrocytes 12, rather than acting specifically upon proliferative chondrocytes 
as postulated in the “dual effector theory”. Previously, there was uncertainty as to the source 
of the IGF-I that would promote the chondrocyte hypertrophy 14. Our study provides strong 
evidence that the source of the IGF-I is the growth plate itself. However, besides having a role 
in differentiation of chondrocytes, IGF-I may still play a role in the clonal expansion of 
proliferative chondrocytes, in a paracrine manner. Our data, however, suggest that the 
“dual effector theory” should be extended with a role for IGF-I in chondrocyte differentiation. 
The type I IGF receptor, which mediates the intracellular effects of both IGF-I and IGF-II 38, 
is mainly expressed in the proliferative and hypertrophic zones of the growth plate 16,34. 
However, in the hypertrophic zone, distinctly higher levels of type I IGF receptor mRNA 
levels are present compared with the proliferative zone 16, supporting the suggestion that in 
addition to stimulating proliferation, IGFs play a role in differentiation of chondrocytes. 
 The distribution of IGF-II transcripts confirms previous data, which showed predominant 
expression in the hypertrophic zone and no (in our study, very low) expression in the 
terminally differentiated chondrocytes at the chondro-osseous junction 16. IGF-II has been 
suggested to play a role in proliferation of chondrocytes, and also in their differentiation 39. 
The presence of both IGFs, their distinct expression patterns and the difference in response to 
GC treatment (see below), strengthens the suggestion that they have a unique and 
complementary role in regulating bone growth in a paracrine manner 14. 
 Concerning the IGFBPs, we are the first to detect expression of IGFBP-2 in the postnatal 
growth plates of sexually maturing mice (P49). The detection of IGFBP-2 is specific and is 
not due to cross-hybridization with other IGFBPs (described in Materials and Methods). This 
contrasts with the fetal situation where expression of IGFBP-2 to -6 in the growth plate 
in vivo has been reported previously in sheep 18 and cows 10. However, expression was at such 
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a low level that detection was only possible using RT-PCR 10,18. In fetal murine growth 
plates 16, radioactive in situ hybridization only showed expression of IGFBP-5 and -6 in the 
growth plate, which rapidly declined with age. IGFBP-5 was no longer detectable after 
embryonic day 18 and only low levels of IGFBP-6 were detectable up to at least P25 16. 
IGFBP-1 has never been detected in the growth plate, neither pre- nor postnatally 10,16,40. In 
our study, IGFBP-2 is mainly expressed in the hypertrophic zone in co-localization with 
IGF-I and IGF-II. Various studies have suggested that IGFBP-2 plays a role in growth and 
development 41,42. In addition, a role of IGFBP-2 in the growth plate is suggested by its 
presence in cultured chondrocytes 24,43. The specific localization of IGFBP-2 in the pre- and 
hypertrophic zone of the growth plate and the fact that IGFBP-2 is the only member of the 
IGFBPs present at this stage of development suggests a modulating role for this IGFBP in 
chondrocyte differentiation and maturation, in collaboration with the IGFs. 
 Treatment of normal mice with DXM induced general growth retardation and a decrease in 
tibial length 3. We now report that total growth plate width was not affected, while the 
proliferative zone decreased and the hypertrophic zone increased. In contrast, in hIGF-II 
transgenic mice, DXM decreased only total body length, whereas tibial length was not 
affected. The DXM-induced reduction in the proliferative zone of the growth plate remained, 
whereas the hypertrophic zone was no longer affected in the hIGF-II transgenic mice. Thus, 
there appears to be a correlation between tibial growth retardation and an increase in the 
hypertrophic zone of the growth plate. This increase of the hypertrophic zone could be caused 
by an accelerated differentiation of proliferative chondrocytes. Premature maturation of 
chondrocytes has previously been shown to lead to growth retardation. In parathyroid 
hormone-related peptide (PTHrP) receptor knockouts for example, an accelerated 
chondrocyte differentiation led to premature ossification 44,45. However, the effect of GCs on 
the proliferative zone could also be important in GC-induced growth retardation, as shown in 
in vitro studies 21,46. 
 Treatment of normal mice with DXM also increased the number of chondrocytes 
expressing IGF-I. The increase of IGF-I-expressing cells can only partially be explained by 
the increase of the hypertrophic zone as, besides hypertrophic chondrocytes, proliferative 
chondrocytes also express IGF-I after DXM treatment. In addition, we also reported elevated 
serum levels of IGF-I 3. We have shown no effects on IGF-II and IGFBP-2 mRNA levels in 
the growth plate, and no effects on serum IGF-II and IGFBP-2 levels have been detected 3. 
The increase in IGF-I due to GC treatment is surprising, since IGFs are thought to promote 
growth. It could be that the increase of IGF-I in the growth plate might counteract the adverse 
effects of GCs on the growth plate in an attempt to diminish growth retardation. The observed 
increase, however, is not sufficient to completely abolish the observed growth deficit. IGF-I 
has indeed been shown previously to be able to counteract the anti-proliferative effects of 
GCs, both in vitro as well as in vivo 22. However, this is the first study to describe an 
upregulation of IGF-I in response to GC treatment, possibly as a compensatory mechanism. 
Another possibility could be that the increase of IGF-I in the growth plate might result in an 
increased differentiation of chondrocytes, resulting in thickening of the hypertrophic zone, 
accelerated ossification and growth retardation. Probably other factors are involved as well, 
such as, for example the Indian hedgehog-PTHrP negative feedbackloop 47, core binding 
factor α-1 (Cbfa1), transforming growth factor-β, fibroblast growth factors and others 7,48. 
The effects of GC treatment on the type I IGF receptor levels in the growth plate in vivo are 
not known. However, in vitro data of chondrocytes showed that DXM had no effect on type I 
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IGF receptor levels 21. However, a possible involvement of the type I IGF receptor in 
GC-induced growth retardation cannot be excluded. 
 It is noteworthy that the hIGF-II transgenic mice also have increased IGF-I mRNA levels 
in the growth plate as compared to normal mice, whereas IGF-II and IGFBP-2 levels are not 
affected. However, this increase in IGF-I has no effect on tibial growth of the hIGF-II 
transgenic mice 3. Transgene-specific hybridization showed that the hIGF-II transgene is not 
expressed in the growth plate, but only in osteoblasts aligning the trabeculae. The transgene in 
osteoblasts could be responsible for the increase in IGF-I levels in the growth plate in a 
paracrine manner as has been shown by us for IGFBP expression in lymphoid tissues 31. In 
addition, the transgene is also thought to be able to regulate circulating IGF-I as in the hIGF-II 
transgenic mice serum IGF-I levels are elevated 3. The hIGF-II transgene in the osteoblasts 
does not result in an increase of IGFBP-2 in the growth plate, and no effect on IGFBP-2 
serum levels has been shown 3. In contrast, in the lymphoid tissues, the presence of the 
hIGF-II transgene results in an increase of IGFBP-2 31. This difference might be due to the 
localization of the hIGF-II transgene and IGFBP-2, which are more co-localized in the 
lymphoid tissues than in the growth plate. This difference in localization apparently does not 
hamper the effect of the transgene on IGF-I expression. These hIGF-II transgenic mice do 
show a similar growth retardation to that of the normal mice when treated with DXM. 
However, while this treatment resulted in a significant reduction in tibial length and weight of 
normal mice, no significant effects on the tibia and the hypertrophic zone of the growth plate 
of hIGF-II transgenic mice were observed. The high levels of IGF-I already present in the 
growth plate of the untreated hIGF-II transgenic mice might be responsible for the observed 
partial protection against the GCs with regards to growth retardation of the tibia. This is 
supported by data that showed that increased IGF-I levels, in the presence of GCs, could 
counterbalance the growth inhibiting effect of the GCs 22. 
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ABSTRACT 
 
The Insulin-like Growth Factor (IGF) system is an important mediator of postnatal 
longitudinal growth, and the growth inhibiting effects of glucocorticoid (GC) treatment 
are suggested to be due to impaired action of the IGF system. However, the precise 
changes of the IGFs and IGF-binding proteins (IGFBPs) in the growth plate, occurring 
upon short-term GC treatment have not been characterized. 
 Prepubertal mice treated daily with dexamethasone (DXM) for 7 days, showed 
significant growth inhibition of total body length and weight and weight of the liver, 
thymus and spleen, whereas the weight of the kidneys was not affected. 
 Analysis of the tibial growth plate showed that the total growth plate width 
significantly decreased to 84.5% of control values, caused by a significant decrease in 
the proliferative zone. The number of PCNA-positive chondrocytes in the proliferative 
zone decreased significantly (to 40%) and TUNEL-staining showed a significant 1.6-fold 
increase in apoptotic hypertrophic chondrocytes.  
 In the growth plates, both IGF-I and IGF-II, and IGFBP-2 mRNAs were detected, 
mainly in the proliferative and prehypertrophic zones. DXM treatment significantly 
decreased the number of chondrocytes expressing IGF-I, whereas the number of 
chondrocytes expressing IGF-II and IGFBP-2 were not affected. The decrease in IGF-I 
expression in the growth plate indicates that GC treatment affects IGF-I at the local 
level of the growth plate, which could contribute to the GC-induced growth retardation. 
 
 
INTRODUCTION 
 
The process of endochondral ossification, which occurs at the growth plates of the long bones, 
results in longitudinal growth. During endochondral ossification, chondrocytes within the 
growth plate proliferate, differentiate, mature and eventually die by apoptosis and are replaced 
by bone 1. This process has to be tightly controlled in order to maintain normal growth. 
 The Insulin-like Growth Factor (IGF) system has been proposed to be the major 
determinant of postnatal longitudinal growth 2-5. The IGF system consists of IGF-I, IGF-II, 
six IGF-binding proteins (IGFBP-1 to -6), which modulate the IGF bioavailability, and the 
IGF receptors 6. The IGFs are produced by multiple tissues and can act both in an endocrine 
and autocrine/paracrine fashion 6. The IGFBPs act mainly as autocrine/paracrine factors at or 
close to their sites of synthesis 6.  
 Whether IGF-I and IGF-II are both expressed by growth plate chondrocytes, was an issue 
of debate for several years 7-10. Recently, we and others showed expression of both IGF-I and 
IGF-II in the growth plate 11-13. However, due to differences in species and ages of the models 
used, discrepant results for localization of IGF-I 3,10,13 and IGF-II 8,9,13 were reported. 
Nevertheless, IGF-I and IGF-II are suggested to each have a unique and complementary role 
in augmenting longitudinal bone growth 4,13. 
 Glucocorticoids (GCs), which are widely used as anti-inflammatory and immuno-
suppressive drugs, result in growth inhibition as a side-effect in both children 14 and 
experimental animal models 1,15-17. GCs act locally to inhibit growth, suggesting a mechanism 
which is intrinsic to the growth plate 18,19. GC-induced growth retardation is suggested to be 
due to impaired action of the components of the IGF system 13,15,20,21. GCs are known to 
regulate the expression of the components of the IGF system in the circulation in vivo 15,17,22,23 
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and in chondrocytes in vitro 20,24,25. While the known in vivo data often describe other effects 
than the effects in the growth plate, in vitro data obtained from chondrocytes usually show 
very short-term effects of GCs for several hours and these results do not reflect growth 
retardation in vivo. In view of the local action of GCs in causing growth retardation, it is 
important to study the regulation of the IGF system by GCs in the growth plate itself. 
 At first, to resolve the discrepancy in IGF localization in the growth plate, we investigated 
the distribution of the IGFs in growth plates of 4-week-old (prepubertal) mice, and compared 
them with data obtained in our previous study on 7-week-old (postpubertal) mice 13. To study 
the possible involvement of the IGF system in GC-induced growth retardation, we have 
previously studied the effects of dexamethasone (DXM) treatment for 4 weeks on the 
expression of the IGFs and IGFBPs in the growth plates of postpubertal mice and showed an 
increased expression of IGF-I in the growth plate, whereas IGF-II and IGFBP-2 mRNA were 
not affected 13. During the first week of this treatment, however, growth velocity decreased 
markedly, while during the further duration of treatment, DXM had little effect on growth 17. 
Therefore, to study the effects of GCs on general growth and the IGF system in the growth 
plate, when the most marked effect on growth is observed, we have treated 3-week-old mice 
for 7 days with 20 µg/day DXM and analyzed the short-term in vivo effects on the growth 
plate. 
 
MATERIALS AND METHODS 
 
Materials 
Restriction enzymes and modifying enzymes were purchased from Roche Molecular Biochemicals (Mannheim, 
Germany). DeadEndTM colorimetric Apoptosis Detection System (TUNEL assay) was obtained from Promega 
(Leiden, The Netherlands). Monoclonal antibody specific for PCNA (PC-10) was purchased from Santa Cruz 
Biotechnology Inc. (Santa Cruz, CA, USA). The biotinylated secondary antibody and the Vectastain ABC kit 
were purchased from Vector Laboratories (Burlingame, CA, USA) and the 3,3’-Diaminobenzidine 
Tetrahydrochloride (DAB) from Sigma Chemical Co. (St. Louis, MO, USA). PVDF membranes (Immobilon-P) 
were from Millipore Corp. (Bedford, MA, USA). Polyvinyl alcohol was obtained from Aldrich (Milwaukee, WI, 
USA). Euparal and DPX mounting medium were purchased from Klinipath (Duiven, The Netherlands). 
 
Mice and tissue preparation 
Three-week-old female FVB mice were divided into two groups of five mice each. The mice were selected to 
ensure equal means and standard deviations for total body length and weight in each group at the start of the 
experiment. The animals were injected subcutaneously with 0.1 ml vehicle (phosphate buffered saline (PBS),  
pH 7.4), or with 20 µg dexamethasone (DXM), once a day for 7 days. The mice were killed by decapitation after 
ether anaesthesia, 2 h after the last injection. The protocol received the approval of the committee for Animal 
Experiments of the University Medical Center Utrecht, the Netherlands. 
 The animals were weighed and measured (nose-tail length) at the beginning and the end of the experiment. 
Organs were immediately removed, frozen in liquid nitrogen and weighed. The tibiae were carefully dissected 
and cleared from adjacent muscle and immediately fixed in buffered 3.8% formalin for 24 h. Tibiae were 
subsequently decalcified for 24 h in 0.45 M phosphate-buffered EDTA, pH 8.0, washed in PBS, dehydrated 
through a series of ethanol and embedded in paraffin in a standardized way to ensure proper orientation.  
 Paraffin tissue sections (10 µm) were cut in a standardized way and mounted on 2% amino-propyl-triethoxy 
silane/3% glutaraldehyde coated glass slides. Sections were deparaffinized and hydrated prior to histochemical 
analyses. 
 
Western Ligand Blot Analysis 
Sera of the five mice of each group were pooled and loaded on a 12% gel for non-reducing SDS-PAGE. IGFBPs 
were visualized by electrotransfer to PVDF membranes followed by incubation with 125I-IGF-II 26. Molecular 
weights were calculated using BioRad (Hercules, USA) broad range markers as standard. Bands were quantified 
by densitometry using the GS-363 Molecular Imager and the Molecular Analyst software program, version 1.5 
(Biorad, Hercules, USA). 
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Determination of serum IGF-I 
Sera of the five mice of each group were pooled and serum IGF-I was measured by heterologous 
radioimmunoassay after Sep-Pak C18 chromatography (Waters Corp., Milford, MA), as described previously 26. 
 
Morphometry of the growth plate 
Growth plate sections were stained with hematoxylin and eosin and pictures of the sections were taken with a 
Zeiss Axiomat HRC camera equipped with the AxioVision software version 3.0 (Zeiss, München-Hallbergmoos, 
Germany). The interactive measurement module was used for measurements of the growth plate width. 
Corresponding sections of the tibia were used to ensure correct comparison between the different groups. Total 
width of the growth plate (distance between the epiphysis and the chondro-osseous junction) was determined 
from the entire transverse area excluding the periphery of the growth plate. Of the images, measurements at 
100 µm intervals were performed (about 20 measurements per growth plate) and averaged. The measuring lines 
were subsequently shortened to the first appearance of regular chondrocyte columns (the boundary between the 
resting and the proliferative zone) and to the first enlargement of the flattened cells (the boundary between the 
proliferative and the hypertrophic zones). From the lengths of these lines the widths of the three different zones 
of the growth plate were calculated. Five animals per treatment group were analyzed (two sections per animal). 
 
Probes 
Standard RNA synthesis reactions using T7- or T3-RNA polymerase were carried out using digoxigenin-UTP as 
substrate 27. cDNAs encoding human IGF-I and IGF-II 28,29 and cDNAs encompassing mouse IGFBP-1, -2, -3, 
-4, -5 and -6 cDNAs (kindly provided by S.L.S. Drop and J.W. van Neck, Dept. of Pediatrics, Erasmus 
University Rotterdam, The Netherlands) 30, were used as templates for the synthesis of antisense and sense 
digoxigenin-labeled cRNA probes. All probes used were specific for the mRNAs analyzed. Probes were checked 
for possible cross-hybridization using in situ hybridization on different types of mouse tissues (spleen, thymus 
and complete mice embryos) 30,31 for the IGFBP probes, and brain for the IGF probes (C. Reijnders, personal 
communication). The various probes displayed distinct expression patterns in these tissues. Northern blot 
analysis of different tissues using the same probes, yielded bands of the expected sizes verifying the correct 
identity of the probes.  
 
In situ hybridization 
Corresponding sections of the tibia of the different groups were used for the same probes to ensure reliable 
comparison between the groups. The in situ hybridization, using digoxigenin-labeled cRNA probes, was 
performed as described previously 13. As a control for specific hybridization, sections were hybridized with the 
appropriate sense probes, which showed no signals. 
 Five different animals per treatment group were used per analyzed mRNA. Analysis of the five different 
animals of both groups was performed in the same in situ hybridization, for each analyzed mRNA. Each 
analyzed glass slide contained six sections, three of a PBS- and three of a DXM-treated mouse. For quantitative 
evaluation of the number of chondrocytes expressing mRNA, sections were coded and the number of positive 
cells in a fixed window was determined using the Image-Pro Plus software program (version 4.5) from Media 
Cybernetics, L.P. (Silver Spring, MD, USA). The total number of all positive cells (including weakly stained 
cells) in all zones of the growth plate (excluding the periphery of the growth plates) was counted and expressed 
relative to the total number of cells in the area that was counted. 
 
Immunohistochemistry (PCNA) 
Deparaffinized sections were treated with 0.1% Triton X-100 in PBS for 2 min at room temperature. After 
blocking with 10% normal horse serum, the sections were incubated with primary antibody to Proliferating Cell 
Nuclear Antigen (PCNA) at a 1:200 dilution for 30 min at 37°C, followed by incubation overnight at 4°C. For 
negative controls, the first antibody was omitted from this diluent, which showed no signal. Biotinylated 
secondary antibodies were used at 1:100 dilution and incubated for 30 min. For detection, the avidin-biotin 
peroxidase complex method in combination with nickel-enhanced DAB as substrate was used. Sections were 
counterstained with nuclear fast red, dehydrated and mounted with DPX. Counting of the number of positive 
cells was performed as described for the in situ hybridization. 
 
Determination of apoptosis 
Apoptotic cell death was determined by the TUNEL reaction, using the DeadEnd colorimetric Apoptosis 
Detection system, which was performed according to the procedures of the manufacturer with some minor 
modifications. Sections were fixed with 4% (w/v) paraformaldehyde/PBS for 15 min and treated with 20 µg/ml 
proteinase K for 10 min at room temperature. Subsequently, sections were postfixed with 4% (w/v) 
paraformaldehyde/PBS for 5 min. The TdT reaction was performed at 37°C for 60 min. For negative controls, 
Chapter 4 
 64
the TdT enzyme was replaced by water, which did not show any signal. Endogenous peroxidases were blocked 
by immersing the slides in 0.3% hydrogen peroxide/PBS for 10 min at room temperature. Biotinylated 
nucleotides were detected by Streptavidin-horseradish peroxidase conjugate. DAB staining was performed for 
30 min at room temperature in the dark, resulting in an insoluble colored substrate at the site of DNA 
fragmentation. Subsequently, sections were counterstained with 0.1% light green, dehydrated and mounted 
with DPX.  
 For quantitative evaluation of the number of TUNEL-positive chondrocytes in the hypertrophic zone, 
sections were coded and the number of positive cells in the hypertrophic zone were counted and expressed 
relative to the total number of cells in the hypertrophic zone, as described for the in situ hybridization. 
 
Statistical analysis 
Data are expressed as the means ± SEM. The effects of the DXM treatment were statistically tested using 
Student’s t-test. A P value of less than 0.05 was considered statistically significant. 
 
RESULTS 
 
DXM-induced growth retardation 
Treatment of 3-week-old prepubertal FVB mice for 7 days with 20 µg/day DXM caused a 
severe decrease in total body weight and length gain, resulting in a significant reduction in 
body weight and length. Tibial length and weight were not significantly reduced. The weights 
of the liver, thymus and spleen were significantly decreased by the DXM treatment, whereas 
the decrease in kidney weight was not significant (Table 1). 
 
 
  Table 1 Effect of dexamethasone (DXM) treatment on body and organ weight and  
  body length. n = 5 in both groups 
 
  PBS DXM P-value 
Total body weight (g) 16.7 ± 0.3 13.6 ± 0.6  <0.01 
 body length (cm) 15.9 ± 0.1 15.3 ± 0.2  <0.05 
 weight gain (g/wk) 6.1 ± 0.1 3.0 ± 0.3  <0.001 
 length gain (cm/wk) 1.9 ± 0.1 1.3 ± 0.1  <0.001 
Tibia weight (mg) 70.3 ± 1.0 65.8 ± 2.5  NS 
 length (mm) 14.8 ± 0.2 14.4 ± 0.2 NS 
Organ liver (mg) 852.3 ± 19.0 678.9 ± 49.7  <0.05 
 kidney (mg) 197.5 ± 6.1 187.3 ± 4.6 NS 
 thymus (mg) 100.2 ± 5.9 21.5 ± 1.9  <0.001 
 spleen (mg) 82.0 ± 3.0 35.8 ± 2.7  <0.001 
   
  P-values are as indicated; NS, not significant, compared to PBS-treated control animals.  
  Means ± SEM are given.  
 
 
 The IGF-I serum levels decreased from 511.8 ng/ml in PBS-treated control animals to 
390.4 ng/ml in DXM-treated animals. Western Ligand Blot analysis of normal mice sera 
showed the expected presence of 4 IGFBPs 17, a doublet of 41.5/38.5 kDa (most probably 
IGFBP-3), a 30 kDa band (probably IGFBP-2), a 26.5 kDa (probably IGFBP-5) band and a 
24 kDa band (probably IGFBP-4). DXM treatment did not affect the IGFBP protein levels 
(data not shown).  
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Growth plate morphology 
The DXM treatment significantly decreased the total width of the proximal tibial growth plate 
to 84.5% ± 4.0% of control values (P<0.05), caused by a significant decrease in the width of 
the proliferative zone to 73.8% ± 6.9% of control values (P<0.01). The width of the 
hypertrophic zone showed a small, non-significant, decrease, whereas the resting zone was 
not affected by the DXM treatment (Table 2 and Fig. 1). 
 
  Table 2 Effect of dexamethasone (DXM) treatment on total growth plate width and width  
  of the 3 zones (µm). n = 5 in both groups. 
 
Treatment total  
growth plate  
resting zone 
 
proliferative zone 
 
hypertrophic zone 
 
PBS 322.6 ± 15.5 32.4 ± 0.4 133.4 ± 5.6 152.3 ± 9.3 
DXM 272.6 ± 10.9* 32.5 ± 1.2 98.4 ± 6.8* 140.5 ± 5.4 
  * P<0.05, compared to PBS-treated control animals. Means ± SEM are given. 
 
 Immunostaining for Proliferating Cell Nuclear Antigen (PCNA), a marker for proliferating 
cells, showed a significant decrease in the number of proliferating chondrocytes from 
24.8% ± 2.2% in control animals (Fig. 1A) to 9.8% ± 1.5% in DXM-treated animals (Fig. 1B) 
(P<0.001) (expressed as a percentage of the total number of cells in the growth plate). 
Staining for PCNA was predominant in the proliferative zone, however, some staining in the 
prehypertrophic and hypertrophic zone was also shown.  
 
 
 
 
 
 
 
 
 In the growth plates of the control animals, only the terminal row of hypertrophic 
chondrocytes contained a low percentage (1.0% ± 0.2%) of apoptotic chondrocytes (expressed 
as a percentage of the number of cells in the hypertrophic zone). DXM treatment induced a 
significant 1.6-fold increase to 1.6% ± 0.1% (P<0.01) (data not shown). 
 
Effects of DXM treatment on IGF axis components in the growth plate 
IGF-I mRNA was predominantly expressed in the proliferative zone and in the early 
hypertrophic zone (or prehypertrophic zone) of the growth plate, in 4-week-old normal 
control mice. Weak staining was observed in some of the resting and hypertrophic 
chondrocytes. In control animals, 56.5% ± 4.7% of the chondrocytes in the growth plate 
expressed IGF-I (Fig. 2A), which was significantly decreased in all zones of the growth plate, 
to 35.4% ± 4.0% in the DXM-treated animals (Fig. 2B) (P<0.01). The expression pattern 
(presence in the various zones) of IGF-I was not affected by the DXM treatment. 
 IGF-II mRNA showed a similar expression pattern as IGF-I and was also predominantly 
expressed in the proliferative and prehypertrophic zones. Some staining was observed in the 
resting and hypertrophic zones. IGF-II mRNA was detected in 53.0% ± 2.6% of the 
Figure 1 Immunohistochemical analysis of Proliferating 
Cell Nuclear Antigen (PCNA) in representative sections of 
tibial growth plates of control (A) and DXM-treated mice 
(B). The protein signal is shown as a dark precipitate. 
Scale bar represents 100 µm.  
 
A B 
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chondrocytes in control animals (Fig. 2C). The number of IGF-II expressing chondrocytes 
was not affected by the DXM treatment (49.0% ± 7.6%) (Fig. 2D). 
 IGFBP-2 was the only IGFBP which could be detected in the growth plate; IGFBP-1, -3, 
-4, -5 or -6 were not detectable. The expression pattern of IGFBP-2 was comparable with that 
of IGF-I and IGF-II, i.e. mainly detected in the proliferative and prehypertrophic zones and a 
weak expression was detected in the resting zone. No IGFBP-2 mRNA was detected in the 
hypertrophic zone. In 41.2% ± 7.2% of the chondrocytes, IGFBP-2 mRNA was detected in 
control animals (Fig. 2E). DXM treatment did not affect the number of IGFBP-2 expressing 
chondrocytes (44.8% ± 6.3%) (Fig. 2F). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
 
In our study, we showed that short-term GC treatment of prepubertal mice i) induced growth 
retardation at body and organ level, ii) significantly decreased tibial growth plate width, 
caused by a decrease in the width of the proliferative zone, iii) decreased the number of 
proliferating chondrocytes and increased the number of apoptotic chondrocytes and 
iv) decreased the number of IGF-I expressing chondrocytes in the growth plate. This study 
also allowed us to compare the localization of components of the IGF axis in prepubertal mice 
IGF-I 
Figure 2 Expression of the IGF system 
in the postnatal growth plate. Expression 
patterns of IGF-I mRNA (A, B), IGF-II 
mRNA (C, D) and IGFBP-2 mRNA (E, F) 
in representative sections of the growth 
plates of 4-week-old mice, A, C, E, 
PBS-treated mice (PBS), B, D, F, DXM-
treated mice (DXM), as analyzed by 
non-radioactive in situ hybridization. 
Sections were counterstained with 
nuclear fast red. The mRNA signal is 
shown as a blue precipitate.  
R, resting zone; P, proliferative zone; 
H, hypertrophic zone. Scale bar 
represents 100 µm. Arrows indicate 
examples of chondrocytes expressing 
IGF-I mRNA, arrowheads indicate 
examples of chondrocytes expressing no 
IGF-I mRNA. 
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(4-week-old), with our earlier study 13 in postpubertal mice (7-week-old). Likewise, a short-
term GC treatment (1 week) could be compared with a longer GC treatment (4 weeks) as 
performed in our earlier study 13.  
 In the growth plates of prepubertal mice, we detected expression of IGF-I, IGF-II and 
IGFBP-2, while the other IGFBPs were not detected. This confirms our previous study, where 
we detected the same three components of the IGF system in the growth plates of postpubertal 
mice 13. IGF-I, IGF-II and IGFBP-2 mRNAs were predominantly detected in the proliferative 
and prehypertrophic zones. In contrast, in our previous report on postpubertal mice, IGF-I and 
IGF-II were predominantly present in the hypertrophic zone and not in the proliferative 
zone 13. The expression of IGFBP-2 also shifts from predominantly in the proliferative and 
prehypertrophic zones in prepubertal mice to hypertrophic chondrocytes in postpubertal 
mice 13. In previous reports on prepubertal animals, also predominant expression of IGF-I 3 
and IGF-II 9 was shown in the proliferative and prehypertrophic zones of the growth plate, 
whereas in rats of 9 weeks of age, IGF-I was predominantly present in the hypertrophic 
zone 10. We are the first to describe expression of IGFBP-2 in the postnatal growth plate, 
previously only low levels of IGFBP-6 were shown in murine growth plates, using radioactive 
in situ hybridization 9. The age-dependent expression pattern of the IGF system in the 
postnatal growth plate might indicate a shift in the function of the IGF system during 
chondrogenesis and postnatal development. Early in postnatal development, the local 
expression of the IGF system in the growth plate is probably important for the clonal 
expansion of chondrocyte columns in the proliferative zone, as postulated for IGF-I in the 
"dual effector theory" 32, as well as for the differentiation of proliferative chondrocytes into 
hypertrophic chondrocytes 3,4,13,33,34. IGF-I has indeed been shown to stimulate growth plate 
chondrocytes at all stages of differentiation 35, which might also be true for the other 
components of the IGF system. It could well be that later on in postnatal development, after 
puberty, the main function of the IGF system is to augment chondrocyte hypertrophy 4,13 and 
in a much lesser extent to stimulate the proliferation of chondrocytes. This latter function 
might become less important as the growth rate at postpubertal age is much lower.  
 The GC treatment of the prepubertal mice for 1 week inhibited body length, weight and 
organ weight to a similar extent as observed after 4 weeks of treatment 17. This suggests that 
most of the inhibiting effects of GCs on growth occur during the early period of the treatment. 
Longitudinal bone growth is also already decreased after 1 week of GC treatment. Differential 
effects on organ growth are observed, since the thymus and spleen are more severely affected 
than the liver and the kidneys by the GC treatment, as also shown after the long-term GC 
treatment 17.  
 GC-induced growth retardation is suggested to involve a mechanism intrinsic to the growth 
plate 18,19. Therefore, we studied the effects of the short-term GC treatment on the growth 
plate. The short-term GC treatment significantly decreased the total tibial growth plate width, 
confirming previous studies in rats 19 and mice 36. The decrease in total growth plate width 
was caused by a significant decrease in the width of the proliferative zone. Proliferating cell 
nuclear antigen (PCNA) staining decreased, indicating a decreased proliferation, which is 
likely to contribute to the decrease in the width of the proliferative zone. Several in vitro 
studies confirm the susceptibility of proliferative chondrocytes to GCs, in which GCs caused 
a decrease in proliferation 21,25,37. The GC treatment also affected the hypertrophic zone, 
increasing the number of apoptotic chondrocytes 1.6-fold. This finding confirms previous 
reports, which showed a similar increase in apoptotic chondrocytes in GC-treated rats 19,38. 
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Both the decreased proliferation and increased apoptosis in the growth plate probably 
contribute to the observed GC-induced growth retardation. 
 The growth retarding effects on GCs are suggested to involve impaired action of the IGF 
system 15,20,21. The short-term GC treatment decreased IGF-I serum levels, which confirms 
previous data in chickens 16. However, in humans 22,23 and during long-term GC treatment of 
mice 17, GC treatment increased IGF-I serum levels. These discrepancies are probably due to 
species, age and/or treatment differences. The IGF-II serum levels are very low in mice and 
are not affected by GC treatment 17. IGFBP serum levels were not affected by the DXM 
treatment, confirming previous reports 16,17. Serum levels of the IGF system, however, are 
reported to provide little insight into the involvement of the IGF system in GC-induced 
growth retardation 23, indicating the importance to study the local effects of GCs on the 
growth plate and the IGF system. 
 The short-term GC treatment decreased IGF-I expression in the growth plate, whereas the 
number of IGF-II and IGFBP-2 expressing chondrocytes was not affected. The decrease in 
IGF-I expressing chondrocytes is probably related to the decrease in proliferation, as 
indicated by the decreased number of PCNA-positive cells. In IGF-I knock-out mice, 
proliferation in the growth plate is decreased 3 and also chondrocyte hypertrophy is 
inhibited 3,34. This further strengthens our suggestion that a decrease in IGF-I expression in 
the growth plate, caused by the GC treatment, results in a decreased proliferation of 
chondrocytes. The differentiation of chondrocytes to the hypertrophic phenotype might also 
be inhibited, as IGF-I expression in the prehypertrophic zone is also decreased. The decreased 
proliferation, and possibly the decreased differentiation, would then result in a retardation of 
the endochondral ossification, causing the retardation of longitudinal bone growth.  
 The decrease in IGF-I due to the short-term GC treatment is in contrast with the increase of 
IGF-I in the growth plate after long-term GC treatment 13. This difference could be linked to a 
decrease in severity of GC effects on growth and the growth plate over time. We showed in 
this study that the growth retarding effect of GCs after a short-term treatment is almost equal 
to the growth retardation after a long-term treatment 17. This suggests that the different organs 
as well as the growth plate do not seem to respond to the GCs anymore. It has been shown 
that the growth plate indeed becomes less sensitive to GCs after a period of time, as the 
number of glucocorticoid receptors is decreased after a 3 week GC treatment in rats 19. The 
observed increase of IGF-I levels in the growth plate and serum, after a long-term treatment, 
might then be part of a compensatory mechanism for the induced growth retardation 13. Both 
in the short-term and the long-term GC treatment 13, IGF-II and IGFBP-2 mRNA levels in the 
growth plate were not affected. This suggests that, in contrast to IGF-I, IGF-II and IGFBP-2 
do not seem to be involved in GC-induced growth retardation. 
 In conclusion, we suggest that the action of IGF-I is impaired by GC treatment during the 
early periods of treatment, contributing to the GC-induced growth retardation. Later on, IGF-I 
becomes part of a compensatory mechanism of the growth plate to diminish the induced 
growth retardation, which is however not sufficient to completely abolish the growth deficit. 
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ABSTRACT 
 
 
Glucocorticoid (GC) treatment of children often leads to growth retardation, and the 
precise target(s) in the growth plate responsible for this effect are unknown. We treated 
6-week-old prepubertal piglets (10 kg) for 5 days with prednisolone (PRDL) and studied 
whether apoptosis and angiogenesis of the growth plate could be possible targets of GCs.  
 In the PRDL-treated animals, the total width of the growth plate decreased to 81% of 
controls (P<0.02), which was explained by a decrease of the width of the proliferative 
zone to 73% (P<0.05). The treatment had no effect on the orderly organization of the 
chondrocyte columns. In the growth plates of control animals, apoptosis was shown in 
5.8% of the hypertrophic chondrocytes and was limited to the terminal hypertrophic 
chondrocytes. In PRDL-treated animals, 40.5% of the hypertrophic chondrocytes was 
apoptotic (P<0.02), with apoptotic chondrocytes also appearing higher in the 
hypertrophic zone.  
 CD31 immunohistochemistry showed fewer capillaries and loss of their parallel 
organization in the metaphysis in the PRDL-treated animals. The capillaries were 
shorter and chaotic in appearance. In contrast to controls, in PRDL-treated animals 
VEGF mRNA and protein could not be detected in the hypertrophic zone of the growth 
plate. Trabecular bone length in the primary spongiosa was also diminished by the 
treatment. 
 These results indicate that short-term GC treatment of growing piglets severely 
disturbs the width of the growth plate, apoptosis of chondrocytes, VEGF expression by 
hypertrophic chondrocytes, the normal invasion of blood vessels from the metaphysis to 
the growth plate and bone formation at the chondro-osseous junction. These effects 
could alter the dynamics of endochondral ossification and thus contribute to 
GC-induced growth retardation. 
 
 
INTRODUCTION 
 
 
Endochondral bone formation and longitudinal bone growth are the result of proliferation, 
differentiation, maturation and eventually apoptosis of chondrocytes within the growth plate 1. 
Apoptosis of terminal hypertrophic chondrocytes (i.e., adjacent to the ossification front) 2-4 is 
associated with extracellular matrix degradation and vascular invasion of the growth plate 1. It 
results in a cartilaginous scaffold on which new bone will be formed by invading osteoblasts. 
To allow osteoblasts to invade the growth plate, vascularization (i.e., angiogenesis) at the 
chondro-osseous junction between metaphyseal bone and the growth plate is required. It has 
been suggested that a mutual control exists between apoptosis and angiogenesis 5. Endothelial 
cells express growth factors that promote the differentiation of chondrocytes to a hypertrophic 
phenotype 5. Conversely, the growth plate secretes factors which promote angiogenesis 6. One 
of these factors, vascular endothelial growth factor (VEGF), is a key regulator of 
angiogenesis 6. VEGF inactivation in mice results in suppression of blood vessel invasion, 
impaired bone formation and expansion of the hypertrophic zone of the growth plate, 
demonstrating that VEGF is essential for attraction of capillaries to the growth plate and 
appears necessary for growth plate function 7. Matrix metalloproteinases (MMPs) are among 
Chapter 5 
 74
the other factors, which are important for angiogenesis and bone formation. They degrade the 
cartilage extracellular matrix and release angiogenic factors such as VEGF from the growth 
plate matrix 8. In MMP-9 knock-out mice, abnormal vascularization of the growth plate, 
delayed apoptosis of hypertrophic chondrocytes and expansion of the hypertrophic zone are 
observed 9. The growth plates of these mice show similar abnormalities as the growth plates 
of mice in which VEGF is inactivated 7. These results suggest a link between cartilage matrix 
degradation, apoptosis, angiogenesis, and VEGF and MMP-9 expression. 
 Agents which disturb longitudinal growth, could potentially act through interference with 
apoptosis and angiogenesis. Glucocorticoids (GCs) are effective drugs in anti-inflammatory 
and immuno-suppressive therapy, but are well known to result in growth retardation in 
children 10,11 and experimental animal models 12-16. GCs act locally to inhibit longitudinal 
bone growth, suggesting a mechanism intrinsic to the growth plate 4,17. 
 Treatment with GCs can also result in osteoporosis 18. One of the mechanisms involved is 
an induction of apoptosis in osteoblasts and osteocytes 18. Treatment of rats for 3 weeks with 
GCs indeed resulted in an increase of apoptosis of osteoblasts and, in addition, of 
hypertrophic chondrocytes 4. This indicates that GCs can also interfere with apoptosis in the 
growth plate. We have previously shown that GC treatment of cultured porcine growth plate 
chondrocytes resulted in a down-regulation of VEGF expression 19. Given the pivotal role of 
growth plate-derived VEGF in vascularization, it is conceivable that, in addition to increasing 
apoptosis, GCs could target vascularization of the growth plate, thus contributing to the 
mechanisms of growth retardation. 
 We aimed to study whether apoptosis, angiogenesis and architecture in the growth plate are 
disturbed by short-term (5 days) GC treatment of growing piglets. The growing piglet is a 
good model for growing children 20. When compared to the growth plates of rodents, the pig 
growth plate more closely resembles the human growth plate in terms of cellular numbers in 
the different zones, cell kinetics and patterns of closure 21,22.  
 
 
MATERIALS AND METHODS 
 
 
Animal studies 
Twelve 6-week-old (prepubertal) female cross-bred (Landrace x Yorkshire) piglets 23 with an average weight of 
10 kg were studied. The animals were fed 50 g/kg per day of a standard diet (De Heus Brokking Koudijs BV, 
Barneveld, The Netherlands). One group of 6 piglets received orally 5 mg/kg bodyweight prednisolone (PRDL) 
daily, for a period of 5 days. Piglets were terminated at the end of the experiment by injection of 1 g pentothal.  
 The experimental protocol was approved by the committee for Animal Experiments of the University 
Medical Center Utrecht, The Netherlands. 
 
 
Tissue preparation 
Tibiae were dissected and the proximal heads were cut sagitally and fixed in buffered 3.8% formalin for 
3-6 days. They were subsequently decalcified in 0.45 M phosphate-buffered EDTA, pH 8.0 for 18-25 days, 
washed in PBS, dehydrated through a series of ethanol and embedded in paraffin.  
 Sections of 10 µm were cut on an ultramicrotome and mounted on 2% amino-propyl-triethoxy silane/3% 
glutaraldehyde coated glass slides. Sections were deparaffinized and hydrated prior to histochemical analyses 
(see below). 
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Morphometry 
Growth plate sections were stained with haematoxylin and eosin and pictures of the growth plate sections were 
taken with a Zeiss Axiomat HRC camera equipped with the Axiovision software, version 3.0 (Zeiss, 
München-Hallbergmoos, Germany). The interactive measurement module was used for measurements of the 
growth plate width.  
 Total width of the growth plate (distance between the epiphysis and the chondro-osseous junction) was 
determined from 4 images (magnification X50) per growth plate section, covering the entire transverse area 
within about 500 µm of the cortex. Of these images, measurements at 200 µm intervals were performed (about 
50 measurements per growth plate) and averaged. The measuring lines were subsequently shortened to the first 
appearance of regular chondrocyte columns (the boundary between the resting and the proliferative zones) and to 
the first enlargement of the flattened cells (the boundary between the proliferative and the hypertrophic zones). 
From the lengths of these lines the widths of the three different zones of the growth plate were calculated.  
 
 
In situ hybridization for VEGF 
cDNA encoding human VEGF was kindly provided by M.F. Gebbink and E.E. Voest (University Medical 
Center Utrecht, the Netherlands) 24 and was used as a template for the synthesis of antisense and sense 
digoxigenin-labeled cRNA probes. Standard RNA synthesis reactions using T7- or T3-RNA polymerase were 
carried out using digoxigenin-UTP (Roche, Mannheim, Germany) as a substrate 25.  
 The in situ hybridization was performed as described previously 26. As a control for specific hybridization, 
sections were hybridized with the appropriate sense probes, which showed no signals. Analysis of the different 
animals of both groups was performed in the same in situ hybridization.  
 To compare the control and PRDL-treated piglets with each other, the glass slides were independently scored 
by three investigators. 
 
 
Immunohistochemistry 
Sections were blocked with 10% serum (Vector Laboratories, Inc., Burlingame, CA, USA) from the species in 
which the secondary antibody was raised. The following primary antibodies directed against human proteins 
were used: rabbit anti-VEGF, goat-anti CD31/PECAM-1 (Santa Cruz Biotechnology Inc., Santa Cruz, CA, 
USA) and goat anti-MMP-9 (R&D Systems, Inc., Minneapolis, MN, USA). A blocking peptide for VEGF was 
from Santa Cruz Biotechnology. Antibodies were used at 1:100 dilution in 1.5% blocking serum in PBS and 
incubated for 1 h at room temperature. For negative controls, the first antibody was omitted from this diluent and 
for VEGF a blocking peptide was also used. Negative controls did not show any signal. Biotinylated secondary 
antibodies (Vector Laboratories) were used at 1:200 dilution and incubated for 30 min. For detection, the avidin-
biotin peroxidase complex method (Vector Laboratories Vectastain ABC kit) in combination with nickel-
enhanced 3,3’-Diaminobenzidine Tetrahydrochloride (DAB, Sigma Chemical Co., St. Louis, MO, USA) as 
substrate was used. Sections were counterstained with nuclear fast red, dehydrated and mounted with DPX 
(Klinipath, Duiven, The Netherlands).  
 Analysis of the different animals of both groups was performed in the same immunohistochemistry. To 
compare the control and PRDL-treated piglets with each other, the glass slides were independently scored by 
three investigators. 
 
 
Determination of apoptosis 
Apoptotic death was determined by the TUNEL reaction (Promega, Leiden, The Netherlands), which was 
performed according to the procedures of the manufacturer. For negative controls, the TdT enzyme was replaced 
by water, which resulted in the absence of any signal. After the DAB staining, sections were counterstained with 
0.1% light green, dehydrated and mounted with DPX.  
 For quantitative evaluation of the number of TUNEL-positive chondrocytes in the hypertrophic zone, 
sections were coded and the number of positive cells in the hypertrophic zone were counted and expressed 
relative to the total number of cells in the hypertrophic zone, by two independent observers. 
 
 
Statistical Analysis 
Results from the TUNEL-staining and growth plate width are expressed as means ± SEM. Statistical differences 
between the control and the PRDL-treated group were determined by the unpaired t-test, using InStat 
version 3.00 (GraphPad Software, Inc., San Diego, CA, USA). A P-value of less than 0.05 was considered 
statistically significant.  
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RESULTS 
 
 
Growth plate morphology 
A 5 day prednisolone (PRDL) treatment (50 mg/day) of prepubertal piglets significantly 
decreased the total width of the proximal tibial growth plate to 81% ± 6% of control values 
(P<0.02) (Fig. 1A, B), caused by a significant decrease of the proliferative zone to 73% ± 9% 
of control values (P<0.05) (Fig. 1C). The hypertrophic zone showed a small, non-significant, 
decrease, whereas the resting zone was not affected by the PRDL treatment. The PRDL 
treatment had no effect on the morphology of the growth plate, the chondrocytes being 
organized in the same orderly columns as in the control animals (Fig. 1A, B).  
 Trabecular bone length in the primary spongiosa of the PRDL-treated piglets was clearly 
diminished when compared to the untreated controls (Fig. 1D, E). At the chondro-osseous 
junction, many of the calcified longitudinal septae of the growth plate did not continue as 
bone trabeculae, but were in direct contact with the marrow cavity.  
 In the growth plates of the untreated piglets, only the row of terminal hypertrophic 
chondrocytes contained a low percentage (5.8% ± 1.7%) of apoptotic cells (Fig. 1F). PRDL 
treatment significantly increased the number of apoptotic chondrocytes in the hypertrophic 
zone to 40.5% ± 5.4% (6.9-fold increase, P<0.02) (Fig. 1G). In addition to the terminal 
hypertrophic zone, also the higher layers of the hypertrophic zone contained apoptotic 
chondrocytes in the PRDL-treated piglets (Fig. 1G). 
 
 
Angiogenesis 
In the control piglets, metaphyseal blood vessels ran parallel to the chondrocyte columns in 
the growth plate and ended at the osteochondral junction, as shown by immunohistochemistry 
for CD31 (Fig. 2A). PRDL treatment resulted in fewer, disorganized and short blood vessels, 
although they still penetrated the hypertrophic zone of the growth plate (Fig. 2B).  
 We studied whether this disturbed angiogenesis could be due to changes in expression of 
VEGF and/or MMP-9 protein. In situ hybridization analysis showed predominant expression 
of VEGF mRNA in the hypertrophic zone and in occasional chondrocytes of the proliferative 
and resting zones (Fig. 2C). Immunohistochemistry showed a similar expression pattern for 
the VEGF protein (Fig. 2E).  
 In the PRDL-treated piglets, VEGF mRNA and protein in the hypertrophic zone were not 
detectable. In the osteoblasts aligning the trabeculae, the levels of VEGF mRNA and protein 
did not appear to be affected by the PRDL treatment (Fig. 2D, F). In control animals, MMP-9 
protein was detected in cells alining the bone trabeculae and at the transverse septae of the 
cartilage-bone junction (Fig. 2G). PRDL treatment did not alter this expression pattern 
(Fig. 2H). 
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Figure 1 Haematoxylin and eosin staining of representative sections of proximal tibial growth plates of 
6-week-old prepubertal control (A, D) and PRDL-treated piglets (B, E). (C) result of measurements of total 
growth plate width of control and PRDL-treated piglets and of the three different zones of the growth plate. 
The data represent the mean ± SEM. *P < 0.05, **P<0.02, PRDL relative to control. Bars represent 500 µm 
in (A, B). and 200 µm in (D, E). T, denotes the total growth plate; R resting zone; P, proliferative zone; 
H, hypertrophic zone.  
(F,G) Apoptosis, as shown by TUNEL-staining, in representative sections of tibial growth plates. (F) control 
piglets; and (G) PRDL-treated piglets; TUNEL staining is shown as a dark precipitate. Arrows indicate 
examples of TUNEL-positive cells. The scale bar represents 50 µm.  
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DISCUSSION 
 
 
In our study, piglets treated with GCs showed i) diminished proliferative zone and total 
growth plate widths, ii) changes in the morphology of the trabecular bone in the primary 
spongiosa, iii) increased apoptosis in hypertrophic chondrocytes and iv) decreased VEGF 
expression in the growth plate and disturbed blood vessel arrangement, but no changes in 
MMP-9. 
 GC treatment results in decreased growth in children 10,11, several experimental animal 
models 12-14 and also in piglets 15,16, which are a good model for growing children 20. 
GC-induced growth retardation occurs at the local level of the growth plate 4,17 and as the pig 
growth plate more closely resembles the human growth plate 21,22, it is important to study the 
effects of GCs on the pig growth plate. We found a 27% reduction in the width of the 
proliferative zone in the piglet tibial growth plate due to GC treatment. In rats, GC treatment 
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Figure 2 Angiogenesis in representative 
sections of tibial growth plates of control 
(A, C, E, G) and PRDL-treated piglets (B, D, 
F, H).  
(A, B) CD31 immunohistochemistry for 
detection of blood capillaries;  
(C, D) VEGF mRNA expression, as analyzed 
by in situ hybridization;  
(E, F) VEGF protein expression, as analyzed 
by immunohistochemistry;  
(G, H) MMP-9 protein expression, as 
analyzed by immunohistochemistry.  
The mRNA signal is shown as a blue 
precipitate and the protein signal as a dark 
precipitate. Scale bars represent 100 µm. 
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suppressed the proliferation rate without changing the width of this zone 27,28 and in mice we 
found a 10% decrease in the proliferative zone, concomitant with dexamethasone-induced 
growth inhibition 12,26. Also in rabbits, dexamethasone decreased bone growth together with 
the width of the proliferative zone 29. In addition to these in vivo data, also in vitro 
experiments using cultured rodent and porcine chondrocytes have shown that GCs inhibit 
their proliferation 30-32. 
 In addition to the proliferative zone, the hypertrophic zone was also affected by the GC 
treatment: there was a 7-fold increase in apoptosis in the PRDL-treated piglets, with apoptotic 
chondrocytes also appearing higher in the hypertrophic zone. In rats, GC treatment resulted in 
a 2-fold increase in apoptosis of hypertrophic chondrocytes, only in terminal hypertrophic 
chondrocytes 4,28. It is possible that these differences are due to different susceptibilities of 
growth plates between species, or due to differences in age and duration of the GC treatment. 
Interestingly, cell death of terminal chondrocytes has been found to inversely correlate with 
the growth rate of the bone 33. GCs, by increasing apoptosis, thus may negatively regulate 
bone growth. In our study, the width of the hypertrophic zone was only marginally decreased. 
Possibly, an accelerated differentiation of proliferative chondrocytes into hypertrophic 
chondrocytes 34 compensates for the enhanced apoptosis, leaving the number of chondrocytes 
in the hypertrophic zone almost unchanged. GC-induced apoptosis could involve the Bcl-2 
protein family, the balance between Bcl-2 (anti-apoptotic) and Bax (pro-apoptotic) 
supposedly determining the rate of apoptosis 35. However, PRDL treatment of our piglets did 
not show an effect on the expression patterns of Bcl-2 and Bax (data not shown). In previous 
studies, the ratio Bcl-2 to Bax could only partly explain the increased apoptosis in the growth 
plate due to GC treatment 28,36, suggesting that the occurrence of apoptosis is not directly 
related to detection of altered Bax and Bcl-2 protein levels. 
 Besides the effects of the PRDL treatment on growth plate cartilage, the structure of 
primary trabeculae and trabecular bone formation of the primary spongiosa were also severely 
disturbed, already after this short-term GC treatment. GCs have also been shown to affect 
bone formation in the secondary spongiosa by decreasing bone formation and increasing bone 
resorption 37,38, both of which could contribute to GC-induced osteoporosis 18. Our study 
demonstrates that the primary spongiosa is affected as well. 
 PRDL treatment also resulted in disorganized and short metaphyseal blood vessels in the 
tibia, which has not been shown before. Normal blood vessel invasion of the growth plate is 
required for endochondral ossification to occur 1,6. Disturbance of angiogenesis has been 
shown to affect endochondral ossification and longitudinal bone growth 7.  
 Many genes have been described to be involved in angiogenesis, with VEGF being one of 
the main modulators 6. In our control piglets, VEGF mRNA and protein are predominantly 
expressed in the hypertrophic zone, which is in accordance with other studies 7,39. In the 
PRDL-treated animals, VEGF mRNA and protein were no longer detectable in the 
hypertrophic zone. In prepubertal rats, GC treatment also resulted in a down-regulation of 
VEGF in the growth plate 28, although this decrease was not as severe as shown in our piglets. 
We have previously shown a down-regulation of VEGF expression by GCs in piglet 
chondrocytes in vitro 19. Together, our findings suggest that GCs decrease VEGF expression 
in the growth plates of growing piglets, which could be the cause of the disturbed 
angiogenesis, resulting in the observed defects in capillary architecture and metaphyseal bone. 
Besides the involvement of VEGF, possibly other angiogenic and/or anti-angiogenic factors 
could be involved in the disturbed angiogenesis in our PRDL-treated piglets. We examined 
MMP-9, which is known to make VEGF bioavailable and is important for angiogenesis to 
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occur 6,8, but found no effect of the GC treatment on the MMP-9 expression pattern. Still 
other factors could be postulated as intermediates in GC action. For instance, TGF-β inhibits 
angiogenesis 40 and stimulates apoptosis 41. IGF-I, on the other hand, protects against 
GC-induced apoptosis 42, stimulates production of VEGF in growth plate chondrocytes 19 and 
is important for angiogenesis 43. We have previously suggested that IGF-I in the growth plate 
could contribute to or counteract the adverse effects of GCs on growth 26.  
 In conclusion, within 5 days, GC treatment suppresses VEGF expression in the tibial 
growth plate of growing piglets, which could be responsible for the observed disturbed 
vascularization of the growth plate. In the growth plate, both proliferative and hypertrophic 
chondrocytes are affected by the GC treatment. These changes indicate a rapid onset in 
disturbance of endochondral ossification, with disturbed growth as a likely result.  
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ABSTRACT 
 
Vascular endothelial growth factor (VEGF) plays an essential role in angiogenesis in the 
growth plate and ultimately in regulating endochondral ossification. Since longitudinal 
bone growth is often disturbed in children who are treated with glucocorticoids, we 
investigated the effects of dexamethasone (DXM) on VEGF expression by epiphyseal 
chondrocytes. Cells were cultured from tibial growth plates of neonatal piglets, which 
expressed the chondrocyte-specific genes aggrecan, collagen II and CD-RAP, as well as 
the glucocorticoid receptor (GR). VEGF protein secreted from these cells was examined 
by ELISA and Western immunoblotting. The VEGF121 and VEGF165 isoforms were 
detected in the supernatant. As determined by RT-PCR, all three major mRNA splice 
variants of VEGF were produced, including the species encoding VEGF189.  
 DXM (100 nM) inhibited both VEGF protein and mRNA expression by 
approximately 45%. Hydrocortisone (cortisol) and prednisolone also inhibited VEGF 
secretion, but they were less active than DXM. The inhibitory actions of DXM were 
almost completely blocked by the GR antagonist Org34116, indicating that the GR 
mediates these actions. Degradation of the VEGF mRNA was not accelerated by DXM. 
Therefore, a transcriptional mechanism seems likely. Downregulation of VEGF could 
lead to disruption of the normal invasion of blood vessels in the growth plate, which 
could contribute to disturbed endochondral ossification and growth.  
 
 
INTRODUCTION 
 
Longitudinal bone growth depends on the proliferation, differentiation and subsequent 
ossification of growth plate cartilage. The rates of  chondrocyte proliferation and 
differentiation to the hypertrophic phenotype are determined by a complex interplay between 
many signaling molecules. Also the ensuing process of endochondral ossification is tightly 
regulated, and involves the interrelated processes of extracellular matrix degradation, 
apoptosis of terminal hypertrophic chondrocytes and angiogenesis: the invasion of the growth 
plate by new blood vessels from the metaphysis. The molecular mechanisms involved in 
chondrocyte differentiation and endochondral bone formation have been reviewed by Stevens 
and Williams 1. Signals that direct the polarity of the growth plate, angiogenesis and bone 
formation originate in the growth plate itself, as was elegantly demonstrated by excising, 
inverting and reimplanting rabbit growth plates 2. While the polarity of the cartilage was 
maintained, the epiphyseal bone, which became adjacent to the hypertrophic zone of the 
growth plate, became the site of blood vessel and bone cell invasion and longitudinal bone 
growth. 
 Angiogenesis can be induced by basic fibroblast growth factor 3, transferrin 4 and other 
factors 5, but vascular endothelial growth factor (VEGF) is the quintessential angiogenic 
factor in this respect, as was demonstrated by treating growing mice with a soluble 
antagonist 6. This treatment resulted in suppression of blood vessel invasion, accompanied by 
impaired resorption of terminal chondrocytes and formation of the primary spongiosa 
(trabeculae of the metaphyseal bone). VEGF is expressed by many tissues and cell types, 
including the growth plate cartilage 6-9. Its expression can be induced by many factors, 
including hypoxia 10, estrogen 11, osteogenic protein-1/BMP-7 12, PDGF 13 and IGF-I 9,14-17.  
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 Given its pivotal role in maintaining the normal structure of the growth plate 6, VEGF 
could be a potential target for agents, which disturb longitudinal growth. Glucocorticoids 
(GCs) are well known to induce growth retardation 18-20 as well as osteoporosis 21. Direct local 
actions of GCs on the growth plate have been demonstrated in vivo 22, which likely occur 
through interaction with the glucocorticoid receptor (GR) 23. Although many of the inhibitory 
actions of pharmacological doses of GCs on skeletal growth appear to be mediated by 
interference with the GH/IGF-I axis 24,25, their effects on angiogenesis and in particular VEGF 
expression in the growth plate are worth investigating. In this study, we set out to characterize 
the effects of pharmacological doses of DXM and other GCs on VEGF expression by cultured 
porcine growth plate chondrocytes.  
 
MATERIALS AND METHODS 
 
Materials 
Recombinant human IGF-I was kindly provided by Eli Lilly & Co. (Indianapolis, IN, USA). Cortisol (HC) 
(hydrocortisone, Solu-Cortef) was from Pharmacia & Upjohn B.V. (Woerden, The Netherlands). Prednisolone 
(PRDL) (Di-Adreson-F) was from N.V. Organon (Oss, The Netherlands). The GR antagonist Org34116 was 
kindly provided by Dr. M. de Gooyer (N.V. Organon, Oss, The Netherlands). DXM (as dexamethasone 
disodium phosphate) was from Merck Sharpe & Dohme (Haarlem, The Netherlands). Platelet-derived growth 
factor (PDGF)-AB, protease (P-6911), collagenase (C-9891), actinomycin D, BSA, salmon sperm DNA and 
Alcian Blue 8GX were from Sigma Chemical Co. (St, Louis, MO, USA). Rabbit polyclonal anti-VEGF antibody 
and blocking peptide were from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Peroxidase-conjugated 
donkey anti-rabbit antibody, Oligo(dT)12-18 primer, RediPrime Random Primer labeling mixture, [α-32P]dCTP 
(10 mCi/ml), Nylon membrane (Hybond-N+, 0.2 µm) and Hyperfilm ECL film were obtained from Amersham 
Pharmacia Biotech (Little Chalfont, UK). Centricon-10 ultrafiltration membranes and PVDF membranes 
(Immobilon-P) were from Millipore Corp. (Bedford, MA, USA). Restriction enzymes, AmpliTaq DNA 
polymerase, modifying enzymes and TriPure isolation reagent were purchased from Roche Molecular 
Biochemicals (Mannheim, Germany). M-MLV Reverse Transcriptase was from Promega Corp. (Madison, WI, 
USA). The TOPO TA Cloning kit was from Invitrogen Corp. (Carlsbad, CA, USA). 
 
Cell culture 
The growth plates were dissected from the distal and proximal tibiae of neonatal piglets. The piglets were used 
and sacrificed for unrelated experiments by the Neonatology Department of the University Medical Center 
Utrecht. These experiments did not interfere with the normal physiology of the growth plate cartilage. 
Subsequently, the epiphyseal growth plate chondrocytes were isolated and grown as described previously 26. 
Generally, second passage cells were used for experiments, but identical results were obtained with first and third 
passage cells. When cells were to be treated with growth factors and hormones followed by VEGF ELISA or 
Western blotting, they were seeded (40,000 or 80,000 cells per well) on 24-well plates  
 Conditioned medium was prepared by incubating the cells in medium containing 10% FCS, which had been 
stripped of steroids by adsorption with dextran-coated charcoal. In order to analyse the secreted VEGF protein by 
electrophoresis and Western immunoblotting, serum-free medium supplemented with 10 nM IGF-I and 0.005% BSA 
was used instead.  
 In a few cases, also the amount of VEGF secreted under these conditions was measured by ELISA, and no 
differences were found between both milieus for collecting conditioned medium, neither in the amount of VEGF 
secreted, nor in the inhibitory effect of DXM. Experiments in which RNA was to be isolated from the cells were 
always performed in the presence of 10% stripped FCS. 
 
Analysis of VEGF protein 
Chondrocyte-conditioned medium (1 ml) was collected after 48 h, centrifuged for 10 min at 3000 x g (4°C) and 
stored at –80°C. VEGF concentrations were measured by ELISA (R&D Systems, Inc., Minneapolis, MN, USA) 
according to the manufacturer’s instructions. The adherent cells were washed three times with PBS and lysed in 
100 µl 2% SDS, 125 mM Tris-HCl pH 6.8, followed by boiling for 5 min. Ten microliter was used to measure the 
protein content (using the BCA reagent, Pierce, Rockford, IL, USA). VEGF levels were normalized to the protein 
content of the cells. 
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 For Western immunoblotting, the conditioned media were concentrated 10-fold on Centricon-10 ultrafiltration 
membranes and loaded on a 12% gel for reducing SDS-PAGE. VEGF was visualized by electrotransfer to PVDF 
membranes, followed by incubation with rabbit polyclonal antibody (1/200 dilution) and peroxidase-conjugated 
donkey anti-rabbit antibody (1/4000 dilution). The bands were visualized using the SuperSignal WestPico 
Chemiluminescent Substrate of Pierce (Rockford, IL, USA) and Hyperfilm ECL film. Molecular weights were 
calculated using BioRad (Hercules, CA, USA) broad range markers as standards.  
 
RNA isolation and Northern blot analysis 
Cells (1 x 106) were cultured in 25 cm2 tissue culture flasks and treated with GCs for 24 h. Cells were directly 
lysed with Tripure solution reagent and total RNA was extracted according to the procedures of the 
manufacturer, based on the single-step acid guanidinium-thiocyanate method 27. Total RNA was separated by 
electrophoresis in a 1% (w/v) agarose/2.2 M formaldehyde gel in 1x 3-(morpholino) propanesulphonic acid 
buffer, transferred to a 0.2 µm nylon membrane and crosslinked to the membrane by UV radiation. 
 The membranes were prehybridized for 2 h at 55ºC in a solution containing 0.1% SDS, 3xSSC, 
5x Denhardt’s solution, 10% dextran-sulfate and 50 µg/ml denaturated salmon sperm DNA. Hybridization was 
performed at 55ºC (65ºC for GAPDH) overnight in the same solution, containing the indicated [α-32P]dCTP-
labeled probe. Probes (see below) were labeled with [α-32P]dCTP using the random hexamer RediPrime kit. The 
blots were washed up to a stringency of 0.5x SSC, 0.1% SDS at 55°C (0.1x SSC, 0.1% SDS at 65°C for GAPDH, 
collagen II).  
 The hybridization signals were analyzed by densitometry using the GS-363 Molecular Imager and the 
Molecular Analyst software program (version 1.5) (Biorad) and the relative abundance of the different mRNAs 
was subsequently normalized to the GAPDH values. In addition, the filters were exposed to Fuji Super RX film 
(Düsseldorf, Germany). 
 The cDNA probes for collagen types I and II, aggrecan and GAPDH were described before 25. A probe for 
porcine CD-RAP (cartilage-derived retinoic acid sensitive protein) 28 was prepared by RT-PCR from total RNA 
isolated from the cultured chondrocytes as described below. The PCR product was ligated into the pCRII-TOPO TA 
Cloning vector as described by the manufacturer and sequenced using a capillary sequencer. The cDNA probe for 
human VEGF was a kind gift of Dr. M.F. Gebbink and Dr. E.E. Voest (University Medical Center Utrecht). The 
520 bp insert encompassing the sequence encoding VEGF121 29 was excised using NcoI / BglII double digestion. 
 
RT-PCR and Southern blotting 
One microgram of total RNA was reverse transcribed using 1 µg of oligo(dT) as primer and 200 U of Reverse 
Transcriptase for 90 min at 42°C in a total volume of 25 µl. Two microliter of cDNA was amplified by PCR 
using the following primers: CD-RAP, forward 5’-ATGCCCAAGCTGGCTGAC-3’ and reverse 
5’-ATGCTACTGGGGAAATAGC-3’ (240 bp product); GR, forward 5’-GTGAGTACCTCTGGAGGACA-3’ 
and reverse 5’-CTTTGCCCATTTCACTGC-3’ (761 bp product). The VEGF primers (forward 
5’-AGTGTGTGCCCACTGAGGAG, corresponding to nt 278-297 in exon 3 and reverse 
5’-ACCGCCTCGGCTTGTCACAT, corresponding to nt 627-648 in exon 8) were selected, because they are 
identical in human and porcine VEGF, and have identical melting temperatures. In each case, the PCR consisted 
of an initial denaturation step for 5 min at 94°C, followed by 30-35 cycles (1 min at 94°C, 1 min at 58°C, 1 min 
at 72°C) and a final extension step (10 min at 72°C) in a total volume of 50 µl containing 10 pmol of primers. 
PCR products were analyzed on a 1% agarose gel. 
 For Southern blotting of VEGF, 4 µl from the PCR reaction was loaded on a 1% agarose gel. Southern 
blotting and hybridization with 32P-labeled VEGF cDNA probe was essentially carried out as described above 
for the Northern blot analysis.  
 
Statistical analysis 
Data from VEGF ELISA were normalized for total protein content and data from Northern blots were 
normalized for GAPDH content. Results are expressed as means ± SEM. Statistical differences between two 
groups were determined by two-tailed Student’s t-test. Statistical differences between multiple treatments were 
determined by one-way ANOVA using InStat version 3.00 (GraphPad Software, Inc., San Diego, CA). The 
Tukey-Kramer post-hoc test was used to determine significance between treatment groups. A P-value of less 
than 0.05 was considered statistically significant. 
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RESULTS 
 
Characterization of growth plate chondrocytes 
The cultured porcine growth plate chondrocytes maintained their chondrocyte phenotype, as 
shown by the mRNA expression of specific chondrocyte markers. Using Northern blot 
analysis, transcripts were detected for collagen II (5.4 kb), aggrecan (8.0 kb) and CD-RAP 
(0.8 kb) (Fig.1). 
 
 
 
 
 
 
 Collagen I mRNA, specific for fibroblasts, osteoblasts and dedifferentiated chondrocytes, 
was expressed at very low levels, whereas in NIH 3T3 mouse fibroblasts a strong signal was 
observed (data not shown). Staining of sulfated proteoglycans in the extracellular matrix with 
Alcian blue also showed that the chondrocyte cultures were not contaminated with fibroblasts 
or osteoblasts and that the chondrocytes were not de-differentiated 30 (data not shown).  
 
Secretion of VEGF protein from chondrocytes 
Chondrocytes, when cultured in the presence of serum, secreted 400-1600 pg/ml 
(1.3-4.6 pg/µg protein) VEGF over a 48 h period, as measured with an ELISA assay. In the 
absence of serum, VEGF production was stimulated by PDGF (threefold at 5 nM) and by 
IGF-I (1.8 ± 0.2 -fold at 10 nM, n = 5 independent experiments, P<0.02). In the presence of 
10 nM IGF-I, 600-1300 pg/ml (2.3-6.1 pg/µg protein) VEGF accumulated over a 48 h period. 
DXM caused a dose-dependent decrease of secreted VEGF protein (Fig. 2A). The GR 
antagonist Org34116 31 largely reversed the inhibitory action of DXM, indicating the 
involvement of functional GRs in the action of DXM.  
 When compared with the inhibitory effect of DXM, hydrocortisone (HC; cortisol) and 
prednisolone (PRDL) were less potent, but at 1000 nM were also able to cause 80% inhibition 
of VEGF secretion (Fig. 2B).  
 On Western immunoblot, two species of secreted VEGF were detected at 20 and 23 kDa 
(Fig. 2C). When the antibody was first preabsorbed with VEGF blocking peptide, these bands 
were not detected (data not shown). Based on their relative weights and the fact that they were 
released from the cells, these forms most likely represent the VEGF121 and VEGF165 isoforms. 
VEGF121 lacks both heparin-binding regions, making it highly diffusible, while VEGF165 still 
retains some cell-binding properties. The intensities of both isoforms decreased in parallel in 
response to DXM treatment, while Org34116 blocked the action of DXM.  
 Thus, the results obtained from the immunoblot completely correspond to the ELISA 
measurements. Similarly, HC and PRDL inhibited the secretion of both VEGF isoforms (data 
not shown). 
 
 
 
 
 
 
Figure 1 Characterization of cultured primary porcine growth plate chondrocytes. 
Total RNA was isolated and subject to Northern blot analysis for the expression of 
chondrocyte-specific markers. Representative Northern blot data are shown. 
Col II, collagen II; aggr, aggrecan; CD-RAP, cartilage-derived retinoic acid-sensitive 
protein. 
Col II aggr CD-RAP 
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RT-PCR and Southern blotting 
RT-PCR was performed on total RNA isolated from epiphyseal chondrocytes to characterize 
the splice variants of VEGF mRNA (Fig. 3A). Oligonucleotide primers were chosen to 
correspond with sequences in exons 3 and 8, allowing to distinguish between forms which 
contain both exons 6 and 7 (VEGF189), or lacking exon 6 (VEGF165) or lacking both exons 6 
and 7 (VEGF121) 32. The major amplicon corresponded with the predicted size of 297 bp for 
the VEGF165 species. Likewise, minor bands representing the VEGF121 (165 bp) and VEGF185 
(369 bp) isoforms were detected.  
 
 
 
 
 
 
 
 
 
 
Also several larger products were weakly visible. None of these bands corresponded to the 
VEGF206 isoform 33, which would contain an extra insertion of 51 bp between exons 6 and 7 
and would thus be expected to yield a PCR product of 420 bp. On the corresponding Southern 
blot (Fig. 3B), all of the PCR-amplified products hybridized with the VEGF probe. As a 
negative control, the PCR product of the GR (761 bp product) was transferred to the filter, but 
did not hybridize with the VEGF probe. In conclusion, porcine epiphyseal chondrocytes 
produce all major splice variants of VEGF, with VEGF165 being the most abundant.  
Figure 2 Inhibitory effect of GCs on VEGF secretion. Conditioned medium was collected 48 h after the addition of 
GCs and/or the GR antagonist Org34116 (Org) (1 µM) (as indicated). (A) VEGF was measured by ELISA assay. 
Values are the means ± SEM of four experiments, each performed in duplicate and normalized for protein content 
in each well. *P<0.01, compared with controls without DXM; # P<0.01, compared with corresponding DXM 
concentration in the absence of Org34116. (B) Values (ELISA assay) are from one experiment (carried out in 
serum-free medium supplemented with 10 nM IGF-I), which was repeated with identical results. DXM, 
dexamethasone; HC, hydrocortisone; PRDL, prednisolone. (C) Western blot of VEGF secreted from chondrocytes 
treated with DXM (as indicated) in the absence (-) or presence (+) of the GR antagonist. VEGF protein was 
detected using a rabbit polyclonal antibody. Numbers on the left indicate the molecular masses (in kDa). 
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Figure 3 Expression of VEGF isoforms. Total RNA from chondrocytes 
was reverse-transcribed to cDNA, followed by PCR using primer pairs 
corresponding with exons 3 and 8. Samples were run in duplicate, and 
either stained with (A) ethidium bromide or (B) subjected to Southern 
blot analysis by hybridization with a 32P-labeled VEGF cDNA probe. In 
addition to PCR for VEGF (V), PCR was performed for the GR (GR) as a 
negative control. Numbers on the left indicate the sizes of the PCR 
products in bp. 
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DXM effect on VEGF mRNA 
Northern blots of total RNA extracted from chondrocytes hybridized with a VEGF cDNA 
probe showed a major transcript of approximately 4.8 kb, together with minor transcripts of 
approximately 1.3 and 5.3 kb (Fig. 4). Expression of all transcripts was inhibited by DXM 
(100 nM), the abundance of the major transcript was decreased to 57.5 ± 5.2% (n = 4 
independent experiments, P<0.01). As for the protein expression, the inhibitory effect of 
DXM was blocked by the GR antagonist (Fig. 4). A time-course experiment, in which RNA 
was isolated from cells at different times after addition of DXM, indicated that the maximum 
inhibition of VEGF mRNA expression was reached after 1 h (data not shown). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 To test whether DXM decreased the abundance of VEGF mRNA by accelerating its 
degradation, the transcription inhibitor actinomycin D was used. Actinomycin D was added to 
the cells 1 h after the addition of DXM, and the stability of the VEGF mRNA was determined. 
As shown in Fig. 5, the halflife was just under 2 h, and was not altered in the presence of 
DXM, indicating that the downregulation of VEGF by DXM is not caused by destabilization 
of its mRNA.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 Stability of VEGF mRNA. (A) Chondrocytes were cultured in 25 cm2 flasks in the presence of 
10% FCS and treated with 100 nM DXM. After 1 h, actinomycin D (5 µg/ml) was added. RNA was 
isolated at 1, 2, 3 and 4 h after the addition of actinomycin D. VEGF mRNA was assayed by Northern 
blot analysis. (B) Quantification of the major VEGF transcript, corrected for GAPDH content. The graph 
shows the average result of two experiments. 
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Figure 4 Expression of VEGF mRNA and effects of DXM treatment. 
Chondrocytes were treated with 100 nM DXM or 10 µM of the GR 
antagonist (Org34116) or the combination of both (as indicated) for 24 h. 
Total RNA was isolated and subject to Northern blot analysis. Re-
hybridization with a GAPDH probe was performed to check for equal 
loading of the lanes. A representative experiment is shown. Sizes of the 
transcripts are indicated on the left. 
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DISCUSSION 
 
In this study we have examined the effects of GCs, in particular DXM, on the expression of 
VEGF. We cultured primary chondrocytes from the epiphyseal growth plates of neonatal 
piglets. This model system was used earlier in the study of DXM effects on the expression of 
the components of the IGF system 26. Although no attempts were made to separate the various 
layers of the growth plate, it is assumed that the in vitro phenotype most closely resembles 
that of the proliferative zone 24,34. We found no evidence of de-differentiation during our 
experiments, as demonstrated by a lack of decreased collagen type II expression or increased 
collagen type I expression during passaging of the cells.  
 We demonstrate here that these chondrocytes synthesize and secrete VEGF, an important 
angiogenic factor, and that its production is regulated by IGF-I and PDGF. VEGF protein has 
been detected earlier by immunohistochemistry in growth plate cartilage of human neonates 7, 
chicken and mouse embryos 8 and human fetuses 9. Similarly, VEGF mRNA expression was 
found by in situ hybridization in juvenile 6 and embryonic 35 mouse growth plates. In most of 
these cases, VEGF was exclusively found in the hypertrophic zone; only 
Garcia-Ramirez et al. 9 also detected VEGF protein in the resting and proliferative zones. In 
agreement with our result, they also found VEGF secreted by cultured proliferative 
chondrocytes.  
 The sizes of the VEGF transcripts cannot be precisely linked to the various splice variants. 
Since the 297 bp PCR product representing the VEGF165 species is the most abundant species, 
it is tempting to speculate that the major 4.8 kb transcript represents this variant. 
Bermont et al. 16 came to the same conclusion for a 4.5 kb transcript. A 4.4 or 4.5 kb 
transcript has been reported for many cell types, e.g. human fetal vascular smooth muscle 
cells 32, endometrial adenocarcinoma cells 16 and human breast cancer cells 36. In all of these 
cell types, also a 3.7 kb transcript was found, which was usually the predominant species. In 
addition, this 3.7 kb form was found in e.g., human fetal epiphyseal chondrocytes 9 and mouse 
osteoblastic cells 37. We did not, however, detect this species, a discrepancy for which we 
have no explanation. The minor 5.3 kb band was also reported by others, including 
Tischer et al. 32 and Bermont et al.16. The 1.3 kb VEGF transcript has not been described 
before, although it is weakly visible on a Northern blot in the paper by 
Garcia-Ramirez et al. 9. 
 Downregulation of VEGF expression by DXM has previously been demonstrated in rat 
glioma cells 39,40, human vascular smooth muscle cells 13, mouse and rat pituitary 
folliculostellate cells 41 and porcine brain endothelial cells 42. Many mechanisms exist by 
which GCs can repress gene function 43. Since the GR is present in our cells, and the specific 
GR antagonist blocked the inhibitory action of DXM on VEGF expression, the 
DXM-GR complex is most likely the mediator of VEGF repression. The 5’ promoter region 
of the VEGF gene does not contain a glucocorticoid responsive element (GRE), but it does 
contain four AP-1 binding sites 32. The transcription factor AP-1 is activated by growth 
factors via mitogen-activated protein (MAP) kinases. Since the induction of VEGF expression 
by IGF-I, at least in NIH3T3 fibroblasts, involves the MAP kinase signaling pathway 17, it is 
likely that in our experiments (in which IGF-I was present) AP-1 activity is involved. It is 
conceivable, therefore, that a mechanism operates by which the ligand-occupied GR prevents 
the AP-1 transactivator complex from stimulating the VEGF gene 44. In this case, GR binding 
to DNA and GR-dependent gene transcription are not required.  
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 It is not known which factors regulate VEGF expression in the growth plate. IGF-I is an 
obvious candidate, however, since others and we have detected expression of this growth 
factor in the growth plate 45,46. IGF-I production in cultured rat epiphyseal chondrocytes, 
especially when stimulated by GH, is inhibited by DXM 24. Similarly, DXM blocks the IGF-I-
stimulated rise in type 1 IGF receptor molecules 24. In addition to a direct effect on the AP-1 
transactivator complex as described above, GCs could therefore also regulate VEGF 
expression indirectly through interactions with the somatotropic axis.  
 Another well established inducer of VEGF expression is hypoxia 10, mediated by the 
transcriptional activator hypoxia-inducible factor 1 (HIF-1) 38. Because the cartilage is not 
vascularized, it has been widely assumed that chondrocytes, especially in the hypertrophic 
zone, are hypoxic. Using a hypoxia-sensing drug and immunohistochemistry, Shapiro et al. 47 
found that hypertrophic cartilage, at least in the chicken, is actually not oxygen deficient. In 
contrast, Schipani et al. 48, using a similar technique, recently reported that hypoxia does 
occur in the growth plates of developing mice. VEGF expression in the growth plate appears 
to be regulated through both HIF-1-dependent and –independent mechanisms 48. The possible 
role of GCs in regulating these mechanisms needs to be addressed, especially since hypoxia-
induced VEGF expression seems to be much less susceptible to DXM inhibition than VEGF 
expression induced by serum and growth factors 39,40.  
 We also explored another possibility by which DXM could regulate VEGF expression, 
namely by destabilizing its mRNA. We found no evidence for such a post-transcriptional 
regulation. When transcription was interrupted by actinomycin D, the halflife of the VEGF 
mRNA was unaffected by the presence of DXM. GC-regulated mRNA turnover is thought to 
involve AUUUA sequences (AU response elements, or AREs) in the 3’ untranslated region of 
mRNAs 49,50, and these sequences are present in the VEGF transcript 51. The regulation of the 
stability of VEGF mRNA is very complex, however, and involves sequences in the 
3’ untranslated region as well as the 5’ untranslated region and the coding region 52. This 
complexity is also illustrated by the different results, which have been reported with respect to 
the ability of IGF-I to stabilize VEGF mRNA. While IGF-I increased VEGF mRNA halflife 
in colon carcinoma cells 15 and endometrial adenocarcinoma cells 16, it had no such effect in 
osteoblastic cells 14 and fibroblasts 17. 
 VEGF is of utmost importance for the vascular invasion of the growth plate cartilage and 
the resulting processes of apoptosis and bone formation 6. It is therefore highly likely that the 
negative effect of GCs on VEGF expression by epiphyseal chondrocytes contributes to the 
mechanism by which these steroid hormones cause growth retardation.  
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ABSTRACT  
 
High (pharmacological) doses of glucocorticoids inhibit the proliferation of growth plate 
chondrocytes, which leads to one of the side-effects of these steroids, namely suppression 
of longitudinal growth. Growth inhibition by glucocorticoids is thought to be mediated 
in part by impaired action of components of the IGF axis, which are important for 
chondrocyte regulation and hence for longitudinal growth. The aim of the present study 
was to determine whether glucocorticoid-induced growth retardation involves changes 
in IGF axis components. Chondrocytes were isolated from epiphyseal growth plates of 
neonatal piglets and treated with pharmacological doses of dexamethasone (DXM) for 
24 h to study glucocorticoid-induced growth retardation. Under IGF-I-supplemented 
(10 nM) culture conditions, IGF-binding proteins (IGFBPs)-2, -4 and -5 were secreted 
by the growth plate chondrocytes and IGFBP-2 protein and mRNA levels were 
decreased by the DXM treatment, whereas IGFBP-4 and -5 were not affected. 
 Proliferation of the chondrocytes, as measured by [3H]thymidine incorporation, was 
3.5-fold higher in serum-supplemented medium in contrast to IGF-I-supplemented 
(10 nM) medium. In the presence of serum, DNA synthesis was significantly inhibited by 
50 - 63% when treated with 100 nM DXM, which was prevented by the glucocorticoid 
receptor antagonist Org34116. mRNA levels of IGF axis components were determined 
using Northern blot analysis. IGFBP-2 to -6 were expressed in the chondrocytes, 
IGFBP-1 was absent and both IGF-I and IGF-II, and the type I and type II IGF 
receptors were expressed. Treatment with dexamethasone (100 nM) resulted in a 2-fold 
increase in mRNA levels of both IGFBP-5 and the type I IGF receptor, whereas IGFBP-
2 mRNA levels decreased by 55%, in concert with the decrease in protein level observed 
under IGF-I-supplemented culture conditions. The changes in mRNA levels due to the 
dexamethasone treatment were prevented by the glucocorticoid receptor antagonist.  
 Our data show that exposure to pharmacological doses of DXM results in inhibition 
of proliferation and changes in components of the IGF axis, IGFBP-2 and -5 and the 
type I IGF receptor, suggesting a role for these components in glucocorticoid-induced 
growth retardation at the local level of the growth plate. 
 
 
INTRODUCTION 
 
Longitudinal bone growth results from the proliferation, differentiation, maturation and 
eventually apoptosis of chondrocytes within the growth plates of the long bones 1. These 
processes must be correctly coordinated in order to maintain normal growth. 
 Glucocorticoids (GCs), although effective drugs in the treatment of several diseases, such 
as asthma, respiratory distress syndrome and rheumatic arthritis, may induce growth 
retardation in children as a side-effect 2. Studies in experimental animal models have also 
shown that high levels of GCs have a growth suppressive effect on longitudinal bone 
growth 1,3-5. Several in vivo studies showed that GCs act locally to restrain growth, suggesting 
a local mechanism which is intrinsic to the growth plate 6,7. 
 The inhibitory actions of GCs on longitudinal growth are suggested to be due to impaired 
action of the components of the insulin-like growth factor (IGF) axis 5,8,9. IGF-I and IGF-II 
are important mediators of longitudinal growth, as shown by in vitro and in vivo 
experiments 10-12. The IGFs are potent mitogenic and differentiation-promoting growth 
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factors 13. They are produced by multiple tissues, and can act in both an endocrine and 
autocrine/paracine fashion. IGFs are bound to members of high-affinity IGF-binding proteins 
(IGFBPs), which modulate the IGF availability and bioactivity 14,15. They act mainly as 
autocrine and/or paracrine factors at or close to their sites of synthesis and have different 
affinities for the IGFs 16. Growth plate chondrocytes produce both IGFs and IGFBPs, which 
are presumed to be important for chondrocyte regulation and hence for longitudinal 
growth 5,17-19. Both IGFs and several IGFBPs are regulated by GCs 20, both in vitro, e.g. in 
fibroblasts 21 and in osteoblasts 22, as well as in vivo, i.e. determined in serum 3,5,23,24 and in 
liver and lung tissue 5. However, scarce data are available with respect to the regulation of 
IGFBPs by GCs on growth plate chondrocytes. We have reported that in rabbit costal 
chondrocytes, IGFBP-5 expression is downregulated and IGFBP-3 expression is induced by 
dexamethasone (DXM) 25. In rat growth plate chondrocytes, GCs impair growth hormone 
(GH)-induced stimulation of local secretion and paracrine action of IGF-I, which would 
contribute to GC-induced growth retardation 8. However, in patients treated with GCs, serum 
IGF-I levels are usually not altered, while its bioactivity is 26, indicating that the IGFBPs 
might be the IGF axis components that are involved in GC-induced growth retardation 5. 
Since locally produced IGFs are suggested to have an autocrine/paracrine action on growth 
and GCs act locally to inhibit longitudinal growth, serum levels of IGF axis components 
provide little insight into the mechanisms by which GCs induce growth retardation 24.  
 The aim of this study was to investigate whether GC-induced growth retardation indeed is 
related to changes in expression of components of the IGF axis (both IGFs, the IGFBPs and 
the IGF receptors) in in vitro cultures of chondrocytes isolated from the neonatal porcine 
growth plate. The obtained data suggest a role for specific components of the IGF axis in the 
regulation of chondrocyte growth by GCs at a local level.  
 
MATERIALS AND METHODS 
 
Materials 
Restriction enzymes, modifying enzymes, Tripure isolation reagent and Agarose Gel DNA extraction kit were 
purchased from Roche Molecular Biochemicals (Mannheim, Germany). Nylon membranes (Hybond-N+), 
RediPrime Random Primer labeling mixture, [α-32P]dCTP (10 mCi/ml), [3H]methyl-thymidine (1 mCi/ml), the 
Hyperfilm ECL film and the horseradisch peroxidase-conjugated secondary antibody were obtained from 
Amersham Pharmacia Biotech. Collagenase (C-9891) and protease (P-6911) enzymes were purchased from 
Sigma Chemical Co. Dulbecco’s modified Eagle’s medium (DMEM), L-glutamine, penicillin, streptomycin, 
fetal calf serum (FCS) and SuperScript II Reverse Transcriptase were obtained from Life Technologies. The 
TOPO TA Cloning kit was obtained from Invitrogen. Cell strainers were purchased from Beckton Dickingson. 
Centricon-10 ultrafiltration membranes and PVDF (Immobilon-P) were from Millipore Corp. BioMax MR X-ray 
films were obtained from Kodak. Supersignal chemiluminescent substrate was purchased from Pierce. Org34116 
(a GC receptor (GR) antagonist) was provided by Organon (Oss, The Netherlands). Dexamethasone disodium 
phosphate (DXM) from Merck Sharp & Dohme was from our hospital pharmacy. Recombinant human IGF-I 
was kindly provided by Eli Lilly & Co. The human IGFBP-2 antibody (rabbit antibody directed against a peptide 
sequence from bovine IGFBP-2), the human IGFBP-5 antibody (rabbit antibody directed against a peptide 
sequence from human IGFBP-5) and the recombinant human IGFBP-2 were purchased from Upstate 
Biotechnology Inc. (Lake Placid, NY, USA). Recombinant human IGFBP-5 was obtained from GroPep 
(Adelaide, Australia). Human IGFBP-1 to -6 cDNAs were kindly provided by Dr. S. Shimasaki (La Jolla, CA, 
USA) 27. GAPDH cDNA was a gift from Dr. H. van Teeffelen (Utrecht, The Netherlands) 28. Rat type I 29 and 
mouse type II IGF receptor cDNAs 30 were a gift from Dr. J.W. van Neck (Rotterdam, The Netherlands). Human 
IGF-I 31 and -II 32 cDNAs were obtained from Dr. M. Jansen (Utrecht, The Netherlands). 
 
Cell culture  
Epiphyseal growth plate chondrocytes were isolated from the distal and proximal tibial growth plate of neonatal 
piglets by splitting the growth plate transversally and dissecting the growth plate free under sterile conditions. 
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The growth plates were minced with a scalpel and digested with 1 mg/ml protease for 30 min at 37ºC with 
constant shaking in DMEM containing 4.5 g/l glucose, 4 mM L-glutamine, 100 U/ml penicillin and 100 µg/ml 
streptomycin, followed by digestion with 0.5 mg/ml collagenase for 6 h at 37ºC in the same medium 
supplemented with 10% FCS. Cells were filtered through a sterile 70 µm nylon cell strainer, centrifuged, 
counted and seeded in 75 cm2 tissue culture flasks. The cells were grown as a monolayer culture at 37ºC in a 
5% CO2 and humid atmosphere. The chondrocyte phenotype of the cells was verified by Alcian blue staining for 
sulfated proteoglycans 33, expression of type II collagen 34 and cartilage-derived retinoic acid-sensitive protein 
(CD-RAP) 35 by Northern blot analysis 36. 
 In general, second and third passage cells were used at subconfluency. Cells were cultured in 10% FCS-
supplemented medium. The amount of GCs contributed by 10% FCS was measured using a chemoluminescent 
immunoassay on the Nichols Advantage System (San Juan Capistrano, CA, USA) and was less than 1 nM. This 
concentration is negligible compared with the doses applied in our experiments. Proliferation of cells cultured in 
dextran-coated charcoal-stripped serum was only 20% of proliferation of cells cultured in 10% FCS (data not 
shown). Therefore, no experiments in dextran-coated charcoal-stripped serum were performed. Proliferation of 
cells in serum-free medium was only 20% of cells incubated with 10 nM IGF-I. Therefore, no experiments were 
performed in serum-free medium; instead, 10 nM IGF-I was added to the serum-free medium. In experiments 
with the GR antagonist (Org34116), cells were preincubated for 1 h with 10 µM of the GR antagonist or an 
equivalent volume of the solvent (ethanol) and subsequently treated with DXM (still in the presence of the GR 
antagonist). 
 Cell viability at the end of the incubations with DXM was determined by the trypan blue exclusion technique. 
 
[3H]thymidine incorporation 
Cells were grown on 24-well plates and incubated with increasing concentrations of DXM for 24 h, with or 
without the GR antagonist, as described above and each experiment was conducted in triplicate, both in serum-
free conditions supplemented with 10 nM IGF-I/ 0.005% BSA and in 10% FCS conditions. The rate of 
chondrocyte proliferation was assessed by incubating the cells in 0.5 µCi/ml of [3H]-thymidine for the final 4 h 
of incubation. Cells were subsequently washed with PBS to remove unincorporated isotope and the DNA and 
protein were precipitated with three incubations of 1 ml 10% (w/v) ice-cold trichloroacetic acid for 15 min at 4ºC 
and solubilized by incubation at room temperature with 0.4 M NaOH for 1 h. Isotope incorporation was 
measured by liquid scintillation counting.  
 
Western blotting 
Cells were first preincubated with serum-free medium for 2 h, after which medium was changed for medium 
supplemented with 10 nM IGF-I and 0.005% BSA. Subsequently, cells were treated with increasing 
concentrations of DXM. Chondrocyte media were collected after 48 h (to assure enough accumulation of protein 
to be measured) and centrifuged for 10 min. at 3000 g (4°C) and stored at -80°C. The chondrocyte-conditioned 
medium (1 ml) was concentrated 10-fold on Centricon-10 ultrafiltration membranes and loaded on a 12% gel for 
non-reducing SDS-PAGE. IGFBPs were visualized by electrotransfer to PVDF membranes followed by 
incubation with 125I-IGF-II (ligand blotting) 37. Molecular masses were calculated using BioRad (Hercules, CA, 
USA) broad range markers as standard. Bands were quantified by densitometry using a GS-363 Molecular 
Imager and Molecular Analyst software program, version 1.5 (Biorad). 
 For immunobloting, 10 ml conditioned medium from 75 cm2 tissue culture flasks was concentrated 10-fold 
on Centricon-10 ultrafilration membranes. IGFBP-2 was detected using a bovine IGFBP-2 antibody at 1/2500 
dilution, followed by a horseradish peroxidase-conjugated secondary antibody at 1/7500 dilution. IGFBP-5 was 
detected using a human IGFBP-5 antibody at 1/2000 dilution, followed by a horseradish peroxidase-conjugated 
secondary antibody at 1/7500 dilution. The bands were visualized using the SuperSignal chemiluminescent 
substrate and Hyperfilm ECL film.  
 
Northern blot analysis 
RNA extraction  
Cells (3 x 106) were cultured in 75 cm2 tissue culture flasks and treated with DXM for 24 h. Cells were directly 
lysed with Tripure solution reagent and total RNA was extracted according to the procedures of the 
manufacturer, based on the single-step acid guanidinium-thiocyanate method 38. 
Probes  
Twenty nanograms of gel-purified inserts of plasmids containing human IGFBP-1 to -6, human IGF-I and -II, rat 
type I IGF receptor, mouse type II IGF receptor and rat GAPDH cDNA, were radiolabeled with 50 µCi 
[α-32P]dCTP, using random primed DNA labeling as described by the manufacturer. 
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Northern blot hybridization  
Twenty micrograms of total RNA was separated by electrophoresis in a  1% (w/v) agarose/2.2 M formaldehyde 
gel in 1x 3-(morpholino) propanesulphonic acid buffer, transferred to a 0.2 µm nylon membrane and crosslinked 
to the membrane by UV radiation. The membranes were prehybridized for 2 h at 60ºC in a solution containing 
0.1% SDS, 3xSSC, 5xDenhardt’s solution, 10% dextran-sulfate and 50 µg/ml denaturated salmon sperm DNA. 
Hybridization was performed at 60ºC overnight in the same solution, containing the [α-32P]dCTP-labeled probe. 
Following hybridization, the membranes were washed to a stringency of 0.2xSSC, 0.1% (w/v) SDS at 60ºC. The 
hybridization signals were analyzed by densitometry using the GS-363 Molecular Imager and the Molecular 
Analyst software program (Biorad) and the relative abundance of the different mRNAs was subsequently 
normalized to the GAPDH values. The signals were also visualized by autoradiography on BioMax MR X-ray 
films. 
 
GR RT-PCR  
Total RNA was isolated as described above. First strand cDNA synthesis of 3.5 µg total RNA was performed 
using SuperScript II reverse transcriptase, as described by the manufacturer. After cDNA synthesis, the final 
volume was diluted to 100 µl. PCR amplification of the GR and GAPDH was performed using 5 µl template and 
10 pmol forward and reverse primers. The following primer pair was used for the GR: forward primer, 
5’-GTGAGTACCTCTGGAGGACA-3’; reverse primer, 5’-CTTTGCCCATTTCACTGC-3’, which were 
expected to yield a 761 bp product. Following an initial denaturation step of 5 min 94ºC, amplification consisted 
of 34 cycles of 30 s at 92ºC, 45 s at 50ºC, 60 s at 72ºC, followed by a final extension step of 10 min at 72ºC. The 
following primer pair was used for GAPDH: forward primer, 5’-CTCAAGATTGTCAGCAATGC -3’; reverse 
primer, 5’-TTGCCCACAGCCTTGGCA-3’, which were expected to yield a 226 bp product. Following an initial 
denaturation step of 5 min 94ºC, amplification consisted of 31 cycles of 30 s at 92ºC, 30 s at 53ºC, 60 s at 72ºC, 
followed by a final extension step of 10 min at 72ºC. PCR products were analyzed on a 1% agarose gel. Initial 
experiments established that the PCR reactions were in the log phase, allowing semi-quantitative determination 
of the mRNA levels. Densities of the bands were measured using digitized images coupled to the Molecular 
Analyst software and normalized for GAPDH expression.  
 
Statistical Analysis  
Data are expressed as means ± SEM. Statistical differences between two groups were determined by 
Student's t-test. Statistical differences between multiple treatments were determined by one-way ANOVA using 
InStat version 3.00 (GraphPad Software, Inc., San Diego, CA, USA). The Dunnett post-hoc test was used to 
determine significance between the control and the treatment groups. Significance of the difference between the 
various treatments with or without the GR antagonist in the [3H]thymidine incorporation were determined using 
the Bonferroni post-hoc test. A P value of less than 0.05 was considered statistically significant. Growth plate 
cultures of at least three different animals were used per analyzed mRNA (both for the Northern Blot analysis 
and for the semi-quantitative RT-PCR) and for the [3H]thymidine incorporation.  
 
RESULTS 
 
Characterization of secreted IGFBPs and regulation by DXM 
The production of IGFBPs by the primary porcine growth plate chondrocytes was determined 
using Western ligand blot analysis. Under serum-free incubations, two IGFBPs of 34 and 
24 kDa, were detected (Fig. 1A). When the medium was supplemented with 10 nM IGF-I the 
expression of a 31/32 kDa doublet was induced and the expression of the 24 kDa protein was 
increased 2.9-fold (Fig. 1A). At 100 nM DXM, the intensity of the 34 kDa IGFBP, in both the 
absence and presence of IGF-I, was decreased to respectively 35% and 50% of control levels. 
The 24 kDa band and the 31/32 kDa doublet were not influenced by DXM treatment in 
neither of the two incubations (Fig. 1A). 
 Immunoblotting identified the 34 kDa band as IGFBP-2 (Fig. 1B) and the 31/32 kDa 
doublet as IGFBP-5 (Fig. 1B). The band of 24 kDa probably represents IGFBP-4 25. 
Therefore, the DXM-sensitive protein was identified as IGFBP-2 and the major IGF-I-
inducible IGFBP produced by growth plate chondrocytes was identified as IGFBP-5. 
IGFBP-4 was increased by IGF-I, but not affected by the DXM treatment. 
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 Northern blot analysis confirmed the expression of IGFBP-2, -4 and -5 at the mRNA level, 
when cultured in IGF-I-supplemented medium. In agreement with the protein levels, mRNA 
levels of IGFBP-2 (1.8 kb transcript) were also decreased by DXM treatment to 69% of 
control values (Fig. 1C). IGFBP-4 and -5 mRNA levels were not affected by the DXM 
treatment (data not shown), in concert with the protein levels.  
 
DXM-induced growth retardation 
To determine the effect of DXM on chondrocyte proliferation, [3H]thymidine incorporation 
into DNA was measured. The [3H]thymidine incorporation decreased significantly to 
66% ± 3% of the control values when the chondrocytes were cultured in IGF-I-supplemented 
medium and subsequently treated with 100 nM DXM (Fig. 2). However, when growth plate 
chondrocytes were cultured in the presence of 10% FCS, basal proliferation (without any 
further treatment) increased 3.5-fold when compared with chondrocytes cultured in IGF-I-
supplemented medium. Subsequent treatment with 100 nM DXM resulted in a 2.0 ± 0.1-fold 
reduction in proliferation (Fig. 2). Culturing in 10% FCS, therefore, resulted in higher cell 
proliferation and a larger decrease in proliferation when treated with DXM. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 Characterization of secreted insulin-like growth factor-binding proteins (IGFBPs) and regulation by 
dexamethasone (DXM). (A) Growth plate chondrocytes were treated with increasing concentrations of DXM in 
serum-free medium in the absence (-) or presence (+) of 10 nM IGF-I. Conditioned media were collected, 
concentrated and IGFBPs were detected by Western ligand blot analysis, using 125I-IGF-II as described in 
Materials and Methods. Numbers on the left and right are molecular masses (in kDa) of the detected IGFBPs. 
(B) Identification of the major IGFBP species produced by the porcine growth plate chondrocytes. Recombinant 
human IGFBP-2 (rBP-2) and IGFBP-5 (rBP-5)were used as positive controls, as indicated, and detected using 
Western ligand blot analysis. IGFBPs in the conditioned media of chondrocytes were detected using 
immunoblotting using an anti-IGFBP-2 (BP-2) and anti-IGFBP-5 (BP-5) antibody, as indicated. (C). Expression of 
IGFBP-2 mRNA in chondrocytes in IGF-I-supplemented serum-free medium in the absence and presence of DXM 
(100 nM). Total RNA was isolated and subjected to Northern blot analysis (as described in Materials and 
Methods). Subsequently, hybridization with a GAPDH probe was performed, which served as an internal control. 
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Figure 2 Modulation of [3H]thymidine incorporation into growth plate 
chondrocytes by DXM. Epiphyseal growth plate chondrocytes of neonatal piglets 
were cultured in 10% FCS-supplemented medium. Treatment with 100 nM DXM 
was for 24 h in 10% FCS or in serum-free medium in the presence of 10 nM 
IGF-I, as indicated. For the final 4 h, [3H]thymidine was added and the 
incorporation assessed as described in Materials and Methods. For the DXM-
treated chondrocytes (bars with diagonal lines), means ± SEM are expressed 
relative to incorporation levels of untreated chondrocytes (open bars), ** P<0.01. 
The Figure shows the results of a typical experiment performed in triplicate. The 
experiment was performed another three times with different chondrocyte 
cultures, derived from three different piglets, each giving similar results. 
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 Further experiments were conducted in the presence of 10% FCS, as this was shown to be 
the optimal condition to study GC-induced growth retardation. A dose-response study showed 
that a significant decrease in the [3H]thymidine incorporation was observed at 50 nM and 
higher concentrations of DXM (Fig. 3). The [3H]thymidine incorporation decreased to 
37% ± 4% of the control values at 100 nM DXM and remained at 40% - 60% of control 
values at higher doses. The trypan blue exclusion technique showed that the viability of the 
cells was the same at the different concentrations used, indicating that the decrease in 
[3H]thymidine incorporation was due to a decrease in proliferation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Treatment with DXM in combination with the GR antagonist Org34116 abolished the 
DXM-induced growth inhibition, as shown in Fig. 3. The GR antagonist on its own resulted in 
a small, but not significant, decrease in proliferation as compared to control values. 
 To exclude the possibility that the GR was down-regulated by the treatment with DXM, we 
also performed RT-PCR of the GR on RNA extracted from our primary chondrocytes and 
found the expected 761 bp product, indicating that these chondrocytes expressed the 
GR (Fig.4). Increasing concentrations of DXM did not affect the mRNA levels of the GR as 
shown by semi-quantitative RT-PCR analysis. Although a decrease in mRNA levels at 
500 nM DXM (74% ± 14% of control values; n=5) was visible, this was not statistically 
significant (Fig. 4).  
 
 
 
 
 
 
 
 
Figure 4 Expression of the GR. Cells were treated with the indicated 
concentrations DXM for 24 h and total RNA was isolated as described in Materials 
and Methods and analyzed using semi-quantitative RT-PCR analysis. GAPDH 
served as an internal control. The Figure shows the results of a typical experiment.
GR 
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Figure 3 Modulation of [3H]thymidine incorporation into growth plate chondrocytes cultured in 10% FCS-
supplemented medium and subsequent treatment with increasing concentrations of DXM (- GR antagonist) for 
24 h and with DXM in combination with  the glucocorticoid receptor (GR) antagonist (+ GR antagonist). 
[3H]thymidine incorporation was assessed as described in Fig. 2. For the DXM-treated chondrocytes, means ± 
SEM are expressed relative to incorporation levels of untreated chondrocytes (0 nM DXM), * P<0.05, ** P<0.01.  
For the co-incubation with the GR antagonist, means ± SEM are expressed relative to incorporation levels of the 
corresponding DXM-treated chondrocytes treated with the same dose of DXM, * P<0.05, ** P<0.01. The Figure 
shows the results of a typical experiment performed in triplicate. The experiment was performed another four 
times with different chondrocyte cultures, derived from four different piglets, each giving similar results. 
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mRNA levels of IGF axis components and regulation by DXM 
Northern blot analysis of primary porcine growth plate chondrocytes cultured in 10% FCS 
showed expression of the same IGFBP species as detected at the protein level (Fig. 1). The 
major transcripts detected (Fig. 5A) were: IGFBP-2 (1.8 kb), IGFBP-4 (2.0 kb) and 
IGFBP-5 (7.0 kb). IGFBP-6 mRNA was detected at low levels (2.0 kb). No IGFBP-1 and 
only very weak IGFBP-3 expression (5.0 kb, in one out of five conducted experiments) was 
found (not shown). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 We determined the effects of pharmacological doses of DXM on the expression of IGF 
axis components in growth plate chondrocytes cultured in 10% FCS, using Northern blot 
analysis. The IGFBP-2 mRNA levels significantly decreased to 45% ± 9% of the control 
values, when treated with 100 nM DXM (Fig. 5A). The 7.0 kb transcript of IGFBP-5 was 
significantly increased by 2.0 ± 0.2-fold at 100 nM DXM (Fig. 5A). The mRNA levels of 
IGFBP-4 and -6 were not affected by the DXM treatment (Fig. 5A). The levels of IGFBP-3 
were too low to be quantified.  
Figure 5 Expression of IGF axis components in porcine growth plate chondrocytes cultured in 10% FCS-
supplemented medium and effects of DXM treatment. Growth plate chondrocytes were treated with DXM (100 
and 500 nM) (as indicated) for 24 h and analyzed as described in Fig. 1C. (A) mRNAs of IGFB-2, -4, -5 and -6 (as 
indicated). The data are expressed relative to mRNA levels of control values (open bars). The bars with diagonal 
lines represent mRNA levels of chondrocytes treated with 100 nM DXM; the bars with horizontal lines, treatment 
with 500 nM DXM. mRNA levels of IGF axis components affected by DXM treatment were also co-incubated with 
the GR antagonist (Org34116), as indicated (+). (B) mRNA levels of IGF-II and the type I and II IGF receptor (as 
indicated). The relative abundance of the different mRNAs was quantified by densitometry (as described in 
Materials and Methods) and normalized to the GAPDH values. The data represent the means ± SEM of at least 
four different animals per analyzed transcript, the means ± SEM are expressed relative to expression levels of 
untreated chondrocytes, ** P<0.01, NS, non significant. Representative Northern blot data are shown. 
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 Besides the IGFBPs, we also studied the presence and effects of DXM treatment on the 
remaining IGF axis components. The growth plate chondrocytes of neonatal piglets expressed 
very low levels of a 5.0 kb IGF-I transcript (data not shown). Northern blots hybridized with a 
32P-labeled human IGF-II cDNA probe revealed four transcripts of IGF-II of 4.6, 2.6, 1.8 and 
1.5 kb respectively (Fig. 5B). Low levels of a transcript of 11 kb of the type I IGF receptor 
were detected (Fig. 5B), and low levels of a transcript of 9.0 kb of the type II IGF receptor 
(mannose-6-phosphate receptor) (Fig. 5B). 
 DXM treatment did not affect the expression levels of the four detected transcripts of 
IGF-II (Fig. 5B). Also, the mRNA levels of the type II IGF receptor were not affected 
(Fig. 5B). The levels of IGF-I were too low to be quantified. In contrast, type I IGF receptor 
expression levels increased when treated with 100 nM DXM (approximately 2- to 3-fold) 
(Fig. 5B); due to the low expression level of the untreated chondrocytes, no precise 
quantification of the increase was possible.  
 Treatment with DXM in combination with the GR antagonist (Org34116) abolished the 
effects of DXM on the mRNA levels of IGFBP-2 and -5, as shown in Fig. 5A. Similarly, the 
GR antagonist prevented the DXM-induced increase of mRNA levels of the type I IGF 
receptor, although quantification was not possible due to the low expression levels as 
described in Fig. 5B (data not shown). 
 
DISCUSSION 
 
This is the first study to describe the possible involvement of all the IGF axis components, the 
IGFs, both IGF receptors and the IGFBPs, in GC-induced growth retardation at the local level 
of the growth plate chondrocytes. Epiphyseal tibial growth plate chondrocytes of neonatal 
piglets were used as a model system for postnatal growth. The chondrocytes were treated with 
high (pharmacological) doses of DXM to induce growth retardation and levels of the IGF axis 
components were determined at the protein and mRNA level. 
 First, we characterized the production and regulation of the IGFBPs by the primary porcine 
growth plate chondrocytes, as the IGFBPs could be the IGF axis components that are involved 
in GC-induced growth retardation 5,39. We have previously reported that IGFBP-5 is the major 
IGF-I-inducible IGFBP produced by rabbit costal chondrocytes 25. The present result in 
porcine epiphyseal growth plate chondrocytes confirmed this finding. In contrast to the costal 
chondrocytes, the growth plate chondrocytes expressed IGFBP-2, and showed upregulation of 
IGFBP-4 by IGF-I. Further differences are noted with respect to the regulation by DXM. 
While DXM inhibited the expression of IGFBP-5 in the costal chondrocytes 25, this binding 
protein was unaffected by DXM at the protein level. In addition, we reported an induction of 
IGFBP-3 in the costal chondrocytes, while IGFBP-3 remained undetected in the growth plate 
chondrocytes in the presence of DXM. As costal chondrocytes of the neonatal piglets showed 
similar results to the porcine tibial growth plate chondrocytes (data not shown), we suggest 
that species and/or age differences can account for these differences and not the difference in 
the origin of the tissue of the chondrocytes. The decrease in IGFBP-2 protein levels was 
paralleled by a decrease of IGFBP-2 mRNA levels, suggesting a regulation at the 
transcriptional level. GCs have indeed been shown to affect IGF axis components primarily at 
the level of gene expression 5,20,22,25.  
 GC treatment of our chondrocytes resulted in inhibition of proliferation without an increase 
in cell death, in accordance with other in vitro studies, e.g. in osteoblasts 22 and in tibial 
growth plate chondrocytes 8,40. It has been previously reported that the decreased proliferation 
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of chondrocytes treated with GCs is due to an increase in cell doubling times with a reduction 
in the number of S phase cells; in addition, no signs of increasing cell death or increase in 
morphological signs of apoptosis were shown 8,40.  
 We found that basal proliferation in IGF-I-supplemented medium was much lower than 
proliferation in serum-supplemented medium. Subsequently, inhibition of proliferation due to 
GC treatment resulted in a larger decrease in proliferation. Therefore, further experiments to 
study GC-induced growth retardation were conducted in these conditions. In addition, 
treatment of the chondrocytes with a GR antagonist prevented the DXM-induced growth 
retardation, which provides evidence for both the specific effects of DXM on growth and the 
presence of an active GR.  
 As a consequence of the presence of serum in the experimental conditions, measurements 
of IGFBP protein production by the porcine tibial growth plate chondrocytes were unreliable. 
Further study of the effects of DXM on the IGF axis components (including also both IGFs 
and IGF receptors) on the growth plate chondrocytes was therefore only performed at the 
mRNA level. Northern blot analysis showed that not all components of the IGF axis were 
expressed in neonatal porcine growth plate chondrocytes. IGFBP-1 was not detectable, as 
described previously 41, and only very low levels of IGFBP-3 and low levels of IGFBP-6 were 
shown. IGFBP-2, -4 and -5 were the predominant IGFBPs expressed by the growth plate 
chondrocytes, which was in accordance with the IGFBPs detected at the protein level in 
IGF-I-supplemented serum-free culture conditions. This is in accordance with data from 
others, who also showed expression of IGFBP-2 to -6 in growth plate chondrocytes 18,41. In 
accordance with others, we found IGF-II to be the most prominent IGF expressed in the 
growth plate 42. Only very low levels of IGF-I were detected. Expression of the type I IGF 
receptor was also previously observed in rat growth plate chondrocytes 43. This is the first 
study to describe expression of the type II IGF receptor in growth plate chondrocytes. 
 Pharmacological doses of DXM did not influence the expression of IGFBP-3, -4, and -6, of 
both IGFs and of the type II IGF receptor. This contrasts with the observed effects of GCs on 
other cell types as downregulation by GCs of the type II IGF receptor 44 and IGFBP-4 22 in 
osteoblasts. IGFBP-6 was shown both to be stimulated in osteoblasts 45 and to be not affected 
by GCs in osteoblasts 22 and in fibroblasts 21. IGFBP-3 expression was stimulated by GCs in 
costal chondrocytes 25. Obviously, the regulation of expression of IGF axis components is cell 
type specific, and also depends on developmental stage and species used 20.  
 DXM treatment did influence the expression levels of the type I IGF receptor, IGFBP-5 
and IGFBP-2. We showed that pharmacological doses of DXM increased the type I IGF 
receptor mRNA levels in the growth plate chondrocytes. This increase of type I IGF receptor 
mRNA by DXM has previously been shown in vivo 5 and might be a response to counteract 
the effect of the GC-induced growth retardation. However, this response is insufficient to 
compensate for the growth inhibition observed. 
 DXM treatment increased IGFBP-5 mRNA levels in the presence of 10% FCS, which has 
not been described previously. In contrast, reduction of IGFBP-5 levels was reported in costal 
chondrocytes 25, osteoblasts 22,46 and in fibroblasts 21, a discrepancy which is probably due to a 
difference in cell type and species used as discussed above 20. In the rabbit costal 
chondrocytes we described before 25, a decrease in IGFBP-5 was shown due to DXM 
treatment, whereas an increase in IGFBP-3 was observed. In contrast, our porcine growth 
plate chondrocytes expressed almost no IGFBP-3, but expressed IGFBP-5 at a high level. It 
has been suggested that IGFBP-3 and IGFBP-5 could have similar functions 47-49. An increase 
in IGFBP-5 due to DXM treatment in piglet growth plate chondrocytes could therefore 
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resemble the increase in IGFBP-3 due to DXM treatment in rabbit costal chondrocytes 25. 
Furthermore, IGFBP-5 inhibits IGF-II-dependent DNA synthesis in growth plate 
chondrocytes 41. An increase in IGFBP-5 thus can inhibit proliferation of growth plate 
chondrocytes by inhibiting IGF-II activity, which is the predominant IGF in our growth plate 
chondrocytes. IGFBP-5 could therefore account in part for the GC-induced growth retardation 
observed in our growth plate chondrocytes. 
 We observed a decrease in IGFBP-2 due to DXM treatment, both in IGF-I-supplemented 
experimental conditions as well as in the presence of 10% FCS. This observation is in 
accordance with data on osteoblasts 50 and in vivo experiments 51. Treatment of chondrocytes 
with GH increased IGFBP-2 levels 52. Together with our data, this implies that IGFBP-2 
levels are correlated with growth in chondrocytes. IGFBP-2 can inhibit, but also stimulate 
IGF activity and it has a preference for binding IGF-II 16, the predominant IGF in the growth 
plate. IGFBP-2 was also suggested to facilitate targeting of the IGFs, in particular IGF-II 
prohormone, to skeletal tissues, resulting in stimulation of proliferation 53. A decrease in 
IGFBP-2 could result in a decrease in IGF targeted to the chondrocytes, resulting in a 
decreased proliferation. Downregulation of IGFBP-2 expression in chondrocytes might 
therefore contribute to the inhibition of growth. This strengthens our conclusion that 
IGFBP-2, the only IGFBP which is affected by DXM in different culture conditions, could 
play a role in the regulation of growth in the growth plate, the mechanisms of which needs to 
be further elucidated. 
 In conclusion, all the IGF axis components (besides IGFBP-1) are present in neonatal 
porcine chondrocytes and some specific components, such as the type I IGF receptor, 
IGFBP-2 and -5, are regulated by GCs at the local level. These specific changes of IGF axis 
components by GCs indicate an impaired function of the IGF axis and might contribute to the 
GC-induced growth retardation 
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ABSTRACT 
 
Glucocorticoid (GC)-induced growth retardation is suggested to involve impaired action 
of the components of the IGF system. In a previous study, we have shown that GC 
treatment of primary porcine growth plate chondrocytes resulted in inhibition of cell 
proliferation, which was accompanied by an increase of IGFBP-5 and type I IGF 
receptor mRNA levels and a decrease of IGFBP-2 mRNA levels.  
 We have studied whether the GC-induced decrease of IGFBP-2 mRNA levels was due 
to a decrease in transcriptional activity of the IGFBP-2 promoter, using transient 
transfections of the porcine IGFBP-2 promoter in porcine growth plate chondrocytes. 
These preliminary studies indicate that GCs significantly decrease the porcine IGFBP-2 
promoter transcriptional activity of both the full-length promoter construct (-1397 bp) 
as well as of a 5' deletion construct (-874 bp), to respectively 73% ± 10% and 
54% ± 15%. This decrease in transcriptional activity explains, at least in part, the 
GC-induced decrease of IGFBP-2 mRNA levels in porcine growth plate chondrocytes. 
 
 
INTRODUCTION 
 
Glucocorticoids (GCs) are widely used as anti-inflammatory and immunosuppressive drugs, 
but they cause growth retardation as a side-effect in both children 1,2 and experimental animal 
models 3-6. GCs act locally to inhibit growth, suggesting a mechanism intrinsic to the growth 
plate 7,8.  
 Impaired action of the IGF system is suggested to be involved in GC-induced growth 
retardation 3,9-11. However, few studies exist which have studied the effects of GCs on the IGF 
system in the growth plate. In rat growth plate chondrocytes, GCs impaired GH-induced 
stimulation of IGF-I expression 9 and in rabbit costal chondrocytes, we have shown that GCs 
decreased IGFBP-5 and increased IGFBP-3 expression 12. In contrast, GC-induced inhibition 
of proliferation of porcine growth plate chondrocytes was concomitant with increased 
IGFBP-5 and type I IGF receptor mRNA levels and decreased IGFBP-2 mRNA levels 13 
(chapter 7 of this thesis). GC treatment of fetal ovine growth plate chondrocytes showed a 
similar decrease in IGFBP-2, but also showed a decrease in IGFBP-5 levels 14. Despite the 
discrepancies between these in vitro studies, the latter two both showed a down-regulation of 
IGFBP-2 due to GC treatment, whereas GH treatment was shown to increase IGFBP-2 levels 
in chondrocytes 15. This suggests a positive association between IGFBP-2 levels and growth 
in chondrocytes. In addition, IGFBP-2 is the only IGFBP detected in the postnatal growth 
plate in vivo 11 (chapters 3 and 4 of this thesis). Together with the in vitro studies, this might 
indicate that IGFBP-2 plays an important role in growth plate chondrocytes.  
 To further study a possible involvement of IGFBP-2 in GC-induced growth retardation, we 
have performed an preliminary study on the transcriptional regulation of the porcine IGFBP-2 
promoter by GCs in porcine growth plate chondrocytes.  
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MATERIALS AND METHODS 
 
Cell culture 
Epiphyseal growth plate chondrocytes were isolated from the distal and proximal tibial growth plates of neonatal 
piglets as described previously 13,16. The chondrocytes were grown as a monolayer culture in Dulbecco's 
modified Eagle's medium (DMEM), containing 4.5 g/l glucose, 4 mM L-glutamine, 100 U/ml penicillin, 
100 µg/ml streptomycine and 10% fetal calf serum (FCS) (Life Technologies Ltd, Paisley, UK), at 37°C in a 
5% CO2 and humid atmosphere.  
 
Transient transfections 
For transfection experiments, the following plasmids were used. The porcine IGFBP-2 promoter region 
(-1397/+73; relative to the first codon) was fused to the promoter-less pGL2-enhancer vector (Promega Corp., 
Madison, WI, USA), containing the firefly luciferase reporter gene 17. Similarly, a 5' deletion fragment of the 
porcine IGFBP-2 promoter (-874/+73) was cloned in the same vector 17 (kind gifts of Dr. F.A. Simmen, 
Gainesville, FL, USA 17). A schematic representation of both porcine IGFBP-2 promoter constructs is shown in 
Fig. 1. The promoter-less pGL2-enhancer (gift of Dr. F.A. Simmen) and the pGL2-control-luc plasmid 
controlled by a SV40 promoter (Promega Corp., Madison, WI, USA), served as transfection controls. The 
pRSV-LacZ 18 was used to monitor transfection efficiency. 
 Second and third passage cells were used for the transient transfection experiments and were plated on 6-well 
plates. One day after plating, the chondrocytes (60% confluency) were transiently transfected using FuGENE6 
(Roche Molecular Biochemicals, Mannheim, Germany), according to the procedures of the manufacturer. 
Briefly, the cells were grown in antibiotic-free DMEM containing 10% FCS and incubated for 6 h at 37°C with 
the FuGENE6 solution, which contained 7.5 µl FuGENE6, 2 µg of the porcine IGFBP-2 promoter construct and 
0.5 µg pRSV-LacZ. Subsequently, the cells received fresh antibiotic-free medium containing 10% FCS, in the 
absence or presence of 100 nM dexamethasone (DXM) (Merck Sharp & Dohm, Haarlem, The Netherlands) for 
24 h. Subsequently, the cells were lysed and luciferase and β-galactosidase assays were performed as described 
in 19. Reagents used for both assays were obtained from Roche Molecular Biochemicals (Mannheim, Germany). 
 Three transfection experiments were performed, each with growth plate cultures of a different animal and 
performed in triplicate. The time response curve was performed in duplicate, using the growth plate culture of 
1 animal. 
 
Statistical analysis 
Data are expressed as the means ± SEM. The effects of the DXM treatment were statistically tested using 
Student’s t-test. A P value of less than 0.05 was considered statistically significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS 
 
We have previously shown that a 24 h treatment of primary porcine growth plate 
chondrocytes with 100 nM DXM 13, decreased the [3H]thymidine incorporation of the 
chondrocytes to 37% ± 4% and using Northern blot analysis, we showed that the IGFBP-2 
mRNA levels decreased to 45% ± 9% of control values (chapter 7 of this thesis). To 
determine whether this DXM-induced decrease of IGFBP-2 mRNA was caused by an 
luc 
Figure 1 Schematic representation of the porcine IGFBP-2 promoter construct, containing the luciferase (luc) 
reporter gene. Both the full-length (-1397) and the 5' deletion (-874) constructs are shown. The arrow indicates 
the position of the transcription start site (-89, relative to the first codon), the translation start site position is 
indicated as +1. The luciferase gene is larger (1649 bp) than suggested in this figure. Putative binding sites for a 
number of transcription factors are indicated; site A is a binding site for AP-1 (-937), B for Sp1 (-147, -747) and 
C for NF-κB (-257). 
–874 
–1397 
+1   +73-89
A B BC
luc 
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inhibition of the transcriptional activity of the IGFBP-2 promoter, we performed transient 
transfections in cultured porcine growth plate chondrocytes, using a construct containing the 
porcine IGFBP-2 promoter linked to the luciferase reporter gene. 
 We performed a time-response experiment from 2 to 24 h, to determine at which time-
point the transcriptional activity of the porcine IGFBP-2 promoter was most affected by DXM 
(100 nM). We used the same concentration of DXM (100 nM) as previously used in the 
[3H]thymidine and Northern blot experiments 13. The transcriptional activity of both the 
full-length IGFBP-2 luciferase construct (-1397 bp) and the 5' deletion IGFBP-2 luciferase 
construct (-874 bp) was maximally inhibited after 24 h of DXM treatment (data not shown). 
Therefore, in subsequent experiments, cells were subjected to 24 h DXM treatment (100 nM) 
(data from one representative experiment are shown, Table 1). Three independent experiments 
showed that basal luciferase activities of both the full-length (-1397 bp) and the 5' deletion 
IGFBP-2 promoter construct (-874 bp) were similar. The region between nt -1397 and nt -874 
seems therefore not important for basal IGFBP-2 promoter activity in these growth plate 
chondrocytes. DXM treatment (100 nM) for 24 h significantly decreased the transcriptional 
activity of the full-length IGFBP-2 construct (-1397 bp) to 73% ± 10% of control levels. 
DXM also decreased the transcriptional activity of the 5' deletion construct (-874 bp), to 
54%± 15% of control levels (Table 1). These inhibitions do not significantly differ from each 
other, and were similar to those found in the time-response experiment.  
 
   Table 1 Transcriptional activity of the porcine IGFBP-2 promoter in primary  
porcine growth plate chondrocytes and the effect of DXM treatment. 
promoter 
construct 
DXM treatment 
(100 nM) 
luciferase activity ± 
SEM 
% ± % SEM 
–1397 bp - 40850 ± 1925 100 ± 5.8 
 + 30000 ± 3401       73 ± 10.2 * 
–874 bp - 39668 ± 3865   100 ± 11.9 
 + 21504 ± 4870    54 ± 15 * 
 
 
 
 
 
DISCUSSION 
 
We have previously shown that GCs decrease the proliferation of porcine growth plate 
chondrocytes, concomitant with decreased IGFBP-2 mRNA levels 13, which was also shown 
by others in fetal ovine growth plate chondrocytes 14.  
 In the present study, we showed that the GC-induced decrease of IGFBP-2 mRNA levels 
in porcine growth plate chondrocytes is, at least partially, caused by a decrease in the 
transcriptional activity of the porcine IGFBP-2 promoter by GCs. The full-length and the 
5' deletion IGFBP-2 promoter construct showed similar basal luciferase activities, indicating 
that the region between nt -1397 and nt -874 of the IGFBP-2 promoter does not contain 
sequences which are important for IGFBP-2 gene transcription in growth plate chondrocytes, 
in serum-supplemented culture conditions. In contrast, in HepG2 liver cells, deletion of this 
same region resulted in a 2-fold decrease of basal luciferase activity, indicating that this 
region is important for IGFBP-2 gene regulation in liver cells 17. In these HepG2 liver cells, 
The effect of DXM (100 nM; 24 h) on the transcriptional activity of the porcine 
IGFBP-2 promoter was examined. The luciferase activity corrected for the 
transfection efficiency is indicated. The representative data from one 
experiment conducted in triplicate are shown. Data are expressed as 
means ± SEM. *P<0.05 compared to untreated porcine chondrocytes. 
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the region between nt -874 and nt -765 of the porcine IGFBP-2 promoter was shown to be 
essential for IGFBP-2 gene regulation. Using deletion and mutation analysis of the IGFBP-2 
promoter, two AP-4 binding sites were identified in this region, which were required for the 
basal activation of the porcine IGFBP-2 promoter 17. 
 To determine whether GC-responsive elements were present in the region between 
nt -1397 and nt -874, we treated chondrocytes transfected with these constructs with DXM. 
Treatment with DXM resulted in a similar decrease in luciferase activity of both IGFBP-2 
promoter constructs, indicating that the region between nt -1397 and nt -874 does not 
significantly contribute to the inhibition of the transcriptional activity of the IGFBP-2 
promoter by GCs.  
 Activation of genes by GCs requires DNA consensus sequences, such as glucocorticoid 
responsive elements (GRE) 20, whereas inhibition of transcription by GCs does not involve 
GREs. Several other mechanisms have been proposed for the inhibition of gene transcription 
by GCs, such as the involvement of other DNA consensus sequences (the negative GRE, 
nGRE) or the interaction with other transcription factors such as AP-1 and NF-κB 21. 
Although the presence of a nGRE in the IGFBP-2 promoter cannot be excluded, sequence 
analysis did not show the presence of a possible nGRE as proposed by others 22. However, 
using a motif searching program (http://motif.genome.ad.jp/), putative DNA binding sites for 
AP-1 (nt -937) and NF-κB (nt -257) were identified, which could be involved in the inhibition 
of the transcriptional activity of IGFBP-2 by GCs. Although the 5' deletion construct of 
IGFBP-2 did no longer contain the proposed AP-1 binding site (Fig. 1), its transcriptional 
activity was similarly decreased by DXM as for the full-length construct. Possibly, NF-κB or 
other transcription factors (including possible non-identified AP-1 sites) might be involved in 
the decrease of IGFBP-2 in our chondrocytes.  
 In contrast, in lung tissue of the rat, GCs increased IGFBP-2 mRNA levels both in vivo 3, 
and in vitro at the transcriptional level 23. The difference with our porcine growth plate 
chondrocytes could be caused by the cell-type and species specific regulation of components 
of the IGF system by GCs 24. 
 Several studies have shown that IGFBP-2 is an important mediator of cell growth 25. In 
growth plate chondrocytes, growth-inhibiting conditions decrease IGFBP-2 levels 13,14, 
whereas growth-stimulating conditions increase IGFBP-2 levels 15, suggesting a positive 
association between IGFBP-2 levels and growth. In addition, in the rat IGFBP-2 promoter a 
silencer element has been identified, using deletion analysis of the promoter, which activity 
depends on cell growth 26. Therefore, the inhibition of IGFBP-2 transcriptional activity in 
growth plate chondrocytes by GCs might play a role in GC-induced growth retardation. 
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Introduction 
 
Glucocorticoids (GCs) are widely used as anti-inflammatory and immunosuppressive drugs in 
various diseases 1. The use of these potent drugs, however, is associated with several severe 
side-effects such as suppression of the hypothalamus-pituitary axis, osteoporosis and growth 
retardation in children 2. In this thesis, we attempted to elucidate some of the mechanisms 
involved in GC-induced growth retardation. GCs act locally to inhibit growth, suggesting a 
mechanism intrinsic to the growth plate 3,4. Growth plate chondrocytes of the different zones 
express the glucocorticoid receptor (GR), suggesting they are indeed target cells for GCs 5-7.  
 It has been suggested, for many years already, that GC-induced growth retardation 
involves impaired action of the components of the IGF system 8-11. However, very few studies 
have analyzed the effects of GCs on the IGF system at the local level of the growth plate, and 
these studies were limited to cell culture systems 12,13. The primary growth plate chondrocyte 
cultures used in these in vitro studies predominantly represent proliferative chondrocytes 12,14. 
Possible effects of GCs on resting and hypertrophic chondrocytes are therefore not included 
in these kinds of studies. Furthermore, the complex architecture of the growth plate cannot be 
mimicked in vitro. This indicates the importance to study also the effects of GCs on the 
growth plate in vivo. Naturally, the in vitro studies remain important to study processes in 
detail. Therefore, we have performed both in vitro and in vivo studies to analyze the effects of 
GCs on the IGF system at the level of the growth plate, as described in this thesis. 
 
The IGF system in the postnatal growth plate 
 
IGF-I and IGF-II 
For several years, there have been conflicting reports whether both IGF-I and IGF-II are 
expressed in growth plate chondrocytes. In fetal growth plates, both IGF-I and -II are 
present 15,16. In cultured growth plate chondrocytes, we also showed expression of both IGFs 
(chapter 7), as shown previously 17. In vivo in the postnatal growth plates of rodents, 
Wang et al. 18 and Shinar et al. 19, could only detect IGF-II, whereas others did show 
expression of IGF-I, but did not study IGF-II 20-23. We demonstrated, for the first time, the 
presence of both IGF-I and IGF-II in vivo in the postnatal growth plate of mice (chapters 3 
and 4). The type I IGF receptor is expressed in all zones of the growth plate 15,24 and we are 
the first to describe the expression of the type II IGF receptor in the growth plate, in vitro 
(chapter 7). 
 We studied the growth plates of prepubertal (4-week-old) (chapter 4) and postpubertal 
(7-week-old) (chapter 3) mice and demonstrated an age-dependent shift in expression pattern 
of both IGF-I and -II (Fig. 1), which could indicate an age-dependent autocrine/paracrine 
function of both IGFs at various stages of chondrogenesis and postnatal development. 
Expression of IGF-I and -II in the proliferative and prehypertrophic zones in prepubertal 
animals (chapter 4) 18,20,23 indicates that they are probably important in the clonal expansion 
of proliferative chondrocytes, as postulated for IGF-I in the “dual effector theory” 25 (see the 
General introduction). They are probably also important in the differentiation of proliferative 
chondrocytes toward a hypertrophic state. 
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 In postpubertal mice, both IGFs are predominantly expressed in the pre- and hypertrophic 
zones (chapter 3) 21,22. At this age, the main function of both IGFs might be to augment 
chondrocyte hypertrophy and to a lesser extent to stimulate proliferation, as the proliferation 
might become less important as the growth velocity decreases in postpubertal mice. IGF-I has 
indeed previously been shown in vivo to be involved in stimulating proliferation and 
augmenting hypertrophy of chondrocytes 23,26.  
 IGF-I and IGF-II are suggested to each have a unique and complementary role in the 
growth plate 27. However, the IGFs have similar expression patterns in the growth plate 
(chapters 3 and 4). Treatment of chondrocytes with either IGF-I or -II has similar effects, on 
IGFBP expression 14 and on clonal expansion of chondrocytes 28. However, concerning clonal 
expansion, IGF-I was more effective in adult chondrocytes and IGF-II in fetal 
chondrocytes 28. This suggests that IGF-I might play a more prominent role in the postnatal 
growth plate and IGF-II in the fetal growth plate. IGF-II knock-out mice indeed indicated a 
predominant role for IGF-II in fetal growth 29. IGF-II does, however, stimulate postnatal 
longitudinal growth 30,31 and clonal expansion of postnatally derived chondrocytes 28, and is 
present in the postnatal growth plate (chapters 3 and 4). This indicates that IGF-II could still 
play a role in the postnatal growth plate, which however, has to be established. Our GC 
treatment studies (see below) did show that IGF-I and -II did not respond in the same way to 
GCs, indicating that IGF-I and -II still may have both a unique function in the postnatal 
growth plate (chapters 3 and 4).  
 
IGFBPs 
In chapters 3 and 4, we demonstrated for the first time the presence of only IGFBP-2 in the 
postnatal growth plate in vivo. Using radioactive in situ hybridization, Wang et al. detected 
only low levels of IGFBP-6 in postnatal murine growth plates in vivo, which rapidly declined 
with age 18. In many cases, a wider array of IGFBPs has been found in cultured 
chondrocytes 16,17,32. In porcine growth plate chondrocytes we demonstrated remarkable 
expression of IGFBP-2, -4 and -5, which is in accordance with several other in vitro 
studies 14,17,32,33. The high expression of IGFBP-2, -4, and -5 in chondrocytes (chapter 7) 14,32 
might be related to the important roles these IGFBPs play in bone formation and 
resorption 34-38. IGFBP-4 and -5 are also known to affect the proliferation of 
chondrocytes 39,40.  
 IGFBP-2 is the only IGFBP which we detected both in vitro (chapter 7) and in vivo 
(chapters 3 and 4) in postnatal growth plate chondrocytes, in co-localization with IGF-I and -II 
in vivo. This suggests that IGFBP-2 might play a specific modulatory role of IGF action in 
Figure 1 Age-dependent expression pattern of 
IGF-I and IGF-II in the postnatal growth plate. 
A schematic representation of the expression of 
both IGFs in the growth plates of (A) prepubertal 
and (B) postpubertal mice, as shown by in situ
hybridization. IGF-I and IGF-II co-localize in the 
different growth plate zones. The age-dependent 
shift in expression pattern might indicate an age-
dependent function of both IGF-I and -II in the 
growth plate. In prepubertal mice, they might be 
important in stimulating proliferation and 
differentiation. In postpubertal mice, the main 
function might be to stimulate differentiation. 
A B reserve 
zone 
proliferative 
zone 
prehypertrophic 
zone 
hypertrophic 
zone 
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growth plate chondrocytes. However, IGFBP-2 knock-out mice did not shown an effect on 
longitudinal growth, which was suggested to be caused by compensation of the other 
IGFBPs 41. In contrast, IGFBP-2 was shown to inhibit GH-induced growth in vivo 42. Also, 
IGFBP-2 transgenic mice, which displayed a reduced body weight gain caused by a reduction 
in carcass weight, showed that IGFBP-2 is a negative regulator of bone growth and 
modeling 34,35. 
 
GC-induced growth retardation and the growth plate 
 
Growth retardation as a side-effect of GC treatment is observed in both children 2,43 and in 
animal models 44-48. In children, already short-term GC treatment can result in growth 
retardation 43,49 and especially just before puberty, children are susceptible to growth 
suppression by GCs 2. We confirmed this in prepubertal mice, where short-term GC treatment 
resulted in growth inhibition (chapter 4). Comparison of the effects of short-term (chapter 4) 
and long-term (chapter 3) 44 GC treatments indicated that the growth inhibition is already 
established, for the large part, during the initial phase of the treatment. Prolonged treatment 
did not seem to have much additional effects on general growth (chapter 4) 44.  
 GCs act locally to inhibit growth 3,50, which is confirmed in several studies showing that 
GCs decreased the total width of the growth plate 4,51,52. In chapters 4 and 5, we showed that 
the total growth plate width already decreased after a short-term GC treatment, which was 
mainly caused by a diminished width of the proliferative zone. This was due to a reduced 
proliferation, resulting in a decreased number of chondrocytes in the proliferative zone.  
 The susceptibility of proliferative chondrocytes to GCs was already shown in chondrocyte 
cultures from rodents 9,12, where GCs decreased cellular turnover and reduced the number of 
cells in S phase 53. In chapter 7, we confirmed these findings and demonstrated that the 
decreased proliferation was a direct effect of the GCs, as a GR antagonist prevented the 
reduced proliferation. The disturbed chondrocyte proliferation likely contributes to a 
disturbed chondrogenesis. Several other stages in endochondral ossification are also affected 
by GCs, as described below. 
 
Disturbed apoptosis and angiogenesis by GC treatment 
 
Vascular invasion (i.e. angiogenesis) of the growth plate is associated with apoptosis of 
hypertrophic chondrocytes 54. In mice in which hypertrophic chondrocyte differentiation is 
inhibited, no vascular invasion of the growth plate occurs 55,56. Vice versa, inhibition of 
angiogenesis delays chondrocyte apoptosis 54. An essential growth factor for angiogenesis is 
VEGF 57, which is expressed by hypertrophic chondrocytes 54,58,59, as we confirmed in 
chapter 5. In chapter 6, we demonstrated that cultured porcine growth plate chondrocytes also 
express and secrete VEGF.  
 We showed that GC treatment increased apoptosis in hypertrophic chondrocytes in 
prepubertal mice (chapter 4) and piglets (chapter 5). The same result was previously shown in 
rats 4,60. Apoptosis of chondrocytes is inversely correlated with the growth rate of the long 
bones 61. Increased apoptosis could therefore contribute to the decreased growth, which is 
observed as a result of the GC treatment. 
 In chapter 5, we demonstrated that GCs severely disturb the architecture of the blood 
vessels in the primary spongiosa, with disorganized and short blood vessels as a consequence. 
VEGF, important for the vascularization, was decreased by GCs in the porcine growth plate, 
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both in vivo and in vitro (chapters 5 and 6), which was also shown in vivo in rats 60. The 
decrease of VEGF in vitro was mediated by the GR, as a GR antagonist almost completely 
blocked the decrease of VEGF expression. The decrease of VEGF expression in the growth 
plate by GCs could be involved in the disturbed angiogenesis, which we observed in our 
GC-treated piglets (chapter 5).  
 In conclusion, several stages in endochondral ossification are affected by GCs, 
e.g. decreased proliferation, increased apoptosis and disturbed angiogenesis. This can all 
contribute to GC-induced growth retardation. 
 
The IGF system in GC-induced growth retardation 
 
The possible involvement of the IGF system in GC-induced growth retardation has mainly 
been studied at the endocrine level. These studies, however, resulted in conflicting data and 
serum levels of the IGF system were suggested to provide little insight into the mechanisms 
of GC-induced growth retardation 62. Although changes in endocrine levels of the IGF system 
may still be involved in GC-induced growth retardation, the local effects on the growth plate 
are probably more important 10. 
 In chapter 7, we addressed the question which components of the IGF system are regulated 
by GCs in neonatal porcine growth plate chondrocytes, concomitant with the decreased 
chondrocyte proliferation. GCs increased type I IGF receptor mRNA expression, confirming 
in vivo data 11. However, decreased type I IGF receptor mRNA expression in the rat growth 
plate has also been reported 60. Although seemingly contradictory, the increase of type I IGF 
receptor levels might be a response to counteract the adverse effects of GCs on growth. The 
GC-induced increase in IGFBP-5 mRNA expression is in contrast with observed reduced 
levels in rabbit costal chondrocytes 13 and fetal ovine growth plate chondrocytes 14. 
GC-regulated expression of IGF components is species- and cell-type specific and depends on 
age and developmental stage 63, possibly explaining the observed differences.  
 
IGFBP-2 
IGFBP-2 was the only component which was both decreased at the mRNA and protein level 
by GCs in vitro. This decrease was mediated by the GR (chapter 7). A similar GC-induced 
decrease of IGFBP-2 was shown in fetal ovine growth plate chondrocytes 14. The observed 
decrease of IGFBP-2 under growth inhibiting conditions is in concert with the observed 
increase of IGFBP-2 under growth stimulating conditions in chondrocytes 64. This suggests 
that the proliferation of chondrocytes in vitro, is positively associated with IGFBP-2 levels. In 
preliminary promoter studies of IGFBP-2, the regulation of IGFBP-2 by GCs appeared to 
occur at the transcriptional level (addendum of chapter 7). However, in vivo GC treatment had 
no effect on IGFBP-2 mRNA expression in the growth plate (chapters 3 and 4), indicating a 
different regulation of IGFBP-2 by GCs in these different model systems.  
 In chapter 2, we showed that growth stimulation in vivo of lymphoid tissues, by the 
presence of a hIGF-II transgene, is also associated with increased mRNA expression of 
IGFBP-2. This suggests that not only in chondrocytes in vitro, but also in other systems, 
IGFBP-2 mRNA expression is positively associated with growth. In turn, this association 
could affect the outcome of the growth modulating condition. In the same way, the 
GC-induced decrease of IGFBP-2 in vitro might play a growth modulating role in the GC-
induced growth retardation. 
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A dual action of IGF-I in GC-induced growth retardation 
 
We are the first to describe the in vivo effects of GCs on the expression of the IGF system in 
the growth plate. Both the short-term and the long-term in vivo GC treatment appeared to 
have no effect on IGFBP-2 mRNA expression. In addition, IGF-II did not change either, 
however, both treatments did affect IGF-I mRNA expression (chapters 3 and 4). This 
contrasts with the in vitro situation in the porcine growth plate chondrocytes, where IGF-I 
was not affected by GCs, whereas IGFBP-2 decreased and IGF-II was also not affected 
(chapter 7).  
 Following 1 week of GC treatment, IGF-I levels decreased both in serum and in the growth 
plate (chapter 4). The decreased IGF-I mRNA expression in the proliferative zone of the 
growth plate probably contributed to the observed decrease in proliferation. In addition, the 
reduced IGF-I mRNA expression in the prehypertrophic zone, might result in inhibition of the 
differentiation of chondrocytes to the hypertrophic phenotype 23,24,26. Also in rat growth plate 
chondrocytes, GCs were shown to inhibit GH-stimulated IGF-I secretion 12. The inhibition of 
IGF-I by GCs was demonstrated to occur at the transcriptional level, in rat osteoblasts 65. 
Although we could not demonstrate a direct relationship between decreased IGF-I levels and 
disturbed endochondral ossification, our data do suggest that the action of IGF-I in the growth 
plate is impaired upon GC treatment.  
 During long-term GC treatment of rats for 3 weeks, GR levels decreased in the growth 
plate 4, indicating that the growth plate becomes less susceptible to GCs in time. GCs can then 
no longer or to a lesser extent exert their actions. Comparing our short-term and long-term GC 
experiment, the same conclusion can be drawn: the organism becomes less susceptible as 
most of the damage seems to occur in the early phase of the treatment (chapters 3 and 4) 44. 
This is supported by the finding in humans that the growth inhibiting effect of GCs is also 
maximal during the initial period of the treatment 66. After 4 weeks of GC treatment, IGF-I 
levels increased, both in the growth plate and serum in our mice (chapter 3). Since IGF-I is 
suggested to be able to counteract the inhibiting effects of GCs 9, the increased IGF-I levels in 
the growth plate might be part of a compensatory mechanism to diminish the growth 
inhibiting effect of GCs, together with the decreased GR levels 4. This suggestion is 
strengthened by the notion that in hIGF-II transgenic mice, which are partially protected 
against the adverse effects of GCs 44, also increased IGF-I mRNA levels are observed in the 
growth plate (chapter 3). Our observations indicate that IGF-I could have a dual action in 
GC-induced growth retardation. During the initial phase of GC treatment, IGF-I action would 
be impaired by GCs, resulting in disturbed chondrogenesis and subsequent longitudinal bone 
growth (in Fig. 2 proliferation is used as an example of the effects of IGF-I). In a later phase 
of the treatment, GCs might not be able to impair IGF-I action anymore, due to the decreased 
GR levels. IGF-I expression is no longer inhibited and IGF-I levels increase, which would be 
part of a mechanism to counteract the adverse effects of GCs (Fig. 2). 
 
 
 
 
 
 
 
 
Figure 2 A dual action of IGF-I in GC-induced growth 
retardation A proposed model for the actions of IGF-I in 
GC-induced growth retardation. (A) In the intial phase of the 
GC treatment, GCs decrease IGF-I levels, resulting e.g. in a 
decreased proliferation of chondrocytes (and affecting several 
other stages in endochondral ossification). (B) In a later phase 
of the GC treatment, GR levels decrease, resulting in a 
decreased sensitivity for GCs. GCs are no longer able to 
impair IGF-I action. IGF-I levels rise, resulting in a 
compensatory mechanism to counteract the adverse effects of 
GC by increasing e.g. proliferation of the chondrocytes. 
A. 
GR IGF-I proliferation GC 
GR IGF-I proliferation GC 
B. 
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A central role for IGF-I in GC-disturbed endochondral ossification 
 
The possible involvement of IGF-I in GC-induced growth retardation is probably not limited 
to chondrocyte proliferation and differentiation, but may involve more stages in endochondral 
ossification (Fig. 3). IGF-I is known to protect cells against GC-induced apoptosis 67. 
Decreased IGF-I levels in the growth plate could therefore contribute to increased levels of 
chondrocyte apoptosis (chapters 4 and 5). Vascularization also depends on IGF-I. It requires 
minimal levels of IGF-I, as shown by inhibited vascularization in the retina of IGF-I knock-
out mice 68 and humans with low IGF-I levels 69. IGF-I might mediate its effects on 
vascularization through VEGF, as IGF-I stimulates VEGF production in both chondrocytes 
(chapter 6) and osteoblasts 70. Moreover, minimal levels of IGF-I seem to be required to 
promote maximal function of VEGF 69. Disturbed angiogenesis caused by GCs (chapter 6), 
could therefore be caused by decreased levels of IGF-I in the growth plate, with VEGF as a 
possible intermediate. However, direct effects of GCs on VEGF or other factors influencing 
vascularization can also be involved. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Another important aspect of endochondral ossification, ECM synthesis, also involves 
IGF-I. IGF-I stimulates the production of proteoglycans 33,71,72. GC-induced down-regulation 
of IGF-I in the growth plate might result in a decreased matrix production by chondrocytes. A 
decreased matrix production is suggested to contribute to GC-induced growth retardation 73. 
Disturbed matrix production might also have an effect on the function of IGFBPs, as their 
biological activity can depend on ECM association 74. 
 Taking into account the different aspects of GC-induced growth retardation, IGF-I is likely 
to play a central role in the different disturbed stages in endochondral ossification caused by 
GCs, at the local level of the growth plate. 
 
Figure 3. Possible central role for IGF-I in endochondral 
ossification. IGF-I could play a central role in different stages in 
endochondral ossification. GCs disturb many of these different stages, 
which could be mediated by IGF-I, as indicated. The effects on the 
ECM are not indicated.  
IGF-I 
proliferation 
differentiation 
apoptosis 
angiogenesis 
GC 
  General discussion 
 125
Therapeutic implications 
 
The suggested involvement of impaired action of the GH-IGF axis in GC-induced growth 
retardation has already resulted in some studies on the use of these components as therapeutic 
agents. GH therapy of children treated with GCs has been shown to attenuate the GC-induced 
growth retardation 75. It resulted in increased serum IGF-I levels, which was suggested to 
mediate the effects of GH 2. Our data on the involvement of the IGF system in GC-induced 
growth retardation indicate that IGF-I might indeed be an important player. IGF-I has been 
shown to restore growth retardation in diabetes-induced growth retardation in rats 76 and also 
partially in GC-induced growth retardation in rats 77. However, whether treatment with IGF-I 
would be beneficial remains to be solved. Another important aspect is that most damage 
caused by GC treatment is suggested to occur in the initial phase of the GC treatment 66. Both 
the search for prevention therapy as well as the development of GCs with less side-effects 78 
is therefore important. 
 
Concluding remarks 
 
The observed effects of GCs on the growth plate suggests that local IGF-I plays a central role 
in GC-induced growth retardation. Although we have been the first to show an effect of GCs 
on the IGF system in the growth plate in vivo, we did not prove a direct relationship between 
changed local IGF-I expression levels, the disturbed stages in endochondral ossification, and 
the subsequent growth retardation. Studies have already been performed to analyze the 
systemic effects of IGF-I on longitudinal bone growth, using the liver-specific IGF-I and ALS 
knock-out mice (described in the Introduction). However, the effects of a total IGF-I 
knock-out on postnatal longitudinal bone growth is more severe. This indicates the 
importance of local IGF-I. For this reason, one should first study the function of local IGF-I in 
the growth plate, which could indicate if there is indeed a direct relationship between IGF-I 
and the different stages in endochondral ossification. Generating a growth-plate specific IGF-I 
knock-out mouse, using the Cre/LoxP system, would be a useful tool for this kind of study. 
To delineate in more detail the function of IGF-I during chondrogenesis, IGF-I expression 
could be suppressed at only particular stages in chondrogenesis, using the mouse 
chondrogenic cell line ATDC5 and antisense oligo's or RNA interference experiments. This 
chondrogenic cell line undergoes a reproducible multistep chondrogenic differentiation 
program in a tightly regulated time-span 79,80, providing an accurate model of the growth 
plate. Using the above mentioned experimental models, one can study whether the main target 
of GCs is indeed IGF-I, as suggested in this thesis and whether other IGF system components, 
as IGFBP-2, or other factors might also be involved. 
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Summary 
 
 
Glucocorticoids (GCs) are widely used as anti-inflammatory and immunosuppressive drugs. 
The use of these potent drugs, however, often results in side-effects, such as growth 
retardation in children. For already many years, this GC-induced growth retardation is 
suggested to involve impaired action of the components of the growth hormone (GH) - 
insulin-like growth factor (IGF) system. The components of this system are among the main 
regulators of postnatal longitudinal bone growth. Longitudinal bone growth is regulated by 
the growth plates, layers of cartilage (containing cartilage cells, chondrocytes) located at the 
proximal and distal ends of the long bones. In the growth plates, the chondrocytes follow a 
tightly controlled program of differentiation (resulting in the different zones of the growth 
plate), which is part of the process of endochondral ossification, resulting in the formation of 
new bone. This bone formation is responsible for longitudinal bone growth. GC-induced 
growth retardation involves a mechanism intrinsic to the growth plate. However, not much is 
known about the effects of GCs on the components of the IGF system at the level of the 
growth plate. In this thesis, we studied the involvement of the IGF system in GC-induced 
growth retardation at the level of the growth plate, using several model systems. 
 In chapter 2, we used non-radioactive in situ hybridization to study mRNA expression of 
the components of the IGF system in lymphoid tissues of human (h) IGF-II transgenic mice. 
In these mice, high transgene expression was observed in the spleen and the thymus, resulting 
in increased growth of the thymus, but not of the spleen. The high IGF-II expression resulted 
in increased mRNA expression of several of the IGF binding proteins (IGFBPs), which 
modulate the bioactivity of both IGF-I and IGF-II. The increased expression of the IGFBPs 
suggest an important role for these proteins in the growth regulation of these lymphoid 
tissues. 
 To study the involvement of the IGF system in GC-induced growth retardation at the level 
of the growth plate, we treated 3-week-old mice with dexamethasone (DXM), a synthetic GC, 
for four weeks, which resulted in growth retardation. Subsequently, we studied the effects on 
the mRNA expression of the IGF system in the growth plate, as described in chapter 3. 
IGF-I, IGF-II and IGFBP-2 were present in the growth plates of control mice, predominantly 
in the pre- and hypertrophic zones. DXM treatment increased the number of IGF-I positive 
cells, whereas the number of chondrocytes expressing IGF-II and IGFBP-2 were not affected. 
In hIGF-II transgenic mice, which are partially protected against the adverse effects of GCs, 
the number of IGF-I positive chondrocytes was elevated, whereas IGF-II and IGFBP-2 
expression was not affected. Subsequent DXM treatment of the hIGF-II transgenic mice 
further increased the number of IGF-I positive chondrocytes, to a similar extent as in the 
DXM-treated normal mice. These data suggest a possible role for IGF-I in GC-induced 
growth retardation. IGF-I could contribute to the GC-induced growth retardation by 
accelerating the endochondral ossification or it could be part of a compensatory mechanism to 
minimize the GC-induced growth retardation. We showed in chapter 4 that already a short-
term DXM treatment (one week) of 3-week-old mice resulted in growth retardation and 
defects of the growth plate. Total growth plate width decreased, mainly due to a decreased 
width of the proliferative zone. Moreover, the number of proliferating cell nuclear antigen 
(PCNA) immunopositive chondrocytes decreased. In the hypertrophic zone the number of 
Summary   
 
132 
apoptotic chondrocytes increased. In these 4-week-old mice, IGF-I, IGF-II and IGFBP-2 were 
predominantly present in the proliferative and prehypertrophic zones. DXM treatment again 
only affected IGF-I. The number of IGF-I positive chondrocytes decreased, which could 
contribute to the observed GC-induced growth retardation. 
 We confirmed the short-term effects of GCs on the growth plates described in chapter 4, in 
the growth plates of piglets in chapter 5. Treatment with prednisolone (PRDL), another 
synthetic GC, of 6-week-old piglets for 5 days also resulted in a decrease of the total width of 
the growth plate, due to a decreased width of the proliferative zone. Also, in the hypertrophic 
zone, apoptosis increased. Apoptosis is closely linked to angiogenesis. This process of 
vascularization is important to allow the formation of new bone. PRDL treatment resulted in 
decreased VEGF expression in the growth plate, an important angiogenic growth factor. The 
decreased VEGF expression could be involved in the observed disturbed vascularization. 
Disturbed apoptosis and angiogenesis could contribute to GC-induced growth retardation. The 
regulation of VEGF by GCs was studied in more detail in chapter 6, using primary growth 
plate chondrocytes derived from neonatal piglets. VEGF expression and secretion were 
inhibited by GCs, which was mediated by the glucocorticoid receptor (GR). 
 In chapter 7, the same primary porcine growth plate chondrocytes were used to study the 
components of the IGF system in more detail. In contrast to the in vivo model, the 
chondrocytes expressed, besides IGF-I, IGF-II and IGFBP-2, also IGFBP-4, -5 and -6 as well 
as the type I and type II IGF receptor (not studied in vivo). DXM treatment inhibited the 
proliferation of the chondrocytes, which was mediated by the GR. Concomitant with the 
decreased proliferation, IGFBP-5 and type I IGF receptor mRNA levels increased, whereas 
IGFBP-2 mRNA levels decreased. In addition, DXM treatment also decreased IGFBP-2 
mRNA and protein levels in serum-free culture conditions, whereas the other components 
were not affected. The decreased IGFBP-2 expression is possibly caused by inhibition of 
transcriptional activity of the IGFBP-2 promoter, as shown in the IGFBP-2 promoter studies 
in the addendum of chapter 7. The decreased IGFBP-2 levels could contribute to 
GC-induced growth retardation observed in this model system. 
 The data in this thesis suggest that the IGF system is indeed impaired at the local level, 
which could contribute to GC-induced growth retardation, as discussed in chapter 8. IGF-I 
might play a role in several GC-disturbed processes, as apoptosis and angiogenesis. In 
addition, IGF-I could have a dual action in GC-induced growth retardation. In the initial phase 
of the GC treatment, decreased IGF-I levels could contribute to GC-induced growth 
retardation, whereas later on in the treatment, increased IGF-I levels might become part of a 
compensatory mechanism.  
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Samenvatting 
 
 
Glucocorticoïden (GCs) worden veel gebruikt als ontstekingsremmers en voor het 
onderdrukken van de immuunreactie. Het gebruik van deze medicijnen geeft vaak bijeffecten, 
zoals groeivertraging bij kinderen. Deze GC-geïnduceerde groeivertraging wordt al sinds 
enige jaren toegeschreven aan een verstoorde werking van de componenten van het 
groeihormoon (GH) en insuline-achtige groeifactor (IGF) systeem. De componenten van dit 
systeem zijn een van de belangrijkste regulatoren van de postnatale lengtegroei. Lengtegroei 
van de botten wordt gereguleerd door de groeischijven, kraakbeenplaten (bestaande uit 
kraakbeencellen, de chondrocyten), die zich aan de uiteinden van de pijpbeenderen bevinden. 
In deze groeischijven ondergaan de chondrocyten een differentiatie programma, wat leidt tot 
de verschillende zones die aanwezig zijn in de groeischijf. Dit differentiatie programma is een 
onderdeel van het proces endochondrale ossificatie, dat resulteert in de vorming van nieuw 
bot. Deze botvorming is verantwoordelijk voor de lengtegroei van het bot. Er is aangetoond 
dat de GC-geïnduceerde groeivertraging plaatsvindt in de groeischijf, wat dus wijst op een 
lokaal mechanisme. Er is echter nog weinig bekend van de effecten van GCs op de 
componenten van het IGF systeem in de groeischijf. In dit proefschrift hebben we de 
mogelijke rol van de componenten van het IGF systeem in GC-geïnduceerde groeivertraging 
op het niveau van de groeischijf bestudeerd, waarbij we gebruik hebben gemaakt van 
verschillende modelsystemen.  
 In hoofdstuk 2 hebben we gebruik gemaakt van niet-radioactieve in situ hybridisatie voor 
het analyseren van de mRNA expressie van de componenten van het IGF systeem, in de milt 
en de thymus van humaan (h) IGF-II transgene muizen. In deze hIGF-II transgene muizen 
kwam het hIGF-II transgen hoog tot expressie in de milt en de thymus, wat bij de thymus, 
maar niet bij de milt, leidde tot versnelde groei. De aanwezigheid van het transgen in deze 
lymfoïde organen leidde tot een toename in mRNA expressie van een aantal IGF bindende 
eiwitten (IGFBPs), in de milt meer dan in de thymus. Deze IGFBPs moduleren de 
bioactiviteit van de IGFs door te binden aan de IGFs. De toename in expressie van deze 
IGFBPs suggereert dat ze een belangrijke rol spelen in de regulatie van de groei van deze 
lymfoïde organen. 
  Om de betrokkenheid van het IGF systeem in GC-geïnduceerde groeivertraging op het 
niveau van de groeischijf te bestuderen, hebben we muizen van 3 weken oud, 4 weken lang 
behandeld met dexamethason (DXM) (een synthetisch GC), wat leidde tot groeivertraging. 
Vervolgens hebben we gekeken naar de effecten van deze GC behandeling op de mRNA 
expressie van de componenten van het IGF systeem in de groeischijf, zoals beschreven in 
hoofdstuk 3. IGF-I, IGF-II en IGFBP-2 waren de 3 componenten die aanwezig waren, 
voornamelijk in de prehypertrofe en de hypertrofe zone van de groeischijf. DXM behandeling 
resulteerde in een toename van het aantal IGF-I positieve chondrocyten, terwijl IGF-II en 
IGFBP-2 mRNA expressie niet beïnvloed werd. In hIGF-II transgene muizen, die gedeeltelijk 
beschermd zijn tegen de negatieve effecten van GCs, waren dezelfde 3 componenten 
aanwezig in de groeischijf, maar er was een toename in het aantal IGF-I positieve 
chondrocyten. DXM behandeling van deze hIGF-II transgene muizen resulteerde vervolgens 
in een verdere toename van het aantal IGF-I positieve cellen, tot hetzelfde niveau als in de 
normale DXM behandelde muizen. Deze gegevens suggereren een mogelijke rol voor IGF-I 
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in GC-geïnduceerde groeivertraging. De toename van IGF-I zou kunnen bijdragen aan de 
groeivertraging door het versnellen van de endochondrale ossificatie, of juist onderdeel 
kunnen zijn van een compensatie mechanisme waarbij een toename van IGF-I de 
groeivertraging zou verminderen. In hoofdstuk 4 hebben we laten zien dat een korte DXM 
behandeling (1 week) van muizen van 3 weken oud al leidde tot groeivertraging en ook al een 
effect had op de groeischijf. De dikte van de groeischijf nam af, doordat de dikte van de 
proliferatieve zone afnam. De afname van de proliferatieve zone correleerde met de afname 
in het aantal chondrocyten positief voor proliferating cell nuclear antigen (PCNA), een 
marker voor prolifererende cellen. In de terminale hypertrofe zone nam het aantal 
apoptotische chondrocyten toe als gevolg van de DXM behandeling. IGF-I, IGF-II en 
IGFBP-2 mRNAs kwamen nu met name tot expressie in de proliferatieve en prehypertrofe 
zone van de groeischijf. Weer was IGF-I de enige component die beïnvloed werd door DXM, 
de mRNA expressie nam af. De afgenomen IGF-I mRNA expressie zou kunnen bijdragen aan 
de waargenomen GC-geïnduceerde groeivertraging.  
 De waargenomen korte termijn effecten in hoofdstuk 4, hebben we bevestigd in de 
groeischijven van biggen van 6 weken oud in hoofdstuk 5. Behandeling met prednisolon 
(PRDL) (een ander synthetisch GC) gedurende 5 dagen, leidde tot een soortgelijke afname in 
de dikte van de groeischijf als waargenomen bij de muis, ook hier als gevolg van een afname 
in de dikte van de proliferatieve zone. Ook hier nam het aantal apoptotische cellen toe in de 
hypertrofe zone van de groeischijf. Het proces van apoptose in de groeischijf is nauw 
verbonden met angiogenese, het proces van bloedvatvorming nodig voor de vorming van 
nieuw bot. Een groeifactor die erg belangrijk is voor angiogenese, VEGF (vasculaire 
endotheel groeifactor), nam af in mRNA en eiwit expressie in de groeischijf door de PRDL 
behandeling. Deze afname in VEGF expressie zou betrokken kunnen zijn bij de waargenomen 
verstoorde bloedvatvorming in het bot onder de groeischijf van de PRDL behandelde biggen. 
De verstoorde angiogenese en apoptose zouden kunnen bijdragen aan GC-geïnduceerde 
groeivertraging. De regulatie van VEGF door GC hebben we nader bestudeerd in 
hoofdstuk 6. In dit hoofdstuk hebben we gebruik gemaakt van primaire groeischijf 
chondrocyten, afkomstig van de groeischijven van neonatale biggen. De VEGF expressie en 
secretie door chondrocyten werd geremd door verschillende GCs, hetgeen gemedieerd werd 
door de glucocorticoïd receptor (GR).  
 In hoofdstuk 7 hebben we dezelfde primaire biggenchondrocyten gebruikt om ook de 
regulatie van de componenten van het IGF systeem door GCs meer in detail te kunnen 
bestuderen. In tegenstelling tot ons muizen in vivo model, brachten deze primaire 
biggenchondrocyten naast IGF-I, IGF-II en IGFBP-2, ook andere IGFBPs zoals IGFBP-4, -5 
en -6, als ook beide type IGF receptoren (hebben we niet bestudeerd in het in vivo model) tot 
expressie. DXM behandeling van deze chondrocyten resulteerde in remming van de 
proliferatie, wat gemedieerd werd door de GR. Samen met de afname in proliferatie, hebben 
we een toename in IGFBP-5 en type I IGF receptor mRNA expressie aangetoond, terwijl 
IGFBP-2 mRNA expressie afnam. IGFBP-2 was de enige component die ook nog veranderde 
op eiwit niveau onder serum-vrije condities. De afname van IGFBP-2 expressie kon, in ieder 
geval gedeeltelijk, worden verklaard door een afname in transcriptionele activiteit van de 
IGFBP-2 promoter, zoals aangetoond in de promoterstudies van IGFBP-2 in het addendum 
bij hoofdstuk 7. De afname van IGFBP-2 zou kunnen bijdragen aan de waargenomen 
GC-geïnduceerde groeivertraging in dit model systeem. 
 De beschreven data in dit proefschrift tonen aan dat de expressie van het IGF systeem 
inderdaad verstoord is door GCs op het niveau van de groeischijf, wat zou kunnen bijdragen 
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aan de GC-geïnduceerde groeivertraging, zoals we bediscussieren in hoofdstuk 8. IGF-I zou 
hierbij een rol kunnen spelen in diverse processen die verstoord zijn door de GC behandeling, 
zoals in apoptose en angiogenese. Daarnaast zou IGF-I op 2 manieren betrokken kunnen zijn 
bij de GC-geïnduceerde groeivertraging. Aanvankelijk zou een afname van IGF-I, zoals 
waargenomen in het begin van de GC behandeling, kunnen bijdragen aan de groeivertraging. 
Later in de behandeling, als IGF-I toeneemt, zou IGF-I betrokken kunnen zijn bij een 
compensatie mechanisme om de groeivertraging te minimaliseren.  
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